Heregulin-Enhanced Tyrosine Phosphorylation in Breast Cancer Cells: Role of PP2A in HER-2/neu Oncogenic Signalling by WONG LEE LEE
HEREGULIN-ENHANCED TYROSINE PHOSPHORYLATION 
IN BREAST CANCER CELLS:  



















A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PATHOLOGY 
YONG LOO LIN SCHOOL OF MEDICINE 
NATIONAL UNIVERSITY OF SINGAPORE 
2010







It would not have been possible to complete my journey in this doctoral thesis without 
the help and support from many kind people around me.  
 
I am heartily thankful to my supervisor, Associate Professor Evelyn Koay, for her 
constant encouragement, guidance and support from the preliminary to the concluding 
level of my graduate study. Despite her hectic schedule, she always makes time for her 
students. I have benefited from her wisdom and her sharing of life experience in Science. 
 
I am grateful to my co-supervisors, Associate Professor Chang Chan Fong and Dr Zhang 
Daohai for their valuable discussion and technical advices as well as sharing their 
expertise in scientific knowledge. 
 
I would like to show my gratitude to my Ph.D. Thesis Advisory Committee members, 
Professor Bay Boon Huat and Associate Professor Yip Wai Cheong, George as well as 
the thesis examiners for their time and effort to make this thesis possible.  
 
I am indebted to my many present and former friends and colleagues at Special 
Histopathology, Department of Pathology, NUS and Molecular Diagnosis Centre, 
Department of Laboratory Medicine, NUH for their kind assistance and precious 
friendship. 
 
This thesis would not have been possible without the immense love and unequivocal 
support from my family. To my loving husband Julian, thank you for being my strong 
support and accompanying me through the joy and sorrow of this wonderful journey. 
 
Last but not least, give thanks to our Lord for His abundant love and blessing to me!  





TABLE OF CONTENTS  
ACKNOWLEDGEMENTS I 
TABLE OF CONTENTS II 
SUMMARY VI 
PUBLICATIONS VIII 
LIST OF TABLES X 
LIST OF FIGURES XI 
LIST OF ABBREVIATIONS XV 
CHAPTER 1   INTRODUCTION 1 
1.1 Breast cancer 1 
1.1.1 Incidence of breast cancer 1 
1.1.2 Classification of breast cancer 3 
1.1.3 Aetiology of breast cancer 6 
1.2 HER-2/neu-positive breast cancer 8 
1.2.1 Definition 8 
1.2.2 Clinical significance of HER-2/neu as a prognostic indicator in breast cancer 11 
1.2.3 Diagnosis of HER-2/neu-positive breast cancer 13 
1.2.4 Signalling networks regulated by HER-2/neu 20 
1.2.5 Therapeutic interventions in HER-2/neu-positive breast cancer patients 22 
1.2.6 Current findings of HER-2/neu-linked studies 24 
1.3 Protein post-translational modifications 29 
1.3.1 Definition 29 
1.3.2 Protein phosphorylation and the role of protein kinases 30 
1.3.3 Protein  phosphorylation and the role of phosphatases 31 
1.4 Protein phosphatase type 2A (PP2A) 32 
1.4.1 PP2A structure and function 32 
1.4.2 PP2A and cancer 34 





1.5 Gene silencing 36 
1.5.1 Definition 36 
1.5.2 Mechanisms of RNAi 38 
1.5.3 RNAi as a tool of analysis 40 
1.6 Rationale and objectives of this research project 41 
CHAPTER 2   MATERIALS AND METHODS 44 
2.1 Materials 44 
2.1.1 Ligand and inhibitors 44 
2.1.2 Antibodies 44 
2.1.3 Cell-lines 45 
2.1.4 Fresh frozen clinical specimens 45 
2.2 Methods 46 
2.2.1 Cell culture treatment 46 
2.2.2 Protein extraction 47 
2.2.3 Immunoblotting /Western blotting 49 
2.2.4 Human phospho-receptor tyrosine kinase (Phospho-RTK) array analysis 49 
2.2.5 Signal transduction antibody array analysis 50 
2.2.6 Immunoprecipitation 51 
2.2.7 Two-dimensional electrophoresis and immunoblotting 51 
2.2.8 Immunohistochemistry and tissue microarray 52 
2.2.9 RNA extraction 53 
2.2.10 Reverse transcription polymerase chain reaction (RT-PCR) amplification 53 
2.2.11 DNA agarose gel electrophoresis and DNA purification 54 
2.2.12 DNA sequencing 54 
2.2.13 Immunofluorescence and confocal microscopy 55 
2.2.14 Biological assays 55 
2.2.15 Statistical analysis 57 
CHAPTER 3   HRG-ENHANCED HER-2/neu SIGNALLING 59 
3.1 Overview 59 
3.2 Results 61 
3.2.1 HRG enhanced HER-2/neu phosphorylation in a dose- and time-dependent 
manner 61 
3.2.2 HRG is a specific activator of EGFR, HER-2 and HER-3 tyrosine 
phosphoryation but not other receptor tyrosine kinases 63 





3.2.3   HRG stimulates phosphorylation of the HER-2 receptor/ErbB2 and its 
downstream interacting signalling molecules 64 
3.2.4 Differential tyrosine phosphorylation profiles between the HRG-treated and 
DMSO-treated (control) BT474 cells, derived using signal transduction 
antibody arrays 65 
3.2.5 Validation of antibody array results 71 
3.3 Discussion 73 
CHAPTER 4   REGULATION OF PP2A BY HER-2/neu 77 
4.1 Overview 77 
4.2 Results 80 
4.2.1 Inhibition of HER-2/neu signalling using AG825 80 
4.2.2 HER2/neu signalling regulates tyrosine phosphorylation of PP2A 81 
4.2.3   Inhibition of PI3K/AKT, MEK/ERK and p38 MAPK pathways 83 
4.2.4 PI3K/AKT and MEK/ERK positively regulate, whereas p38 MAPK negatively 
regulates tyrosine phosphorylation of PP2A 84 
4.2.5 Stimulation of PP2A by HRG and the effects of inhibitors on tyrosine 
phosphorylation of PP2A 87 
4.3 Discussion 89 
CHAPTER 5   CORRELATION OF PP2A AND BREAST CANCER 92 
5.1 Overview 92 
5.2 Results 94 
5.2.1 pY307-PP2A was highly expressed in HER-2/neu-positive breast cancer cell 
lines 94 
5.2.2 pY307-PP2A was highly expressed in HER-2/neu-positive breast tumours 96 
5.2.3 Expression levels of pY307-PP2A correlated with breast cancer progression 97 
5.2.4 DNA sequencing of the PP2A catalytic subunit 100 
5.3 Discussion 101 
CHAPTER 6   FUNCTIONAL ROLE OF PP2A IN HER-2/neu BREAST CANCER 
CELL LINES 105 
6.1 Overview 105 





6.2 Results 107 
6.2.1 Silencing of PP2A/C using siRNA 107 
6.2.2 Silencing of PP2A/C caused a decrease in pY307-PP2A expression and 
attenuated tyrosine phosphatase activities 110 
6.2.3 Silencing of PP2A/C led to a slight increase of the sub G1 phase in the cell 
cycle 112 
6.2.4 Silencing of PP2A/C facilitated cell apoptosis 113 
6.2.5 Silencing of PP2A/C caused cell apoptosis via the p38 MAPK/Hsp27 signalling 
pathway 117 
6.3 Discussion 119 
CHAPTER 7   GENERAL DISCUSSION AND CONCLUSION 124 
7.1 The significance of deciphering the role of tyrosine phosphorylation in             
HER-2/neu breast cancer cells 124 
7.2 Antibody array-based technologies for cancer protein profiling and  
functional proteomics analyses 126 
7.3 PP2A as a tumour suppressor or proto-oncogene? 128 
7.4 The role of PP2A in HER-2/neu-overexpressing breast cancer 131 
7.5 Use of siRNA in cancer therapy 132 
7.6 Conclusion 134 
7.7 Future works 135 
REFERENCES   137 
APPENDICES 162 






HER-2/neu is an established adverse prognostic factor of breast cancer. Patients with 
tumours overexpressing HER-2/neu have significantly shortened overall survival. 
Studying the mechanisms by which HER-2/neu overexpression translate into the more 
aggressive biological phenotype would not only provide a better understanding of the 
increased virulence of breast cancers overexpressing this oncogene but may also lead to 
rational targeted therapeutic strategies to arrest cancer growth.  
 
Activation of HER-2/neu leads to activation or suppression of multiple signalling 
cascades and plays a vital role in cell survival and growth. A signal transduction antibody 
array was used in this study to characterize the tyrosine phosphorylation profiles in 
heregulin (HRG)-treated BT474 breast cancer cells.A group of 80 molecules in which 
tyrosine phosphorylation was highly regulated by HRG-enhanced HER-2/neu signalling 
was identified. These phosphoproteins included many known HER-2/neu-regulated 
molecules (e.g., Shc, AKT, Syk and Stat1) and proteins that had not been previously 
linked to HER-2/neu signalling, such as Fas-associated death domain protein (FADD), 
apoptosis repressor with CARD domain (ARC), and protein phosphatase type 2A 
(PP2A).  
 
Pharmacological inhibition with the HER-2/neu inhibitor AG825, PI3K inhibitor 
LY294002, MEK1/2 inhibitor PD98095, and p38 MAPK inhibitor SB203580, confirmed 
that PP2A phosphorylation was modulated by the complicated, HER-2/neu-driven 
downstream signalling network, with the PI3K and MEK1/2 positively, while the p38 
MAPK negatively, regulating its tyrosine phosphorylation.  





In breast tumour specimens and cell lines, expression of tyrosine307-phosphorylated PP2A 
(pY307-PP2A) was highly increased in the HER-2/neu-positive breast tumours and cell 
lines, and significantly correlated to tumour progression, thus enhancing its potential 
prognostic value. The data in this thesis provides meaningful information in the 
elucidation of the HER-2/neu-driven tyrosine phosphorylation network, and in the 
development of phosphopeptide-related targets as prognostication indicators.  
 
PP2A, in its activated form as a phosphatase, is a tumour suppressor. However, when 
PP2A is phosphorylated at the tyrosine residue (pY307), it loses its phosphatase activity 
and becomes inactivated. A higher expression of pY307-PP2A in HER-2/neu- positive 
breast tumour samples, which was significantly correlated to tumour progression was 
reported here, and in this context, PP2A could function as a proto-oncogene.  
 
The above and subsequent findings led us to postulate that the critical role of PP2A in 
maintaining the balance between cell survival and cell death may be linked to its 
phosphorylation status at its Y307 residue. Hence,  further investigatation on the effects 
of knocking down the PP2A catalytic subunit which contains the Y307 amino acid 
residue in two HER-2/neu-positive breast cancer cell lines, BT474 and SKBR3 were 
carried out. The results showed that this caused the silenced HER-2/neu breast cancer 
cells to undergo apoptosis and furthermore, that such apoptosis was mediated by p38 
MAPK-caspase 3/ PARP activation. Understanding the role of PP2A in HER-2/neu-
positive cells might thus provide insight into new targets for breast cancer therapy.  







Publications related to this thesis: 
 
1. Wong L.L., Zhang D., Chang C.F., Koay E.S. (2010) Silencing of the PP2A catalytic    
subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis. 
Experimental Cell Research. In press (DOI number: 10.1016/j.yexcr.2010.06.007), 
PMID: 20558158. Impact factor: 3.589 
 
2. Wong L.L., Chang C.F., Koay E.S., Zhang D. (2009) Tyrosine phosphorylation of 
PP2A is regulated by HER-2 signalling and correlates with breast cancer progression. 




1. Zhang D., Wong L.L., Koay E.S. (2007) Phosphorylation of Ser78 of Hsp27 
correlated with HER-2/neu status and lymph node positivity in breast cancer. 
Molecular Cancer. 6:52. Impact factor: 4.160 
 
2. Zhang D., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., Koay E.S. (2005) Proteomics 
study reveals that proteins involved in metabolic and detoxification pathways are 
highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics. 
4(11):1686-96. Impact factor: 8.791 
 
3. Zhang D.H., Tai L.K., Wong L.L., Sethi S.K., Koay E.S. (2005) Proteomics of breast 
cancer: enhanced expression of cytokeratin19 in human epidermal growth factor 
receptor type 2 positive breast tumours. Proteomics. (7):1797-805. Impact factor: 
4.426 
 
4. Zhang D.H.*, Wong L.L.*, Tai L.K., Koay E.S., Hewitt R.E. (2005) Overexpression 
of CC3/TIP30 is associated with HER-2/neu status in breast cancer. J. Cancer Res. 
Clin. Oncol. 131(9):603-8. Impact factor: 2.261 




1. Wong L.L., Zhang D., Chang C.F., Koay E.S. Deciphering the PP2A-mediated 
signalling modulation in breast cancer. Keystone Symposia Conference. 25-30 Jan 
2009. Taos, New Mexico, USA 
 
2. Wong L.L., Zhang D., Chang C.F., Koay E.S. Tyrosine-phosphorylated signal 
modulators regulated by Heregulin-enhanced HER-2/neu signalling. HUPO 6th 
Annual World Congress. 06-10 Oct 2007. Seoul, Korea.  





3. Wong L.L., Zhang D., Chang C.F., Koay E.S. Dissecting the heregulin-regulated 
tyrosine phosphoproteome in breast cancer using antibody arrays. Joint Third 
AOHUPO and Fourth Structural Biology and Functional Genomics Conference. 4-7 
Dec 2006. Singapore. 
 
4. Wong L.L., Boo X.L., Koay E.S., Zhang D. Hsp27 phosphorylation at residue Ser78 
was regulated by HER-2/neu-p38 MAPK pathway and strongly correlated with HER-
2/neu status and lymph node positivity in breast cancer. National Health Group Annual 
Scientific Congress. 30 Sep-1 Oct 2006. Singapore 





LIST OF TABLES 
 
Table 1-1 Breast cancer incidence and mortality worldwide 
Table 1-2 Ten most frequent cancers affecting Singapore women, 2003-2007 
Table 1-3 Risk factors for breast cancer 
Table 1-4 HER-2/neu status and breast pathology 
Table 1-5 Summary of HER-2/neu tests for breast cancer 
Table 1-6 Comparison of IHC, FISH, CISH and SISH 
Table 1-7 Mutations or abnormal expression of PP2A subunits found in human 
cancers 
Table 2-1 Amount of inhibitors used for different treatments 
Table 2-2 PCR amplification steps 





















LIST OF FIGURES 
 
Figure 1-1 Number of cases with breast cancer and all cancer types in Singapore 
females 1968-2002, by 5-year period 
 
Figure 1-2 Gross anatomy of the human breast 
 
Figure 1-3 Stages of breast tumour progression 
 
Figure 1-4 Female breast cancer: age-specific incidence, 1998-2002 
 
Figure 1-5 Structure of the c-erbB2 receptor, encoded by the HER-2/neu gene 
 
Figure 1-6 IHC staining of HER-2/neu-encoded c-erbB2 receptors and the 
scoring system 
 
Figure 1-7 FISH staining of HER-2/neu gene copies 
 
Figure 1-8 CISH staining of HER-2/neu gene copies 
 
Figure 1-9 Schematic diagram of HER-2/neu signalling pathways that contribute 
to tumorigenesis 
 
Figure 1-10 Structure of PP2A 
 
Figure 1-11 Summary of the multiple ways of intracellular PP2A regulation 
 
Figure 1-12 Mechanism of RNAi 
 
Figure 3-1  HRG stimulation of HER-2/neu activation 
 
Figure 3-2 HRG is specific in its activation of EGFR, HER-2 and HER-3, as 
shown by the Human Phospho-RTK array 
 
Figure 3-3 HRG stimulated phosphorylation of HER-2 and its downstream 
interacting signalling molecules 
 
Figure 3-4 Differential tyrosine phosphorylation profiles between the HRG-
treated and DMSO-treated (control) BT474 cells, detected on signal 





transduction antibody arrays 
 
Figure 3-5 Validation of differential tyrosine phosphorylation of identified 
proteins by Western blotting 
 
Figure 4-1 Inhibition of HER-2/neu activation by AG825 
 
Figure 4-2 Regulation of tyrosine phosphorylation (pY307) of PP2A by 
HER2/neu signalling 
 
Figure 4-3 Inhibition of PI3K/AKT, MEK/ERK, and p38 MAPK pathway 
activation using their respective inhibitors 
  
Figure 4-4 Effects of different inhibitors on tyrosine phosphorylation of PP2A 
 
Figure 4-5 Stimulation of HRG and the effects of different inhibitors on tyrosine 
phosphorylation of PP2A 
 
Figure 5-1 Expression of PP2A and tyrosine-phosphorylated PP2A (pY307-
PP2A) in breast non-tumorigenic and cancer cell lines 
 
Figure 5-2 Expression of PP2A and tyrosine-phosphorylated PP2A (pY307-
PP2A) in clinical breast non-tumour and tumour specimens 
 
Figure 5-3 Representative immunohistochemical staining of pY307-PP2A on 
tissue cores in a breast tissue microarray 
 
Figure 5-4 DNA sequencing of the PP2A catalytic subunit (PP2A/C) 
 
Figure 6-1 Silencing of PP2A/C using siRNA from siGENOME SMARTpool® 
PP2A  
 
Figure 6-2 Silencing of PP2A/C reduced pY307-PP2A expression and its tyrosine 
phosphatase activity 
 
Figure 6-3 Silencing of PP2A/C caused a slight increase of the sub G1 phase in 
the cell cycle 
 
Figure 6-4 Silencing of PP2A/C caused caspase 3-dependent apoptosis 
 





Figure 6-5 Silencing of PP2A/C reduced phospho-ERK 1/2 expression and 
enhanced phospho-AKT, phospho-p38 MAPK and phospho-Hsp27 
Ser 78 expression 
 
Figure 6-6 Proposed role of PP2A in HER-2/neu signalling pathway 





LIST OF ABBREVIATIONS  
 
2-DE  2-dimensional electrophoresis 
5-HT  5-hydroxytryptamine 
ADH  Atypical ductal hyperplasia 
Ago  Argonaute 
AKT  Protein kinase B 
Alg-2  Alpha-1, 3-mannosyltransferase 
ALH  Atypical lobular hyperplasia  
APC  Adenomatosis polyposis coli 
ARC  Apoptosis repressor with CARD domain protein 
ATCC  American Type Culture Collection 
ATP  Adenosine triphosphate 
BAD   BCL-2 associated death promoter 
BCL-2  B-cell lymphoma 2 
BPE  Bovine pituitary extract 
BRCA  Breast cancer susceptibility protein 
BSA  Bovine serum albumin 
CDC25A Cell division cycle 25 homolog A 
Cdk  Cyclin-dependent kinase 
cDNA  Complementary DNA 
CEP17  Chromosome 17 centromere 
CHAPS 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate 
CISH  Chromogenic in situ hybridization 
CLA  Conjugated linoleic acid 
COX-2 Cyclooxygenase-2 
CXCR4 Chemokine receptor 
DAB  3, 3’ Diaminobenzidine 
DCIS  Ductal carcinoma in situ 
Dicer  dsRNA-specific RNAse III family ribonuclease 
DMEM Dulbecco’s modified Eagle medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
dUTP  2´-Deoxyuridine, 5´-Triphosphate 
dsRNA Double stranded RNA 
EDTA  Ethylenediaminetetraacetic acid 
EGFR  Epidermal growth factor receptor 
ELISA  Enzyme-linked immunosorbent assay 
ER  Estrogen receptor 
ETS  E26 transformation specific  
FADD  FAS-associated death domain protein 
FAK   Focal adhesion kinase-1 
FBS  Fetal bovine serum 





FDA  Food and Drug Administration (USA) 
FISH  Fluorescence in situ hybridization 
GTPase Guanosine triphosphate hydrolase enzyme 
HUT  Hyperplasia of usual type 
H&E  Hematoxylin and eosin 
HER-2/neu Human epidermal growth factor receptor type 2 
hpRNAs Hairpin RNAs 
HRG  Heregulin 
HRP  Horseradish peroxidase 
Hsp  Heat shock protein 
hTERT Telomerase reverse transcriptase 
IDC  Invasive ductal carcinoma 
IHC  Immunohistochemistry 
IgG  Immunoglobulin G 
ILC  Invasive lobular carcinoma 
IMAC  Immobilized metal ion/metal chelate affinity chromatography 
IPG  Immobilized pH gradient 
LCIS  Lobular carcinoma in situ 
LCMS  Liquid chromatography mass spectrometry 
MAPK  Mitogen-activated protein kinase 
MEGM Mammary epithelial cell complete medium 
miRNA MicroRNA 
mRNA  messenger ribonucleic acid 
MUC4  Mucin-4 
Myc  Myelocytomatosis viral oncogene homolog (avian) 
OA  Okadaic acid 
PAR  Partition protein 6 
PARP  Poly (ADP-ribose) polymerase  
PDCD-6  Programmed cell death protein 6 
PDGFR Platelet-derived growth factor receptor 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
PI3K  Phosphatidylinositol 3-kinase 
PKC  Protein kinase C 
PLC  Phospholipase C 
PPP  Phosphoprotein phosphatases 
PP1  Protein phosphatase 1 
PP2A  Protein phosphatase type 2A 
PTP1B  Protein tyrosine phosphatase 1B 
PTEN  Phosphatase and tensin homolog 
PTM  Protein post-translational modifications 
PVDF  Hybond-P polyvinylidene fluoride 
pYMT  Polyoma middle T 
RISC  RNA-induced silencing complex  
RNAi  RNA interference 
RTK  Receptor tyrosine kinase 





rTDT  Terminal deoxynucleotidyl transferase  
RT-PCR Reverse transcription-polymerase chain reaction 
SD  Standard deviation 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Shc  Src homology 2 domain-containing transforming protein 
SILAC  Stable isotope labeling with amino acids in cell culture 
SISH  Silver in situ hybridization 
siRNA  Small RNA 
Src  Sarcoma 
ST  Small tumour antigen 
SV40  Simian virus 40 
Syk  Src-related protein tyrosine kinases 
TBE  Tris/Borate/EDTA 
TBS-T  Tris-buffered saline containing 0.1% Tween-20 
TMA  Tissue microarray 
TNF  Tumour necrosis factor 
TUNEL Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling 
TP53  Gene coding for p53 








CHAPTER 1  
INTRODUCTION 
1.1      Breast cancer 
1.1.1 Incidence of breast cancer 
Breast cancer is the second leading cause of cancer deaths in women today after lung 
cancer and is the most common cancer among women globally (American Cancer 
Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009). 
According to the American Cancer Society, about 1.3 million women will be diagnosed 
with breast cancer annually and about 465,000 women will die from this disease.  In 
general, the incidence of breast cancer has risen about 30% in the past 25 years in 
western countries. Due to the increased early detection screening, the breast cancer rates 
are reported to be on a rising trend in many countries, on the contrary, the deaths caused 
by breast cancer is on a decreasing trajectory, presumably as a result of improved 
screening and treatment. Based on the GLOBOCAN 2002 worldwide statistics on breast 
cancer incidence, mortality and prevalence, Singapore ranked as having the highest breast 
cancer incidence and mortality rates in Asia, after the western countries (Table 1-1).  
From 1968 to 2002, Singapore experienced an almost 3-fold increase in breast cancer 
incidence and the observed dissimilarity among the different ethnic groups suggested 
ethic differences in exposure or response to certain risk factors (Sim et al., 2006). 
According to the Singapore Cancer Registry, breast cancer is the top cancer type 
affecting the women in Singapore (Table 1-2). In the past 35 years, breast cancer has 
remained the most frequent cancer among the women and an upward trend in incidence 
has continued (Figure 1-1).  





Breast Cancer Worldwide 
Breast (All ages) Incidence Deaths 
United States 101.1 19 
France 91.9 21.5 
Denmark 88.7 27.8 
Sweden 87.7 17.3 
United Kingdom 87.2 24.3 
Netherlands 86.7 27.5 
Canada 84.3 21.1 
Australia 83.2 18.4 
Switzerland 81.7 19.8 
Italy 74.4 18.9 
Singapore 48.7 15.8 
Brazil 46 14.1 
Japan 32.7 8.3 
India 19.1 10.4 
Zimbabwe 19 14.1 
China 18.7 5.5 
 
Table 1-1. Breast cancer incidence and mortality worldwide. Note: numbers are per 
100,000. Data adapted from J. Ferlay, F. Bray, P. Pisani and D.M. Parkin. GLOBOCAN 
2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, 
version 2.0. IARC Press, Lyon, 2004, with modification. 
 
 
Site Ranking No. of Cases % of all cancers 
Breast 1 6798 36.2 
Colo-rectum 2 3375 18.0 
Lung 3 1868 9.9 
Corpus Uteri 4 1332 7.1 
Ovary 5 1327 7.1 
Cervix Uteri  6 1009 5.4 
Stomach 7 885 4.7 
Skin (including melanoma) 8 840 4.5 
Lymphoma 9 698 3.7 
Thyroid 10 645 3.4 
 
Table 1-2. Ten most frequent cancers affecting Singapore women, 2003-2007. Breast 
cancer is the top cancer type affecting the women in Singapore. Data extracted from 
Singapore Cancer Registry, Interim Report: Trends in Cancer Incidence in Singapore 
2003-2007, with modification. 
 







Figure 1-1. Number of cases with breast cancer and all cancer types in Singapore 
females 1968-2002, by 5-year period. Breast cancer has remained the most frequent 
cancer among the women and an upward trend in incidence has continued over the past 
35 years. Data extracted from the Singapore Cancer Registry Report No. 6: Trends in 
Cancer Incidence in Singapore 1968-2002, with modification. 
 
1.1.2 Classification of breast cancer 
The breasts are fascinating organs that are composed of fatty tissue that contains the 
glands responsible for milk production in late pregnancy and after childbirth. Within each 
breast, there are about 15 to 25 lobes formed by groups of lobules which are the milk 
glands. Each lobule is composed of grape-like clusters of acini (also called alveoli), the 
hollow sacs that make and hold breast milk. The lobules are arranged around the ducts 
that funnel milk to the nipples. About 15 to 20 ducts come together near the areola (dark, 
circular area around the nipple) to form ampullae – dilated ducts where milk accumulate 
before it reaches the nipple surface (Figure 1-2). 




                    
Figure 1-2. Gross anatomy of the human breast. Figure was adapted with permission 
from http://www.cancer.gov/cancertopics/wyntk/breast/page2, last accessed on 10 June 
2010. 
 
Breast cancer occurs when the cells start to grow abnormally. It is a complex and 
heterogeneous disease, comprising a myriad of tumour entities associated with distinctive 
histological patterns and different biological features and clinical behaviours. 
Histological aspects of breast cancer taxonomy have been described in the literature. In 
general, the tumour progression occurs in a sequence of defined stages. The primary 
lesion of neoplastic breast disease could arise from either the ducts or the lobular region 
of the breast. The precursor for ductal breast carcinoma which is named ‘hyperplasia of 
usual type’ (HUT) will then develop into atypical ductal hyperplasia (ADH), whereas, the 
initial stage of lobular breast carcinoma is defined by atypical lobular hyperplasia (ALH). 
This could then progress into ductal carcinoma in situ or lobular carcinoma in situ (DCIS 
or LCIS). The malignant epithelial cells are enclosed in the normal ducts for DCIS and 




lobules for LCIS whose basal membrane persists intact. If undetected or untreated, DCIS 
or LCIS could advance to ductal or lobular invasive carcinoma (IDC or ILC). At this 
stage the cancer cells infiltrate through the basal membrane into the stroma (Pinder and 
Ellis, 2003; Guinebretière et al., 2005) (Figure 1-3). This ultimately leads to metastasis of 
the tumour cells to other parts of the body such as bone, liver, lung (Hasebe et al., 2008) 




Figure 1-3. Stages of breast tumour progression. A. Range of normal cells to invasive 
ductal cancer cells. B Upper panel: Normal large duct. H&E Staining x100. Its lumen is 
irregular with pseudo papillary projections, lined with a flat epithelium. Middle panel: 
Lobular carcinoma in situ. H&E Staining x400. The tumour cells have small round and 
regular nuclei. They have distended into the lumen of the acini where they are enclosed, 
without breaking through the basal membrane. Lower panel: Invasive ductal carcinoma. 
H&E Staining x200. This tumour associates an invasive component, which is responsible 
for lymph node and distant metastasis, a fibrous stroma and an in situ component where 
the largest microcalcifications are located. H&E staining inset figures were adapted with 
permission from Guinebretière, J.M., Menet, E., Tardivon, A., Cherel, P., and Vanel, D: 
Normal and pathological breast, the histological basis. Eur J Radiol 2005, 54: 6-14, with 
modification. 
 




1.1.3 Aetiology of breast cancer 
When a patient is diagnosed of breast cancer, it is natural to ask the doctor what may 
have caused the disease. Like any other forms of cancer, breast cancer is a multifactorial 
disease. Breast cancer results from molecular alterations that are genetically and/or 
environmentally induced which later on led to uncontrolled abnormal cell proliferation. A 
number of risk factors listed in Table 1-3 are allegedly associated with the development 
of breast cancer. 
Risk factors for breast cancer 
High (relatively) Low (relatively) 
Increasing age Early menarche/late menopause 
Breast cancer in a first-degree relative Elevated levels of oestrogens and androgens 
Atypical ductal or lobular hyperplasia Age at first live birth over 30 years or 
nulliparity 
Lobular carcinoma in-situ Diet and alcohol consumption 
Prior history of breast cancer Postmenopausal obesity 
BRCA1 and BRCA2 mutations Exercise 
Increasing mammographic breast density  
 
Table 1-3. Risk factors for breast cancer. Data extracted and summarized from Higa, 
G.M. Breast cancer: beyond the cutting edge. Expert Opin Pharmacother 2009, 10, 
2479-2498, with modification. 
 
 
Aside from being female, age is probably the most important risk factor of breast cancer. 
According to the data on age-specific incidence of breast cancer in Singapore 1998-2002, 
there was a notable shift of peak age-specific incidence from premenopausal (45-49 
years) in the period 1993-1997, to postmenopausal (50-55 years) in the period 1998-1999 
(Jara-Lazaro et al., 2010). The age pattern suggests that the highest age-specific 
incidence rate is occurring progressively later in life. The incidence rate continues to 
increase after the menopause and 45% of all cases occurred of women 50 years of age 
and older (Figure 1-4). 




      
Figure 1-4. Female breast cancer: age-specific incidence, 1998-2002. Data extracted 




Risk is also enhanced by a personal or family history of breast cancer and inherited 
genetic mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 (Miki et 
al., 1994; Wooster et al., 1995). Most studies on familial risk of breast cancer have found 
about two-fold relative risks for first degree relatives of affected patients. With affected 
second-degree relatives, there is a lesser increase in risk (Pharoah et al., 1997). In the 
early 1990, specific mutations were identified in both the tumour suppressor genes 
BRCA1 and BRCA2, which are responsible for familial breast and ovarian cancers.  
Although these mutations cause approximately 5-10% of all breast cancer cases, they are 
rare in the general population. Another two genes that are also known to confer high risk 
of breast cancer are TP53 and PTEN. Despite all these genes conferring a high risk, they 




account for a relatively small proportion of inherited breast cancer. HER-2/neu which 
encodes for the epidermal growth factor receptor type-2, c-erbB2, expressed on the 
surface of breast cells, is another commonly affected gene in breast cancer. Amplification 
of the HER-2/neu gene or overexpression of the HER-2/neu encoded receptor, c-erbB2, 
occurs in 20-30% of breast cancer and is associated with the more aggressive phenotype 
of breast cancer (Schnitt, 2001; Vernimmen et al., 2003). 
 
Epidemiological studies of breast cancer have established a few risk factors playing a key 
role in the causation of this disease (Key et al., 2001). Other evidences such as increased 
exposure to oestrogens, early menarche, late menopause, obesity in postmenopausal 
women, oral contraceptives, hormonal therapy and alcohol consumption have also been 
shown to increase the risk of breast cancer. Breastfeeding, childbearing, regular exercise 
and low fat diet are associated with a lower risk of breast cancer. 
 
1.2      HER-2/neu-positive breast cancer  
1.2.1 Definition 
The human epidermal growth factor receptor 2 (c-erbB2) and its encoding gene (HER-2, 
HER-2/neu) had been functionally implicated in the pathogenesis of human breast cancer 
for more than two decades and more than 10,000 publications are in print to study the 
role and significance of this receptor. The HER-2/neu gene was first originally identified 
in rat neuroectodermal tumours (Shih et al., 1981) and later its close human relative was 
isolated (Schechter et al., 1984). It is located on chromosome 17q21 and encodes a 185-
kDa transmembrane tyrosine kinase receptor protein that is a member of the epidermal 




growth factor receptor (EGFR) family. The HER-2/neu encoded protein, also known as c-
erbB2, contains a 95-110 kDa cysteine-rich extracellular ligand binding ectodomain, a 
hydrophobic membrane-spanning domain (3 kDa) and a short juxtamembrane segment, 
and an intracellular tyrosine kinase domain (70-90 kDa) linked to a carboxyl (C)-terminal 






                                  





Figure 1-5. Structure of the c-erbB2 receptor, encoded by the HER-2/neu gene. The 
c-erbB2 receptor consists of extracellular ligand-binding domain with two cysteine-rich 
regions, a hydrophobic short transmembrane domain, and an intracellular domain that 
contains a catalytic tyrosine kinase domain and a carboxyl terminal tail.  Numerous sites 
of tyrosine phosphorylation within the tyrosine kinase and carboxyl terminal domains are 
indicated by circled P. The letters on the right point to specific areas that are altered or 
mutated in certain naturally occurring or experimentally induced cancers. (A) Site of 
somatic mutations found in tumours arising in MMTV-neu mice. (B) Site of the 48 bp 
deletion in the naturally occurring human ∆HER2 isoform. (C) Site of the mutation in the 
neuT oncogene initially discovered in a rat carcinogen-induced tumour model and 
subsequently used in numerous in vitro and transgenic experimental models. (D) Site of 
mutations found in rare cases of human lung cancers. Figure was adapted with permission 
from MM Moasser: The oncogene HER2: its signalling and transforming functions and 








To date, no known ligand(s) for the c-erbB2 receptor has yet been identified. Like other 
RTKs, upon ligand binding to their extracellular domain, the receptor undergoes 
heterodimerization with either HER-1 (Pinkas-Kramarski et al., 1996; Pinkas-Kramarski 
et al., 1997) or HER-3 or HER-4 (Tzahar et al., 1996; Burden and Yarden, 1997; Pinkas-
Kramarski et al., 1998) that lead to autophosphorylation at its carboxyl terminal. These 
phosphorylation sites will then become docking sites responsible in translating the 
activated signals initiated into downstream physiological actions. In normal cells, the 
HER-2/neu plays a role in cell growth and differentiation. However, amplification of the 
gene that leads to overexpression of the receptor caused the development of many types 
of cancers including the breast, ovarian (Slamon et al., 1989), small subset of lung 
(Hirsch et al., 2002), certain gastrointestinal tract tumours (Khan et al., 2002, Yano et al., 
2006) and bladder (Latif et al., 2003). These patients have poor response rates as well as 
short overall and disease-free survival compared to patients whose tumours do not 
overexpress this receptor. 
 
1.2.2 Clinical significance of HER-2/neu as a prognostic indicator in breast cancer 
HER-2/neu gene amplification and/or receptor overexpression has/have been identified in 
10-34% of breast carcinoma (Schechter et al., 1984). HER-2/neu gene amplification is 
associated with increased cell proliferation, cell motility, tumour invasiveness, 
progressive regional and distant metastases, accelerated angiogenesis and reduced 
apoptosis (Moasser, 2007).  As a clinicopathological parameter, HER-2/neu-positive 
breast cancer is scored as intermediate or high histological grade, usually with the 
features of lacking estrogen receptors and progesterone receptors and exhibiting positive 




lymph node metastases. The association of HER-2/neu-positive status with specific 
pathologic conditions is summarized in Table 1-4. HER-2/neu-positive cases are usually 
associated with the higher-grade and extensive forms of DCIS. The HER-2/neu-positive 
tumour cells usually expressed more than 10- to 100- fold with up to 2 million receptors 
(Burstein, 2005) compared to the normal breast epithelial cells that have only 2 copies of 
the HER-2/neu gene and express between 20,000 and 50,000 HER-2/neu receptors 
(Lohrisch and Piccart, 2001) on the cell surface.  
Pathologic condition HER-2 status 
DCIS High-grade subtype, multifocal disease, and cases 
with comedonecrosis are positive 
ILC versus IDC ILC lower HER-2-positive rate (<10%) restricted to 
the pleomorphic ILC subtype 
Tumour grade in IDC and ILC HER-2-positive status in low-grade tumours 
extremely rare 
Paget’s disease Virtually all are HER-2-positive 
Inflammatory carcinoma No association between HER-2 status and 
inflammatory carcinoma confirmed to date 
Mucinous (colloid) carcinoma Rare HER-2-positive mucinous carcinomas pursue 
an aggressive clinical course 
Medullary carcinoma Typical are HER-2-positive 
Primary versus metastatic carcinoma A near uniform consensus of multiple published 
studies states that HER-2 status of matched primary 
and metastatic breast cancer samples maintain the 
same HER-2 status throughout the course of the 
disease in (at least) 70% to 80% of cases 
BRCA1/BRCA2 mutation-associated carcinomas Hereditary breast cancer consistently features a 
lower incidence of HER-2-positivity than sporadic 
disease 
Breast sarcomas These tumours are HER-2 negative 
Male breast carcinoma No consistent association of HER-2 status or 
response to anti-HER-2 targeted therapy fpr male 
breast cancer, the low number of cases limits 
confidence in these observations 
Benign breast conditions A near significant association with low-level HER-2 
expression in benign breast biopsies with 
subsequent development of invasive breast cancer 
has been reported 
 
Table 1-4. HER-2/neu status and breast pathology. Table extracted from Ross JS, 
Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 
receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized 
medicine. The Oncologist 2009, 14 (4):320-68, with modification. 
 




1.2.3 Diagnosis of HER-2/neu-positive breast cancer  
There are a series of morphology-driven, slide-based assays employed to detect the HER-
2/neu gene amplification and HER-2/neu protein overexpression.  The in vitro laboratory 
techniques used to diagnose HER-2/neu-positive breast tumours are categorized in Table 
1-5. Slide-based assays include immunohistochemistry (IHC), fluorescence in situ 
hybridization (FISH), chromogenic in situ hybridization (CISH) and silver in situ 
hybridization (SISH). The non slide-based assays include Southern and slot blotting, 
reverse transcription-polymerase chain reaction (RT-PCR), mRNA microarray and 
enzyme-linked immunosorbent assay (ELISA).  Among all the techniques, IHC and FISH 
are the most widely used to evaluate HER-2/neu status. 




Table 1-5. Summary of HER-2/neu tests for breast cancer. Table extracted from Ross JS, Slodkowska EA, Symmans WF, Pusztai L, 
Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized 
medicine. The Oncologist 2009, 14 (4):320-68, with modification. 
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IHC CTA Genetech 1995 Not 
submiited  







On the market √ IHC Protein Decentralized in 
clinical trial and 
labs 









On the market X IHC Protein Decentralized in 
clinical trial and 
labs 









On the market X FISH Gene Decentralized in 












Abbott Molecular 2002 Premarket 
approved 
On the market √ FISH Gene Decentralized in 












Dako 2005 Premarket 
approved 
On the market X FISH Gene Decentralized in 









Invitrogen 2008 Premarket 
approved 
On the market X FISH Gene Decentralized in 











SISH EnzMetTM Ventana Medical 
Systems 
2008 Pending In 
development 







Genomic Health 2005 Not 
approved 
On the market X RT-PCR mRNA Centralized at 
company 
NA NA 
mRNA Various 2005 Not 
approved 
Homebrews X RT-PCR mRNA Decentralized in 






























clinical trial and 
labs 
15 ng/ml NA 




IHC is performed on formalin-fixed-paraffin-embedded tissue and occasionally on frozen 
samples.  Specimens are scored as 0, 1+, 2+ and 3+, based on the staining intensity and 
3+ depicts the strongest staining intensity. In order to have a better interpretation of the 
immunostain, it is beneficial to establish a relationship between the number of receptors 
on a cell surface and the distribution and intensity of the immunostaining. This is 
achievable by using cell lines to establish a standardized IHC scoring system (Figure 1-
6). This method is fast, widely available and relatively inexpensive. However, the results 
can vary significantly between different laboratories due to the different antibodies used 
or to subjective judgment criteria in the scoring system. The IHC tests that are approved 
by U.S. Food and Drug Administration (FDA) to identify patients with HER-2/neu-
overexpressing breast cancer are the Dako Herceptest™ IHC assay (DAKO, Carpinteria, 
CA) and the Ventana Pathway™ IHC assay (Ventana, Tucson, Az) (Perez and Baweja, 
2008). 





Figure 1-6. IHC staining of HER-2/neu-encoded c-erbB2 receptors and the scoring 
system. There are four categories of IHC staining scores of HER-2/neu. Top panels 
depict 0, in which cells containing <20,000 receptors would show no staining; and 1+, in 
which cells containing approximately 100,000 receptors would show partial membrane 
staining. Bottom panels indicate 2+, in which cells containing approximately 500,000 
receptors would show moderately complete membrane staining; and 3+, in cases with 
cells containing approximately 2,300,000 receptors would show strong and complete 
membrane staining. Scoring of positives is based on the American Society Clinical 
Oncology-College of American Pathologists guidelines for HER-2/neu IHC scoring.  
Figure was extracted with permission from Ross JS, Slodkowska EA, Symmans WF, 
Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years 
of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 2009, 14 
(4):320-68, with modification. 
 
The FISH technique is a morphology-driven slide-based DNA hybridization assay using 
fluorescent probes. It tests the gene copies in tumour cells using fluorescent probes on 
formalin-fixed-paraffin-embedded tissue (Figure 1-7). HER-2/neu-positive breast cancers 
may express as many as 50-100-fold of the gene copies, compared to breast cancers 




without HER-2/neu gene amplification. FISH has a better scoring system than IHC and 
incorporates an internal control in its protocol. However, the cost of performing FISH is 
higher and it is more time-consuming as compared to IHC. Currently, most laboratories 
performing HER-2/neu testing use IHC as a screening test, with results of 0 and 1+ 
considered as negative, and 3+ scores as positive; those with 2+ scores will be considered 
as equivocal and will be further subjected to FISH for confirmation, (Tubbs et al., 2001; 
Kobayashi et al., 2002). The two FISH assays that have been approved by FDA for 
diagnostic use to identify HER-2/neu gene amplification are the Oncor/Ventana Inform™ 
FISH test and the Abbott/ Vysis PathVysion™ FISH assay (Perez and Baweja, 2008). 
       
Figure 1-7. FISH staining of HER-2/neu gene copies. Left panel shows a negative 
HER-2/neu gene amplification. Right panel shows a positive HER-2/neu gene 
amplification with fluorescent detection in nucleus (arrow). Figures were extracted with 
permission from Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES: Evaluation of HER-
2/neu oncogene status in breast tumours on tissue microarrays. Hum Pathol. 2003, 
34(4):362-8, with modification. 
 
CISH is a new method for detection of HER-2/neu expression. It uses the technology of 
FISH in situ hybridization and the chromogenic signal detection of IHC to detect HER-
2/neu gene amplification as shown in Figure 1-8. This method has emerged as a more 
practical and cost effective option compared to FISH.  




                             
Figure 1-8. CISH staining of HER-2/neu gene copies. This image depicts an invasive 
duct carcinoma with significant HER-2/neu gene amplification (arrow) determined by the 
Invitrogen Spot-Light™ CISH assay. Figure was extracted with permission from Ross JS, 
Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 
receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized 
medicine. The Oncologist 2009, 14 (4):320-68, with modification. 
 
Studies have confirmed a very high concordance between CISH and FISH, typically in 
the 97-99% range (Wixom et al., 2004; Li-Ning-T et al., 2005; Bilous et al., 2006; 
Pothos et al., 2008). In 2008, FDA approved the Spot-Light™ CISH assay (Invitrogen, 
Inc., Carlsbad, CA) for diagnostic use in identifying patients with HER-2/neu gene 
amplification. Another method that is currently under FDA review is Silver in situ 
hybridization (SISH) which employs both HER-2/neu and chromosome 17 centromere 
(CEP17) probes hybridized on separate slides (Ross et al., 2009). A comparison between 
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Table 1-6. Comparison of IHC, FISH, CISH and SISH. Data extracted and 
summarized from Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, 
Rüschoff J, van de Vijver M: Emerging technologies for assessing HER2 
amplification.Am J Clin Pathol. 2009 ;132(4):539-48, with modification. 
 
 
1.2.4 Signalling networks regulated by HER-2/neu 
HER-2/neu activation triggers a plethora of downstream second messenger signalling 
cascades and resultant crosstalk with other transmembrane signalling pathways, leading 
to diverse biological effects (Figure 1-9). Overexpression of HER-2/neu causes increased 
HER-2/neu heterodimerization with EGFR (HER-1) or HER-3. Stimulation of EGFR-
HER-2 heterodimerization, in turn, causes the HER-2/neu overexpressing cells to exhibit 
significantly prolonged activation of downstream mitogen-activated protein kinase 
(MAPK) and c-jun (Figure 1-9 I) (Karunagaran et al., 1996). Activation of HER-2/neu 
also interrupts apical-basal polarity by associating with PAR6-aPKC, and thus disrupts 
the normal epithelial organization, resulting in cell proliferation as well as protecting the 
cells against apoptosis (Figure 1-9 II) (Aranda et al., 2006; Nolan et al., 2008).  
 
Upon binding of ligands such as Heregulin (HRG) (Wallasch et al., 1995), HER-3 
heterodimerizes with HER-2/neu and induces cell transformation via activation of the 
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway, which 
subsequently induces tumorigenesis (Figure 1-9 III) (Alimandi et al., 1995; Wallasch et 




al., 1995; Ram and Ethier, 1996). Evidence from the above studies shows that HER-
2/neu and HER-3 dimers are the most active and potent signalling heterodimers. In 
addition, large numbers of the ∆HER-2 transcript, a normal byproduct of HER-2/neu 
transcription,  have been detected in breast tumours, and it has been proposed that the 
increased ∆HER-2 transcript levels found in HER-2/neu-positive breast tumours could be 
one of the driving factors towards tumorigenesis (Figure 1-9 IV) (Siegel et al., 1999; 
Castiglioni et al., 2006). Several other transcription factors that are activated by HER-
2/neu overexpression will generate gene expression profiles that are involved in cell 
proliferation and survival (Figure 1-9 V). Transcription factors that have been reported as 
direct targets of HER-2/neu are cyclooxygenase-2 (COX-2) (Subbaramaiah et al., 2002), 
E26 transformation specific transcription factor (ETS) (Shepherd et al., 2001; Goel and 
Janknecht, 2003) and the cheomokine receptor (CXCR4) (Li et al., 2004). These 
transcription factors are involved in mammary tumorigenesis and metastasis. In addition, 
heterodimers containing HER-2/neu undergo slower dissociation and endocytosis, and 
thus are more frequently recycled back to cell surface and prolonging the potent 
downstream signals (Citri and Yarden, 2006).  





Figure 1-9. Schematic diagram of HER-2/neu signalling pathways that contribute to 
tumorigenesis. I. HER-2/neu overexpression enhances the HER-2/EGFR dimerization 
and drives the cells to proliferate and invade. II. Homodimerization of HER-2 disrupts 
the cell polarity. III. Heterodimerization of HER-2/HER-3 enhances the cell proliferation, 
survival, invasion and increases intracellular metabolism. IV. Augmented HER-2/neu 
expression also results in an increase of the rare ∆HER-2/neu isoforms with more potent 
signalling characteristic. V. Several transcription factors that are induced by HER-2 
overexpressing cells result in a plethora of gene expression changes. Figure was adapted 
with permission from MM Moasser: The oncogene HER2: its signalling and 
transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26 
(45): 6469-87, with modification. 
 
1.2.5 Therapeutic interventions in HER-2/neu-positive breast cancer patients 
The intense research work on HER-2/neu in relation to breast cancer has yielded at least 
two drugs that have successfully passed clinical trials and secured FDA approval for 
treatment of patients with metastatic breast cancer that overexpress HER-2/neu. 




Trastuzumab (Herceptin®, Genentech, Inc., South San Francisco, CA) was approved by 
FDA in 1998. It is a monoclonal IgG1 class humanized murine antibody that has been 
widely used in combination with chemotherapy in patients with metastatic breast cancer. 
More recently, in 2007, Lapatinib (Tykerb®, GlaxoSmith Kline) was approved by FDA 
for use in combination with capecitabine (chemotherapy drug) for treatment of HER-
2/neu-positive metastatic breast cancer. Lapatinib is an orally available small molecule 
with dual inhibitory effects on EGFR and HER-2/neu tyrosine kinases.   
 
Trastuzumab recognizes and binds with high affinity to an epitope on the extracellular 
domain of HER-2/neu receptor (Vogel et al., 2002; Burstein et al., 2003). This antibody 
therapy has become an important therapeutic option for patients with HER-2/neu-positive 
breast cancer and is widely used for its approved indications in both the adjuvant and 
metastatic settings (Hortobagyi, 2001; Perez and Baweja, 2008; Dahabreh et al., 2008; 
Whenham et al., 2008). However, there are evidences showing that use of trastuzumab 
combined with anthracyclines (chemotherapy drug) may cause congestive heart failure 
(Tan-Chiu et al., 2005). Therefore, the use of this drug should be given only to patients 
with a low risk for cardiovascular morbidity.  
 
Lapatinib causes prolonged downregulation of tyrosine phosphorylation of EGFR and 
HER-2/neu in tumour cells (Wood et al., 2004). It binds to the intracellular domains of 
EGFR and HER-2/neu, blocking the activation of downstream MAPK signalling (Nahta 
et al., 2007). A recent study in evaluating Lapatinib as a first-line therapy in HER-2/neu-
positive metastatic breast cancer showed that this drug is effective in halting the disease 




progression. Approximately 24% of 138 patients treated with Lapatinib for 17.6 weeks 
showed an overall response with 31% deriving some clinical benefit. Furthermore, 
progression-free rates were 63 and 43% at 4 and 6 months, respectively (Gomez et al., 
2008). Treatment with Lapatinib has proven clinically active and tolerable, warranting its 
further investigation as a first-line therapy in HER-2/neu-positive breast cancer.  
 
Other drugs that are in clinical trials are perutuzumab, a monoclonal antibody that 
sterically blocks dimerization of HER-2/neu with EGFR and HER3 at different epitopes 
as compared to trastuzumab (Bernard-Marty et al., 2006); and  Neratinib, an irreversible 
pan-HER inhibitor that inhibits EGFR, HER-2/neu and HER-4 (Rabindran et al., 2004; 
Wong et al., 2009). So far, all the drugs being developed are promising despite some 
showing major adverse events such as nausea and myelosuppression. There are cases of 
patients who were not responsive to trastuzumab due to the presence of other 
glycoproteins such as mucin-4 (MUC4) that might mask the binding of trastuzumab to 
HER-2/neu (Nagy et al., 2005). Overall, the anti-cancer drugs are expensive due to the 
enormous research expenditure spent on their development. Multidrug therapy based on 
the targeted drug approach is definitely an attractive advancement in breast cancer 
treatment but it is important to ensure it is affordable, in order to benefit all patients. 
  
1.2.6 Current findings of HER-2/neu-linked studies 
Research focused on HER-2/neu has a history of more than two decades since it was first 
functionally implicated in the pathogenesis of a subtype of human breast cancer. 
However, understanding of the precise mechanism(s) by which HER-2/neu signalling 




induces tumorigenesis remains as a challenge to researchers.  
 
HER-2/neu signalling has been reported to crosslink with many other pathways. In a 
mouse model with inactive serotonin receptors (5-hydroxytryptamine, 5-HT), that 
normally regulate cardiovascular functions during embryogenesis and adulthood, 
embryonic and neonatal death were reported to be accompanied by reduction in the 
expression levels of HER-2/neu, which may have led to midgestation lethality (Nebigil et 
al., 2000). This model suggested that 5-HT receptors use the HER-2/neu signalling 
pathway for cardiac differentiation. Loss of HER-2/neu signalling in cardiac tissues was 
shown to cause dilation in cardiomyopathy in adult mice and may thus explain the 
clinical implication for the use of HER-2/neu targeted therapy (Garratt et al., 2003; 
Negro et al., 2004).  Another observation by Andrechek et al. indicated that HER-2/neu 
plays a critical role in the initial stages of mammary gland morphogenesis. The in vivo 
studies showed that ablation of HER-2/neu led to a striking ductal elongation defect and 
reduced branching in the adult mammary gland. However, targeted disruption of HER-
2/neu had little impact on the ability of these animals to lactate (Andrechek et al., 2005).  
 
Heat shock protein 90 (Hsp90) is a ubiquitously expressed molecular chaperone that 
controls the folding, assembly, intracellular disposition, and proteolytic turnover of many 
proteins. Hsp90 interacts with HER-2/neu and promotes the maturation of HER-2/neu to 
a state of competent readiness for dimerization and activation (Citri et al., 2004). Sidera 
et al. demonstrated a novel interaction between surface Hsp90 and the extracellular 
domain of HER-2/neu and further suggested the involvement of Hsp90 in heregulin-




induced HER-2/neu activation and signalling, leading to cytoskeletal rearrangement, 
essential for cell invasion (Sidera et al., 2008).  
 
The role of HER-2/neu is well known in oncogenesis due to its overexpression in tumour 
cells. Overexpression of unaltered HER-2/neu coding sequences in NIH/3T3 cells was 
shown to cause cellular transformation and tumorigenesis (Hudziak et al., 1987). In 
addition, when HER-2/neu complementary DNA was expressed in NIH/3T3 cells under 
the control of the SV40 promoter, high levels of the HER-2/neu product associated with 
malignant transformation of NIH/3T3 cells were observed in human mammary tumour 
cells that overexpressed this gene (Di Fiore et al., 1987). Overexpression of HER-2/neu 
engineered into the EGF receptor-negative cell line, NR6, displayed a highly transformed 
and tumorigenic phenotype as compared with the control cells (Chazin et al., 1992). 
These findings demonstrate the effect of overexpression of HER-2/neu in the 
development of several human malignancies. In breast cancer, overexpression of HER-
2/neu in MCF7 breast cancer cell lines resulted in enhanced HER-2/neu signalling 
through the PI3K pathway and led to tumorigenesis (Benz et al., 1992). In another study 
using the non-tumorigenic human breast cell line MCF10A, overexpression of HER-
2/neu increased cell proliferation, reduced cell apoptosis and promoted the formation of 
solid multi-acinar structures resembling early epithelial transformation (Muthuswamy et 
al., 2001). Furthermore, HER-2/neu has also been implicated in cell invasion in HER-
2/neu overexpressing human mammary epithelial (HME) cells via PI3K-dependent and 
p38 MAP kinase-dependent pathways which lead to activation of AKT, and activation of 
PKC-delta, via PI3K, and result in mediating cell invasion (Woods Ignatoski et al., 






Overexpression and/or activity of src kinases are associated with breast cancer 
progression. Src kinases are important second messengers of HER-2/neu and increases in 
their activated forms correlate with HER-2/neu positivity, high tumour grade, necrosis 
and elevated epithelial proliferation (Wilson et al., 2006). Reported evidence showed that 
src kinases may function upstream (Ishizawar et al., 2007) and downstream 
(Muthuswamy and Muller, 1995; Vadlamudi et al., 2003; Kim et al., 2005; Xu et al., 
2007) of the transforming functions of HER-2/neu and making them critical enhancers of 
HER-2/neu-driven tumorigenesis.  
 
The polarized glandular organization of epithelial cells is frequently lost during 
development of carcinomas. Homodimerization and activation of HER-2/neu also disrupt 
the apical-basal polarity by associating with Par6-aPKC, components of the Par polarity 
complex (Aranda et al., 2006). The heterodimerization of EGFR and HER-2/neu was 
found to induce cell invasion by activating PI3K, Ras/MAPK and PLCγ signalling 
pathways in HER-2/neu-positive breast cancer (Zhan et al., 2006). Numerous 
downstream signals have been reported to associate with the invasive phenotype of HER-
2/neu-positive breast cancers.  These downstream signal molecules comprise of PI3K 
(Ignatoski et al., 2000), PKCα, src, focal adhesion kinase (Benlimame et al., 2005), α4 
integrin, β4 integrin (Gambaletta et al., 2000) and transforming growth factor-β (Seton-
Rogers et al., 2004). In the cell cycle, deregulation of the G1/S phase can lead to 
uncontrolled cell proliferation. HER-2/neu overexpression in breast epithelial cells 




deregulates the G1/S phase control through upregulation of cyclin D1, E and cdk6 and 
enhance degradation of p27 (Timms et al., 2002).  
 
In addition to the crosstalk with other cell signalling pathways, HER-2/neu gene 
amplification in breast cancer tissues also leads to various genomic alterations. For 
instance, protein tyrosine phosphatase 1B (PTP1B) is often amplified in HER-2/neu 
amplified breast cancers (Tanner et al., 1996) and is required for HER-2/neu 
transformation in human breast epithelial cell. Inhibition of PTP1B delays HER-2/neu-
induced mammary tumorigenesis (Julien et al., 2007; Bentires-Alj and Neel, 2007; Arias-
Romero et al., 2009). Although the tyrosine phosphatases frequently play a negative 
feedback role in growth factor receptor signalling, the overexpression of PTP1B has led 
to a hypothesis that phosphatases play an important role in regulating cancer cell activity. 
A plausible functional link between the HER-2/neu and phosphatases may yet represent 
an additional signalling pathway. 
 
All these findings have added valuable information to the complexity of HER-2/ne- 
mediated breast cancer progression. However, there are yet more to be unraveled in order 
to have a detailed understanding of the mechanisms underpinning HER-2/neu-mediated 
signalling. This will aid in the design and development of targeted drug therapies and 
may help overcome the effects of drugs resistance currently encountered by HER-2/neu-
positive breast cancer patients.  
 
 




1.3      Protein post-translational modifications 
1.3.1 Definition 
Proteins are the building blocks from which cells are built; they also execute all cell 
functions. Proteins are translated from mRNA and undergo chemical modifications 
before becoming functional in different body cellular activities, from DNA replication 
and protein synthesis to sensory perception or the acquisition of nutrients. These 
modifications are collectively termed as post-translational modifications (PTM). It is a 
crucial process in generating the heterogeneity in proteins, which is required in the 
utilization of the same proteins for different cellular functions in different cell types.  
 
PTM occurs in two broad categories: 
1. Covalent modification of a nucleophilic amino acid side chain by an electrophilic 
fragment of a cosubstrate.  
2. Cleavage of a protein backbone at a specific peptide bond.  
The first category is by enzyme-catalyzed covalent additions of a chemical group to a 
side chain residue such as phosphorylation, methylation, glycosylation, etc. The second 
category is covalent cleavage of peptide backbones by proteases or autocatalytic cleavage 
(Walsh et al., 2005). The modified proteins coordinate with other discrete proteins and 
form small complexes that are involved in various metabolic routes. To date, there are at 
least 100 functional pathways annotated, classified and stored (Kanehisa et al., 2008; 
Matthews et al., 2009).  
 
 




1.3.2 Protein phosphorylation and the role of protein kinases 
Protein phosphorylations play an important role in signal transduction pathways and 
control many cell biological processes. The concept was proposed by Fishcer and Krebs 
in 1955, when they biochemically reconstituted the conversion of phosphorylase b  to 
phosphorylase a  in a cell-free muscle extract and showed that such reaction required 
phosphorylase kinase and ATP (Fischer and Krebs, 1955). The mammalian 
phosphoproteomes consist of phosphorSer (pS), phosphorThr (pT) and phosphoTyr (pY) 
residues. The enzymes dedicated to protein phosphorylation are among the largest class 
of PTM enzymes which is the superfamily of protein kinases termed kinome, with over 
500 members (Manning et al., 2002). Protein kinases can be categorized into two big 
groups: Ser/Thr-specific kinases and Tyr-specific kinases (Hornbeck et al., 2004; 
Ubersax and Ferrell, 2007). All kinases have a common catalytic domain that catalyses 
the transfer of the γ-phosphate group of ATP to the hydroxyl oxygen of the Ser, Thr or 
Tyr residue of the substrate (Ubersax and Ferrell, 2007; Turk, 2008). Most kinases work 
within complex networks with phosphatases and other effector proteins. For example, 
receptor tyrosine kinases such as HER-2/neu-encoded receptors dimerize upon binding of 
ligand and phosphorylate each other’s multiple Tyr sites, as described in 1.2.4. The 
downstream effectors then specifically recognize these phosphorylated sites through SH2 
domains and trigger the subsequent signal amplifications. In cancer cells, overexpression 
of kinases cause the unabated cell proliferation and thus phosphoproteomics is necessary 
to fully unveil the phosphorylation patterns and regulation of signalling networks. 
 
 




1.3.3 Protein  phosphorylation and the role of phosphatases 
The reversible phosphorylation of protein is accomplished by the opposing activities of 
kinases and phosphatases and is an essential mechanism of cell regulation. To provide a 
tight reversible and adjustable control of protein phosphorylation, there exists a similar 
complexity in the number of phosphatases (Virshup and Shenolikar, 2009). Phosphatases 
control the specific dephosphorylation of thousands of phosphoprotein substrates. Protein 
phosphatases also demonstrate a strict specificity for phosphorSer (pS), phosphorThr 
(pT) or phosphoTyr (pY) residues (Charbonneau and Tonks, 1992). The two most 
abundant and extensively studied phosphoprotein phosphatases (PPPs) are members of 
the protein phosphatase 1 (PP1) and protein phosphatase type 2A (PP2A) family. The 
catalytic subunit of the phosphatases is able to associate with a myriad of regulatory 
subunit components that determine their functional specificity. The cellular functions of 
protein phosphatases have been increasingly studied and documented over the past 
decade. A few phosphatases have been directly implicated in the aetiology of tumours. 
For example, the protein phosphatase, PTEN, was reported to be mutated or deleted in 
various cancers (Di Cristofano and Pandolfi, 2000); the dual specificities of the protein 
phosphatases, CDC25A and CDC25B, are important regulators of cell cycle progression 
and both exhibit oncogenic potential (Galaktionov et al., 1995); and PP2A, a phosphatase 
that functions to reverse the action of kinases in many signalling cascades, might be a 








1.4 Protein phosphatase type 2A (PP2A) 
1.4.1 PP2A structure and function 
PP2A is a serine/threonine phosphatase that plays a crucial role in cellular physiology. It 
is a heterotrimeric holoenzyme consisting of a structural or scaffolding A subunit 
(PP2A/A or PR65 subunit), a regulatory B subunit (PP2A/B) and a catalytic C subunit 
(PP2A/C). Each subunit plays a different role: the 36-kDa C subunit is the enzymatically 
active component; the 54-, or 55-, or 72-kDa B subunit acts as the targeting module that 
directs the enzyme to various intracellular locations and also provides distinct substrate 
specificity, and the 60-kDa A subunit appears to function primarily as a scaffolding 
protein that serves to assemble the different subunits into one holoenzyme (Figure 1-11) 
(Shi, 2009). All of these subunits come in various isoforms, so that the ABC holoenzyme 
is a structurally diverse enzyme in which a single catalytic C subunit can associate with a 
wide array of regulatory B subunits (Schönthal, 2001). The regulatory B subunit 
comprises four families: B (also known as B55 or PR55), B’ (B56 or PR61), B” 
(PR48/PR72/PR130) and B”’ (PR93/PR110). Each family consists of two to five 
isoforms: α, β, γ, δ, and ε (Shi, 2009). The finding of tyrosine phosphorylation of 
PP2A/C in response to growth stimulation and v-src transformation of fibroblasts 
provided strong evidence of PP2A activity being acutely regulated by tyrosine 
phosphorylation (Chen et al., 1992; Chen et al., 1994; Brautigan, 1995) . 
Phosphorylation at the tyrosine 307 residue (pY307-PP2A) inhibits the recruitment of the 
regulatory B subunits to the core enzyme (Longin et al., 2007). 




                         
Figure 1-10. Structure of PP2A.  Structure of the PP2A holoenzyme consists of a B 
regulatory subunit that binds to the scaffolding A subunit and C catalytic subunit. The 
highly conserved ridge is highlighted in magenta. Figure was adapted with permission  
from Shi et al.: Assembly and structure of protein phosphatase 2A. Science in China, 
Seriec C, Life Sciences  2009, 52 (2): 135-46, with modification. 
 
PP2A is highly abundant, ubiquitous and remarkably conserved. It plays an important 
role in development, cell proliferation and death, cell motility, cytoskeleton dynamics, 
cell cycle and numerous signalling pathways (Janssens and Goris, 2001; Sontag, 2001). 
The multiple ways of PP2A regulation responsible for PP2A functional specificity is 
summarized in Figure 1-12 (Sontag, 2001). 





Figure 1-11. Summary of the multiple ways of intracellular PP2A regulation. Figure 
was adapted with permission from Sontag E: Protein phosphatase 2A: the Trojan Horse 
of cellular signalling. Cellular Signalling, 2001, 13 (1): 7-16. 
 
1.4.2 PP2A and cancer 
PP2A was first suggested as a tumour suppressor based on the study using okadaic acid 
(OA), a PP2A inhibitor. Treatment of mice using OA resulted in tumour formation 
(Fujiki and Suganuma, 1993) by activating cancer promoting pathways (Schönthal, 
2001).  SV40 small tumour antigen (ST) and polyoma middle T (pyMT) induce cellular 
transformation in human cells by altering PP2A activity and displacing the regulatory B 




subunit from the holoenzyme complex (Campbell et al., 1995). pyMT appears to activate 
the MAP kinase pathway while ST stimulate AKT phosphorylation in a PP2A-dependent 
pathway and thus promoting cell survival (Rodriguez-Viciana et al., 2006; Andrabi et al., 
2007). Different PP2A subunits are found to be either mutated or aberrantly expressed in 
a number of malignancies as shown in Table 1-7 (Perrotti and Neviani, 2008).  
Subunit Genetic and/or functional alteration Malignancy 
PP2AB56γ Aberrant expression Metastaic melanoma cells 
PP2AAβ Somatic mutations Lung tumor; Colorectal carcinoma; 
Breast cancer 
PP2AAβ Deletion; alternative splicing; 
downregulation 
B-CLL 
PP2AABC Loss of phosphatase activity through 
the inhibitor SET 
CML-BC 
PP2AABC Loss of phosphatase activity through 
the inhibitor SET 
Ph(+)B-ALL 




Table 1-7. Mutations or abnormal expression of PP2A subunits found in human 
cancers. Figure was adapted with permission from Perrotti et al.: Protein phosphatase 
2A (PP2A), a druggable tumour suppressor in Ph1 (+) leukemias. Cancer Metastasis 
Rev,  2008, 27 (2): 159-68, with modification. 
 
The PP2A/B has been found to be overexpressed or truncated in metastatic melanoma 
and due to the impaired PP2A in dephosphorylating focal adhesion protein, this led to 
cell invasion (Francia et al., 1999; Ito et al., 2000). Recent findings also reported the 
involvement of PP2A/B in Wnt/β-catenin signalling and MAPK pathways (Eichhorn et 
al., 2009), that elicited caspase-dependent apoptosis. Due to the diversified PP2A/B 
interactions with many targets such as c-myc (Arnold and Sears, 2006), anti-apoptotic 
protein BCL-2 (Ruvolo et al., 2002), pro-apoptotic protein BAD (Chiang et al., 2003) 
and p53 (Li et al., 2007), it is therefore not surprising that abnormal expression of 
PP2A/B can cause cell metastasis and transformation and that PP2A is suggested as a 




putative tumour suppressor.  
 
Mutation of PP2A/A isoforms were reported in lung, colorectal and breast cancers (Wang 
et al., 1998; Ruediger et al., 2001; Esplin et al., 2006). The loss of function of PP2A/A 
cooperates with the expression of the large-T antigens, hTERT and H-RAS, to transform 
human cells (Sablina et al., 2007). PP2A/A also interacts with GTPase RalA, a regulator 
of membrane transport, apoptosis, transcription cell migration and cell proliferation. Loss 
of PP2A/A causes hyperphosphorylation of RalA that leads to tumour formation (Sablina 
et al., 2007).  
 
Due to the complexity of the role of PP2A in cellular behaviour, deregulation of any of 
its subunits can affect its holoenzyme functions. The individual roles of PP2A subunits in 
cancer and their specific roles in signalling pathways can be further dissected using gene 
knockdown technology. 
 
1.5      Gene silencing 
1.5.1 Definition 
RNA interference (RNAi) is a process of sequence-specific, post-translational gene 
silencing induced by double-stranded RNA (dsRNA), resulting in null or hypomorphic 
phenotypes. This phenomenon was first observed by Fire and Mello et al. in the 
nematode Caenorhabditis elegans (C. elegans). They proposed that it is the presence of 
dsRNA that is responsible for producing the interfering activity (Fire et al., 1998) and a 
Nobel prize in medicine was awarded to them in 2006 for this discovery. Methods that 




exploit RNAi mechanisms have since been developing rapidly and scientists employ it as 
a research tool to elucidate the functions and interactions of mammalian genes.   
 
The characteristics of RNAi are as follows: 
 it is highly specific to the targeted gene of interest 
 it is remarkably potent as only a few dsRNA molecules per cell can induce a 
robust response (Mello and Conte, 2004) 
 the interfering activity (and presumably the dsRNA) can cause interference in 
cells and tissues far removed from the site of introduction  
 
The canonical inducer dsRNA is introduced directly into the cytoplasm or taken up 
exogenously from the environment (Mello and Conte, 2004) before being processed into 
siRNAs that directly silence the gene. siRNAs were originally observed in transgene- and 
virus-induced silencing plants that play a role in natural genome defense (Mello and 
Conte, 2004). Shortly thereafter, functional studies of siRNA in plants led to the 
discovery of trans-acting siRNAs that are diced from specific genomic transcripts and 
function to regulate discrete sets of genes (Vazquez et al., 2004; Allen et al., 2005). 
Recently, endogenous sources of siRNA such as convergent mRNA transcripts and other 
natural sense-antisense pairs, duplexes involving pseudogene-derived antisense 
transcripts and the sense mRNA from their cognate genes as well as hairpin RNAs 
(hpRNAs) were identified (Golden et al., 2008). 
 
 




1.5.2 Mechanisms of RNAi 
There are two subgroups of post-translational gene-silencing small RNAs: siRNAs and 
microRNAs (miRNAs). siRNAs exist in both mammalians (Svoboda et al., 2004; 
Watanabe et al., 2006) and lower eukaryotes (Ketting et al., 1999; Tabara et al., 1999), 
while miRNAs have been found only in mammalians but not in lower eukaryotes. RNAi 
processes occur at two stages: initiation and effector stages (Ashihara et al., 2010). In the 
initiation stage, dsRNA is introduced exogenously or endogenously into the target cells 
and is processed into shorter-length dsRNAs (of 21-23 nucleotides), termed siRNAs, by 
the ribonuclease activity of the dsDNA-specific RNAse III family ribonuclease, Dicer 
(Bernstein et al., 2001). In the effector stage, the siRNAs then enter into an RNA-induced 
silencing complex (RISC) assembly pathway (Hammond et al., 2000) that involves 
duplex unwinding, culminating in the stable association of only one of the two strands 
with the Argonaute (Ago) effector protein (Meister and Tuschl, 2004; Meister et al., 
2005; Tomari and Zamore, 2005; Carthew and Sontheimer, 2009). The antisense strand, 
also called the guide strand, is selected by the Ago2 protein and will bind to the 
sequence-specific base pairs of its mRNA target and will direct the silencing. The sense 
strand or also known as the passenger strand, is then degraded (Matranga et al., 2005). 
The antisense strand will then cleave the targeted mRNA, resulting in the decreased 
expression of the target gene (Figure 1-13).  





Figure 1-12. Mechanism of RNAi. The dsRNA is introduced into the cells and 
processed into siRNA lengths of 21-23 nucleotides by Dicer. siRNA then enters the RISC 
assembly pathway and unwinds into two single strands of RNA. The sense or passenger 
strand is rapidly degraded whereas the antisense or guide strand binds to the target 
mRNA and causes the target mRNA to degrade. Figure was sourced from Ashihara E et 
al.: Future prospects of RNA interference for cancer therapies. Current Drug Targets 
2010, 11 (3): 345-60, with modification.  
 
 




1.5.3 RNAi as a tool of analysis 
The discovery of RNAi proffers the power of performing loss-of-function testing in 
mammalian cells and leads to elucidatation of gene functions on an unprecedented scale. 
Several libraries of siRNA are available commercially, through collaboration or in-house 
production. Even limited scale RNAi screenings in druggable targets (Lee et al., 2009) or 
in protein kinases and oncology targets (Quon and Kassner, 2009) are yielding important 
information regarding intermediary pathways and cellular responses to therapeutics and 
other treatments. 
 
Due to the high specificity and efficiency of the RNAi technology, it has been recently 
evaluated as a potential therapeutic strategy for cancer treatment. Targeted genes such as 
antiapoptotic proteins, cell cycle regulators, transcription factors, signal transduction 
proteins and oncogenes are all targets of RNAi technology as many of them are 
associated with poor prognosis in cancer patients. A few research groups have recently 
demonstrated the success of using siRNA treatment as cancer therapy in a xenograft 
mouse model (Yano et al., 2004; Fu et al., 2005; Sonoke et al., 2008). These studies have 
demonstrated that siRNA treatment against antiapoptotic Bcl-2 proteins inhibited the 
tumour cell proliferation. Synthetic Bcl-2 siRNA was administered using a cationic 
liposome and shown to suppress tumour progression in the xenograft mouse model (Yano 
et al., 2004; Fu et al., 2005; Sonoke et al., 2008). As overexpression of β-catenin was 
detected in many types of cancer, others have used siRNA against β-catenin and showed 
that this suppressed the proliferation of colon cancer cells and melanoma cells by 
activating caspase-dependent apoptosis (Verma et al., 2003; Ashihara et al., 2009). 




Likewise, similar results were obtained against the vascular endothelial growth factor 
(VEGF) receptor, which plays an important role in angiogenesis and lymphangiogenesis 
and promotes cancer cells motility and metastasis. Treatment with siRNA against VEGF 
successfully halted metastasis in breast cancer in a mouse xenograft model  (Chen et al., 
2005).  
 
RNAi remains as a powerful strategy not only to aid the researchers in understanding the 
functions of specific genes and their interacting partners, it also may offer attractive 
therapeutic options for physicians on patient treatments. 
 
1.6    Rationale and objectives of this research project 
The HER-2/neu proto-oncogene is an established adverse prognostic factor of breast 
cancer. Studying the mechanisms by which HER2/neu overexpression translate into the 
more aggressive biological behaviour manifested would not only provide a better 
understanding of the biological basis of the increased virulence of breast cancers 
overexpressing this oncogene but may also provide rational, target-based therapeutic 
strategies to stop the accelerated cancer growth and metastasis in this sub-group of 
patients. Despite numerous proteomics techniques having been employed to study its 
mechanisms of action, the challenges of understanding HER-2/neu activation are still to 
be met and further work is fuelled by the emergence of new biomarkers. 
 
Hypothesis: The hypothesis in this study is that HER-2/neu activation causes multiple 
phosphorylation of downstream signaling modulators that are involved in cell 




proliferation and growth, as such, in this research, the focus is  to study the 
phosphoproteomic profiles of the tyrosine phosphorylation changes initiated by HRG-
mediated HER-2/neu activation. HER2/neu activation was found to be able to cause the 
downstream phosphorylation of PP2A phosphatase, a putative tumour suppressor protein 
that is involved in many signalling pathways in mammalian cells. The PP2A/C subunit 
(more specifically, phosphorylation at its tyrosine residue pY307 residue and/or 
methylation) is known to be critical in regulating its activity in cancer cells. Although 
much work on the association of PP2A/A and PP2A/B subunits with cancer had been 
reported (Francia et al., 1999; Ito et al., 2000;  Ruvolo et al., 2002; Chiang et al., 2003; 
Arnold and Sears, 2006; Li et al., 2007; Sablina et al., 2007), the precise role of PP2A/C 
in breast cancer remained to be studied in detail. We aimed to fill in some of the gaps in 
this area. 
 
The bigger aims of the ongoing PP2A-related research  are to elucidate the HER-2/neu-
driven tyrosine phosphorylation network and to identify some putative phosphopeptide 
targets as new prognostic markers. Thus, the aim of this thesis project is to further to test 
on the hypothesis that one of the identified proteins, PP2A/C, plays a critical role in 
HER-2/neu-mediated breast tumorigenesis. An interactive functional relationship 
between HER2/neu and PP2A/C in several breast cancer cell-lines was investigated, and  
its findings were reported herein.  
 
The specific aims of this thesis are:  
1. To identify the differential tyrosine phosphorylation of various signal modulators 




activated by HRG mediated HER-2/neu signalling using an antibody array.   
 
2. To verify the selected identified protein using 1D and 2D immunoblotting methods. 
This will confirm the antibody array results. 
 
3. To study the role of HER-2/neu signalling in the regulation of PP2A phosphorylation. 
 
4. To further examine if there is any differential expression of PP2A and pY307-PP2A 
in both breast non-tumorigenic cancer cell lines as well as clinical samples. 
 
5. To investigate the resultant consequences of PP2A/C knockdown on cellular 
behaviour in HER-2/neu-positive breast cancer cells and its downstream signalling 
cascade. 
 
Understanding the mechanisms underlying HER-2/neu tumorigenesis and metastasis, and 
whether there is differential involvement of various critical pathways in the more 
aggressive HER-2/neu positive breast cancer patients, will provide significant insights 
into the biology of breast cancer progression. More importantly, these insights may 
inform on chemo-preventive measures. 




CHAPTER 2  
MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Ligand and inhibitors 
Heregulin α1 (HRG), a ligand of HER-3 and HER-2/neu, was from Neomarkers 
(Fremont, CA, USA). LY294002, a specific inhibitor of the p110 catalytic subunit of 
PI3K; AG825, a specific inhibitor of HER-2/neu tyrosine kinase, and SB203580, a 
specific inhibitor of p38 MAPK, were purchased from Calbiochem (San Diego, CA, 
USA). PD98059, a specific inhibitor of MEK, was from USBiological (Swampscott, MA, 
USA). All the inhibitors were dissolved in dimethyl sulfoxide (DMSO) and stored at -
200C in the dark as stock solutions until use.  
 
2.1.2 Antibodies 
The following antibodies were used for immunoblot analysis: rabbit anti-phospho-HER-
2/neu (Tyr1248) (1:1000), mouse anti-ERK1/2 (1:1000), rabbit anti-phospho-ERK1/2 
(1:500), rabbit anti-ARC (1:200), rabbit anti-FADD (1:200), rabbit anti-N-Shc (1:1000), 
rabbit anti-phospho-Shc (Tyr239/240) (1:200), rabbit anti-PP2A (1:200), rabbit anti-
phospho-PP2A (Tyr307) (1:1000), mouse anti-Stat1 (1:200), and rabbit anti-phospho-
Stat1 (Tyr701) (1:200), mouse anti-Hsp27( 1:5000) and rabbit anti-Hsp27 Ser78 (1:200) 
were obtained from Santa Cruz Biotechnology, Inc. (CA, USA). Rabbit anti-PP2A 
(1:1000) and rabbit anti-PP2A (Tyr307) (1:1000) were procured from Epitomics Inc. 
(CA, USA). Mouse anti-phosphotyrosine 4G10 (1:1000) was purchased from Upstate 
Biotechnology Inc. (Lake Placid, NY, USA). Mouse anti-HER-2/neu (1:1000) was 




obtained from Neomarkers (Fremont, CA, USA). Mouse anti-Ezrin (1:100) was bought 
from BD Biosciences PharMingen (San Diego, CA, USA) and horseradish peroxidase 
(HRP)-conjugated phosphotyrosine (1:1000) was procured from Hypromatrix 
(Worcester, MA, USA). Mouse anti β-actin  was purchased from Sigma-Aldrich (MO, 
USA) and  rabbit anti-caspase 3, rabbit anti-PARP, rabbit anti-AKT, rabbit anti-AKT 
(Ser473), rabbit anti-p38 MAPK, rabbit anti-p38 MAPK (Tyr182/Thr180) were obtained 
from Cell Signalling Technology (MA, USA).  
 
2.1.3 Cell-lines  
All cell lines used in this research project were purchased from the American Type 
Culture Collection (ATCC, VA, USA). The human HER-2/neu-positive BT474 and 
SKBR3 breast cancer cell lines were grown in Dulbecco’s modified eagle medium 
(DMEM) and McCoy’s 5A medium respectively supplemented with 10% fetal bovine 
serum (FBS, GIBCO); the human non-tumorigenic MCF12A mammary epithelial cell 
lines were grown in mammary epithelial cell complete medium (MEGM), supplemented 
with bovine pituitary extract (BPE). All the cells lines were grown at 37oC in a 
humidified 5% CO2 incubator.  
 
2.1.4 Fresh frozen clinical specimens 
Six HER-2/neu-positive, and five HER-2/neu-negative frozen breast tumours and nine 
frozen non-tumour tissues were obtained from the Tissue Repository, National University 
Hospital (Singapore). All the breast tumours and matched normal tissues were obtained 
with patients’ consent and complied with the regulations set by the Institutional Review 








2.2.1 Cell culture treatment  
I. Treatment with HRG and optimization 
For HRG stimulation, BT474 cells (70~80% confluence) were serum-starved for 20 h 
and the amount of HRG used was optimized (final concentration: 3 nM) and added into 
the culture medium. Cells were then incubated for the indicated time periods (5, 10, 30 
and 60 min). Cells treated with an equal volume of DMSO were used as control. Each 
experiment was carried out in triplicates and the optimization for HRG used was accessed 
by Western blotting analysis. 
 
II. Treatment with inhibitors 
For the inhibitor treatment (with AG825, SB203580, PD98059 and LY294002), the 
BT474 cells (at 70~80% confluence) were fed with fresh medium, supplemented with 
different individual inhibitors at the indicated concentrations in Table 2-1, for 10 and 30 
min. Cells were then harvested for Western blotting. For the cell treatment with both 
HRG and inhibitors, serum-starved cells were induced with HRG for 30 min, followed by 
treating with different inhibitors in the presence of HRG, or followed by inhibitor 
treatment after removing HRG, for 10 and 30 min. Cells treated with an equal volume of 
DMSO were used as control. Each treatment was performed in triplicates and each 
treatment was repeated thrice. 




Inhibitors Targeted Pathway Amount used 
AG825 HER-2/neu  Tyrosine Kinase 100 µM 
SB203580 p38 MAPK 40 µM 
PD98059 MEK 10 µM 
LY294002 PI3K 10 µM 
 
Table 2-1. Amount of inhibitors used for different treatments. 
 
III. Treatment with siRNA 
The siGENOME SMARTpool® PP2A (M-003598), alpha isoform (siPP2A/Cα) 
(NM_002715) from Dharmacon, Inc. (Thermo Fisher Scientific, CO, USA), was used to 
specifically knock down the PP2A/C alpha gene in the breast cancer cell lines. Non-
specific control pool from Dharmacon, Inc. was used as the scrambled siRNA control. 2 
X 105 cells were seeded in a 6-well plate one day prior to transfection. For each well, the 
siRNA stock was diluted in the appropriate amount of Opti-MEM®I reduced serum 
medium and the cells were transfected with LipofectAMINETM 2000 (Invitrogen, CA, 
USA), according to the manufacturer’s instructions. Cells were incubated at 37oC in a 
CO2 incubator for 24-72 h and the effect of gene silencing was analysed by immunoblots. 
 
2.2.2 Protein extraction  
I. Total cell lysates 
To prepare cell lysates, cells were collected after trypsin treatment and washed three 
times with ice-cold phosphate-buffered saline (PBS, pH 7.4). Cells were then 
resuspended in cold RIPA buffer (1% Igepal, 1% sodium deoxycholate, 0.15 M sodium 




chloride, 0.01 M sodium phosphate, pH 7.2, and 2 mM EDTA) supplemented with 
protease inhibitors (Roche Diagnostics, Indianapolis, IN) and phosphatase cocktail 
inhibitors I and II (1:100; Sigma-Aldrich, Steinheim, Germany), and kept on ice for 30 
min. Cell lysates were then centrifuged at 4oC and the supernatants were collected. 
Protein concentrations were determined using the Coomassie Plus Bradford assay 
(Pierce, Rockford, IL).  
 
II. Fresh frozen tumour tissues  
Frozen aliquots of pre-selected tumour tissues were immersed in liquid nitrogen and 
ground into powder form with a pestle and mortar. The cells were lysed in 250–350 µl of 
lysis buffer (Reagent 1) from the Sequential Extraction Kit (Bio-Rad, Hercules, CA), 
supplemented with 1U of DNase and protease inhibitor cocktails (Complete Mini, 
Roche). The sample mixtures were incubated on ice, vortexed vigorously every 10 min 
for 1 h and centrifuged for 20 min at 16 000 x g, 4°C to remove the cell debris. The 
supernatant was transferred into a new tube and 100% acetone was added to the 
supernatant at four times sample volume and incubated overnight at -20°C for protein 
precipitation. The precipitated proteins were washed two times with acetone: water (4:1) 
before 80-150 µl of sample solution containing 8 M Urea, 4% CHAPS, 60 mM DTT and 
2% IPG buffer (pH 3-10) was added. The actual volume added being adjusted according 








2.2.3 Immunoblotting /Western blotting 
Proteins were separated on 10-12% SDS-PAGE gels using Mini-PROTEAN 3 
Electrophoresis Cells (Bio-Rad, Hercules, CA, USA) at 70 V for 30 min and 85 V until 
the dye front reached the edge of the gel. The proteins were then transferred onto 
Hybond-P Polyvinylidene Fluoride (PVDF) membrane (GE Healthcare, Uppsala, 
Sweden) using the wet transfer apparatus (Bio-Rad, Hercules, CA) at 110V for 1hr. The 
membrane was blocked with 5% non-fat milk (Santa Cruz Biotechnology, Inc., CA, 
USA) in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) and incubated 
overnight with respective antibodies to be tested at 4ºC. Secondary antibodies – the HRP-
conjugated goat anti-mouse IgG (Molecular Probes, Invitrogen, Oregon, USA) at 1:5000 
dilutions in TBS-T or HRP-conjugated goat anti-rabbit IgG (ZYMED Laboratories Inc. 
San Francisco, CA, USA) at 1: 10 000 dilutions in TBS-T were applied for 1 h after 
washing off any unbound primary antibodies. The chemiluminescent signals were 
detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, 
USA). Signals were then captured with the MULTI GENIUS BioImaging System 
(Syngene, Frederick, MD, USA) and the signal intensities were analyzed using the 
GeneTools software (Syngene, Frederick, MD, USA). The same membrane was reprobed 
with antibody for β-actin to control for protein loading and transfer. 
 
2.2.4 Human phospho-receptor tyrosine kinase (Phospho-RTK) array analysis 
The serum-starved BT474 cells treated with HRG or with DMSO were rinsed with PBS 
before adding the NP-40 Lysis buffer. The lysates were gently rock at 2-8oC for 30 min 
and microfuged at 14,000 x g for 5 min. The extracted proteins concentrations were 




determined using the Coomassie Plus Bradford assay (Pierce, Rockford, IL, USA). 300 
µg of extracted protein was used for the human phospho-receptor tyrosine kinase 
(Phospho-RTK) array (R&D Systems, Inc., Minneapolis, MN, USA) analysis according 
to the manufacturer’s protocol. The array was blocked with Array Buffer 1 for 1 h on a 
rocking platform shaker followed by overnight incubation with the diluted lysates at 4oC 
overnight. After washing, the anti-phospho-tyrosine-HRP conjugated antibody was 
applied on the array for 2 h at room temperature with gentle agitation. The 
chemiluminescent signals were then visualized using the SuperSignal® West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA) and captured with the MULTI 
GENIUS Bio Imaging System (Syngene, Frederick, MD, USA). The signal intensity of 
each spot was analyzed using the GeneTools software (Syngene, Frederick, MD, USA).  
 
2.2.5 Signal transduction antibody array analysis 
The serum-starved BT474 cells were treated with HRG (3 nM) or with DMSO for 30 min 
and the total proteins were extracted. After the array was blocked with 5% non-fat milk in 
TBS-T for 1 h, equal amounts of proteins from both the HRG-treated and the DMSO-
treated (control) cells were diluted to 1 mg/ml and then probed with the signal 
transduction antibody array (Hypromatrix, Inc., Worcester, MA, USA), respectively, for 
2 h at room temperature, according to the manufacturer’s instructions. The arrays were 
washed with TBS-T buffer and further incubated with HRP-conjugated anti-
phosphotyrosine antibody (Hypromatrix, Inc., Worcester, MA, USA) for 2 h with gentle 
agitation. The chemiluminescent signals were then visualized using the SuperSignal® 
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) and captured with 




the MULTI GENIUS Bio Imaging System (Syngene, Frederick, MD, USA). The signal 
intensity of each spot was analyzed using the GeneTools software (Syngene, Frederick, 
MD, USA). The relative tyrosine phosphorylation level of each protein was interpreted as 
the ratio of the spot intensity in the HRG-treated sample to the spot intensity in the 
control sample. 
 
2.2.6 Immunoprecipitation  
For immunoprecipitation, 500 µg of proteins was immunoprecipitated with selective 
antibodies (anti-FADD, anti-ARC, and anti-Ezrin) at 40C and gently agitated overnight. 
Protein A-Sepharose or protein G-Sepharose (GE Healthcare, Uppsala, Sweden) was then 
added and the mixture incubated at 40C for 2 h. The agarose beads were collected, 
washed and resuspended in 50 µl of sample buffer containing 50 mM Tris-HCl, pH 7.6, 
2% SDS, 10% glycerol, 10 mM DTT and 0.2% bromophenol blue. After boiling for 5 
min, samples were cooled down on ice and analyzed by Western blotting as described in 
2.2.3.  
 
2.2.7 Two-dimensional electrophoresis and immunoblotting 
Protein separation by 2-dimensional electrophoresis (2-DE) was carried out to examine 
the phosphorylation profile of protein of interest. Briefly, 50 µg of protein was mixed 
with 125 µl of rehydration buffer (7 M urea, 2% CHAPS, 3.5 mg DTT and 1% IPG 
buffer, pH 3-10 or pH 4-7) and separated using precast Immobiline IPG DryStrip (70 
mm, pH 3-10 or pH 4-7, GE Healthcare, Uppsala, Sweden) with the EttanTM IPGphorTM 
Isoelectric Focusing System (GE Healthcare, Uppsala, Sweden). Prior to SDS-PAGE, the 




strips were then equilibrated for 20 min in equilibration buffer (50 mM Tris-HCl, pH 8.8, 
30% glycerol, 7 M Urea, 2% SDS) containing DTT (100 mg per strip), followed by 
further equilibration with the same buffer with iodoacetamide (250 mg per strip). Protein 
transfer and immunoblotting were performed and signals were detected, as described in 
2.2.3. 
 
2.2.8 Immunohistochemistry and tissue microarray 
A breast disease spectrum tissue array including 206 cases was purchased from US 
Biomax (Rockville, MD, USA). The array contained 32 metastatic carcinomas, 68 
invasive ductal carcinomas, 22 each of lobular and intraductal carcinomas, 16 normal 
tissues, and 44 other non-malignant tissues. Immunohistochemical (IHC) staining of 
pY307-PP2A was conducted using the DAKO Envision system. Briefly, sections were 
deparaffinised, rehydrated, and the antigens unmasked using the DAKO® Target 
Retrieval Solution. Endogenous peroxidases were removed using 3% hydrogen peroxide, 
followed by incubating with anti-pY307-PP2A (1:25) antibody for 1 h at room 
temperature. The sections were further treated with labelled dextran polymer conjugated 
with HRP for 30 min and incubated with DAB+-substrate chromogen solution for 5-10 
min. Sections were counterstained with Mayer’s hematoxylin and mounted. The degree 
of staining of pY307-PP2A was scored as 0 (negative to weak), 1 (moderate) and 2 
(strong), according to the staining intensity of the tumour cells. Scoring was performed 
by two pathologists and supervisor, independently. Cases with discrepant scores were re-
scored by the same or additional scorers, to obtain a consensus score, failing which the 
scores were excluded from the data analysis.  




2.2.9 RNA extraction 
RNA from both cell lines and tissue were extracted using NucleoSpin® RNA II 
(Macherey-Nagel GmbH & Co. KG, Germany) kit according to the manufacturer’s 
protocol. 20 mg of frozen aliquots of pre-selected normal and tumour paired tissues were 
ground into powder form using a pestle and mortar in the presence of liquid nitrogen. 
5x106 cultured cells trypsinized from the culture flask were washed and pelleted. Lysis 
buffer RA1 containing β-mercaptoethanol was added to both tissue and cell lines sample 
followed by filtration. Cleared lysates were passed through the provided NucleoSpin® 
RNA II Column for RNA binding followed by DNA digestion. Purified RNA was eluted 
and its concentration was determined using Nanodrop Spectrophotometer ND-1000 
(Thermo Fisher Scientific, Lafayette, CO, USA).  
 
2.2.10 Reverse transcription polymerase chain reaction (RT-PCR) amplification 
0.5 µg purified RNA template was used for first strand cDNA synthesis using RT-PCR 
System kit (Promega, WI, USA).  Reverse transcription was performed at 42oC for 1 h, 
followed by 70oC for 15 min. Second strand cDNA synthesis and PCR amplification was 
carried out as showed in Table 2-2 using Thermal Cycler GeneAmp®PCR System 9600 
(Applied Biosystems, CA, USA). 
Steps Temperature (oC) Time 
1. Initializing 94 5 min 
2. Denaturation 94* 30 s 
3. Annealing 60* 30 s 
4. Extension/Elongation 72* 30 s 




5. Final Elongation 72 7 min 
6. Final Hold 4 ∞ 
 
Table 2-2. PCR amplification steps.  *30 cycles (Steps 2-4) 
 
Primers used in the PCR were designed based on the Homo sapiens protein phosphatase 
2A, catalytic subunit, alpha isoform, mRNA (PubMed accession no: NM_002715) using 
online Primer Quest Software (Integrated DNA Technologies, Inc.). The sequence for 
both forward and reverse primers were as followed: 
 
Forward primer: 5’-TTG GTG GAT GGG CAG ATC TTC TGT-3’ 
Reverse primer: 5’-GGT GCT GGG TCA AAC TGC AAG AAA-3’ 
 
2.2.11 DNA agarose gel electrophoresis and DNA purification 
1.5% DNA agarose gel (Seakem®LE Agarose, Cambrex Bio Science Rockland, Inc., 
Rockland, ME, USA) in TBE containing 1 µl of Ethidium Bromide (10 mg/ml) was 
casted and the DNA gel electrophoresis was carried out at 90 V for 40 min to visualize 
the full length of PP2A catalytic subunit cDNA. The cDNA gel band was excised and 
purified using QIAquick Gel Extraction Kit (QIAGEN, CA, USA) according to the 
manufacturer’s protocol. 
 
2.2.12 DNA sequencing 
Purified cDNA was sequenced with the BigDye® Terminator v3.1 Cycle Sequencing Kit 




(Applied Biosystems, CA, USA). Insertions, deletions and single base mutations causing 
amino acid replacement were analyzed by comparing the sequence on the Locus ID NM-
002715 database. 
 
2.2.13 Immunofluorescence and confocal microscopy 
The cells were grown on glass coverslips and treated with siPP2A/Cα before fixation 
with 4% paraformaldehyde (Sigma-Aldrich, Steinheim, Germany) in PBS for 15 min.  
They were then washed with PBS and permeabilized with 0.1% Triton X-100 for 10 min. 
After a wash with 0.02% PBST, the cells were blocked with 3% BSA in PBST for 1 h 
followed by incubation with polyclonal rabbit-anti PP2A primary antibody (1 :50, Cell 
Signalling Technology®). The cells were then washed with 0.02% PBST followed by 
incubation with Alexa Fluor® 532 (1:1000, Invitrogen, Inc., Carlsbad, CA) for 1 h. Slides 
were mounted using the antifade mounting fluid containing DAPI and the images were 
visualized and captured using Olympus Fluoview FV500 (Olympus, Japan). Raw images 
were analyzed using the Olympus FV10-ASW Viewer Software (Olympus, Japan). 
 
2.2.14 Biological assays 
I. Tyrosine phosphatase assay 
Protein tyrosine phosphatase activity was analyzed using the Tyrosine Phosphatase Assay 
System (Promega, WI, USA), according to the manufacturer’s instructions. Both control 
and siRNA-treated cells were harvested and cell lysates were then passed through the 
Sephadex® G-25 resin spin column to remove endogenous phosphatase. The sample 
lysates collected were then incubated with or without the substrates, Tyrosine 




Phosphopeptide-1 (PP-1) and -2 (PP-2). The reaction was carried out at 30oC for 5 min, 
and then stopped by adding 50 ul Molybdate Dye/Additive mixture, and the tyrosine 
phosphatase activity was determined from its optical density at 620 nm.  
 
II. Cell apoptosis TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP 
nick end labeling) assay 
The effect of PP2A/C silencing on cell apoptosis was performed using the TUNEL assay 
according to the manufacturer’s instructions. Both the control and siRNA-treated cells 
were suspended in PBS and adjusted to 3x105 cells/ml for each slide preparation. The 
cells were then fixed in 4% paraformaldehyde (Sigma-Aldrich, MO, USA) for 25 min at 
4oC and permeabilized in 0.2% Triton X-100 for 10 min. The cells were then equilibrated 
at room temperature for 10 min followed by incubation with the Terminal 
Deoxynucleotidyl Transferase (rTdT) enzyme incorporated with Fluorescein-12-dUTP 
for 60 min at 37oC. The reaction was terminated using 2xSSC for 15 min at room 
temperature. After the washing with PBS, the samples were mounted in 
VECTASHIELD®+DAPI (Vector Laboratories, Inc, CA, USA). The samples were then 
analyzed under a fluorescence microscope (Olympus Fluoview FV500 confocal 
microscope, Japan) with the filter set to view the green rTdT-labeled apoptotic cells at 
531 nm and the blue DAPI-stained nuclei at 358 nm. Raw images were analyzed using 
the Olympus FV10-ASW 1.7 Viewer software (Olympus, Japan). The number of 
apoptotic fluorescent cells was calculated based on five randomly selected fields per 
sample. 
 




III. Caspase 3 activity assay 
Caspase 3 activity was assessed using the Caspase-Glo® 3/7 assay system (Promega, WI, 
USA), a homogenous, luminescent assay that measures both caspase 3 and 7 activities. 
Briefly, the cells were seeded in a white-walled 96-well plate and treated with siRNA. 
For each well, 100 µl of Caspase- Glo® 3/7 assay reagent was added and the mixture was 
gently mixed using a plate shaker at 400 rpm for 30 s and incubated at room temperature 
for 2 h. The wells containing culture medium served as assay blanks. Emitted 
luminescence from each sample was measured with the Tecan Infinite F200 plate-reading 
luminometer (Tecan Trading AG, Switzerland). 
 
IV. Flow cytometric analysis 
The siRNA treated cells were trypsinized and collected, followed by washing with ice-
cold PBS (pH 7.4) prior to fixation with 70% ice-cold ethanol for 1 h at 4oC. The cells 
were then suspended with 1 ml of Propidium Iodide/RNAase for 1 h at room temperature 
in the dark. The DNA content and distribution of cells in the various phases of cell cycle 
were analyzed using a flow cytometer (CyAn ADP Analyzer, Dako, Glostrup, Denmark). 
Cell cycle data analysis was performed by using the SummitTM software (Dako, Glostrup, 
Denmark). 
 
2.2.15 Statistical analysis 
The Student’s t-test was used to compare the significance of relative phosphorylation of 
each signalling molecules between controls and treated samples, as well as between 
breast cancer cell lines and non-tumorigenic cell line; and the efficiency of siRNA 




knockdown between the control and siRNA-treated cells. The difference of tyrosine-
phosphorylated PP2A (pY307-PP2A) between different types of tissues (lymph node 
metastasis, malignant, non-malignant and normal tissues) was analyzed with Fisher’s 
exact test. Two-sided p < 0.05 was considered as of significance. All the cell culture 
experiments were carried out in triplicate and repeated at least twice. All the cell-based 
functional assays were carried out at least 3 times and data were interpreted as mean ±SD 
as indicated. One-way analysis of variance or Student t-test was used to analyze the 
significance of differences. Two-tailed p<0.05 was considered significant and data are 
represented as means ± SD. 
 






HRG-ENHANCED HER-2/neu SIGNALLING 
3.1 Overview 
The HER-2/neu-encoded transmembrane protein is a member of the family of receptor 
tyrosine kinases (RTKs) (Reese and Slamon, 1997). The RTKs command central roles in 
several signal transduction pathways regulating cell proliferation, differentiation, and 
survival (Holbro et al., 2003). The ligandless HER-2 receptor has an extracellular 
domain, a transmembrane domain and a C-terminal intracellular domain. Receptor 
dimerization of HER-2 with other RTK members (EGFR/HER-1, or HER-3) induces the 
activation of its downstream signalling by autophosphorylation of tyrosine residues at its 
C-terminal sites and recruitment of other docking molecules, such as Grb2, Stat and Shc. 
The key HER-2-regulated signalling pathways include the Ras/Raf/mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) pathways, which are 
essential for cell proliferation and transformation (Grant et al., 2002). However, the 
details of the signalling network regulated by HER-2/neu, remain largely unclear. 
Dissecting the exceedingly complex protein phosphorylation and dephosphorylation 
events involved within the tumour cell microenvironment remains an area of intense 
research.  
 
Recently, a group of tyrosine-phosphorylated proteins regulated by HER-2/neu signalling 
have been identified using proteomics strategies (Mukherji et al., 2006; Bose et al., 2006; 
Friedman et al., 2007; Wolf-Yadlin et al., 2006; Kumar et al., 2007; Löbke et al., 2008). 
By profiling the tyrosine-phosphorylated proteins in HER-2/neu-overexpressing breast 
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and ovarian cancer cell lines, Mukherji et al. found that the adaptor/docking proteins, 
kinases and other proteins involved in cell proliferation and migration were highly 
tyrosine-phosphorylated and treatment with Herceptin attenuated their phosphorylation 
(Mukherji et al., 2006). In addition, several uncharacterized RNA binding proteins, e.g., 
SRRM2 and SFRS9, were also highly phosphorylated in the HER-2/neu-overexpressing 
cells (Mukherji et al., 2006).  When these cells were treated with HRG α1, an EGF-like 
growth factor, proteins such as paxillin, FAK and GIT1 were highly tyrosine-
phosphorylated and the signal network involved in cell migration was amplified (Kumar 
et al., 2007).  Bose et al. reported that inhibition of HER-2/neu signalling with the 
specific tyrosine kinase inhibitor, PD168393, led to the identification of several 
previously uncharacterized phosphoproteins, including Axl tyrosine kinase, the adaptor 
protein Fybs and the calcium-binding protein PDCD-6/Alg-2 (Bose et al., 2006). Löbke 
et al. used protein microarrays to analyze the pathway activation after stimulation with 
epidermal growth factor and HRG, or its inhibition after blocking with Gefitinib or 
Herceptin, to characterize the distinct signalling properties of the different ErbB receptor 
subtypes (Löbke et al., 2008). Thus, it is possible, with appropriate use of different 
complementary phosphoproteomics investigative methods, to dissect, identify and 
characterize the tyrosine-phosphorylated proteins in the HER-2-driven signal network 
and achieve a better understanding of the mechanisms underlying the cellular response. 
Profiling the tyrosine-phosphorylated proteome is the logical first step to elucidate the 
dynamic phosphorylation and dephosphorylation of a variety of proteins which constitute 
the complicated network controlling cellular behaviour under the influence of receptor 
tyrosine kinase signalling. 
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In this study, HRG as an activator of the HER-2/neu signalling pathway was used. HRG 
is a member of the epidermal growth factor (EGF)-like growth factor family. It modulates 
the cell proliferation and differentiation by stimulating the activation of the ErbB tyrosine 
kinase receptor (TKR) family, and thus, enhances the HER-2/neu-related signalling 
network. This HRG-induced heterodimerization of HER-2 with HER-3 is an example of  
the involvement of TKR heterodimerization in the development of human malignancies, 
at the molecular level (Wallasch et al., 1995). Li Li et al. created and used the HRG-null 
mice to demonstrate that HRG is an important mammary gland mitogen regulating 
alveolar development and lactogenesis (Li et al., 2002). To further understand the 
complex tyrosine-phosphorylation profiles of the interactive downstream proteins 
involved in the HER-2/neu signalling cascade, HER-2/neu-expressing BT474 cells were 
treated with HRG. Using an antibody array, a group of 80 signal modulators which are 
differentially tyrosine-phosphorylated by HRG-enhanced HER-2/neu signalling were 
identified. After undergoing post-translational modifications, these signal modulators are 
involved in multiple cellular functions such as apoptosis, signal transduction, 




3.2.1 HRG enhanced HER-2/neu phosphorylation in a dose- and time-dependent 
manner 
Breast cancer cells from the HER-2/neu-overexpressing BT474 cell-line were treated 
with DMSO (to serve as controls) or HRG at 3 different concentrations of HRG at 0.3 
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nM, 3.0 nM, and 5.0 nM at 2 time points (10 and 30 minutes). Activation of HER-2/neu 
signalling was measured by the extent of its phosphorylation level via Western blotting. 
As shown in Figure 3-1 A, BT474 cells responded to HRG treatment at 3.0 nM at 30 min 
with a significant increase in the phosphorylation of HER-2/neu, compared to the control. 
The cells were further treated with 3.0 nM HRG for various longer time periods, to 
observe the prolonged pattern of HER-2/neu activation by HRG. In Figure 3-1 B, HER-
2/neu activation was detected at 5 min post-HRG treatment, showing a gradual increase 
at 10 min and 30 min, when it peaked, followed by a drop of phosphorylation in 60 min. 
Therefore, for the subsequent experiments,  the optimized condition of treating the cells 
at 3.0 nM HRG for 30 minutes was applied.   
A                                                                  
B   
 
Figure 3-1. HRG stimulation of HER-2/neu activation. A. BT474 breast cancer cells at 
70-80% confluence were serum-starved for 20 h and then treated with different amount 
of HRG or DMSO (control) for 10 minutes and 30 minutes. Cells were harvested and 
phosphorylation levels were determined by Western blotting with their respective 
antibodies as described in Materials and Methods. HER-2/neu was activated by HRG in a 
dose- and time-dependent manner. B. Activation of HER-2/neu increased from 5 min 
onwards and peaked at 30 min, followed by attenuation in phosphorylation after 60 min. 
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3.2.2 HRG is a specific activator of EGFR, HER-2 and HER-3 tyrosine 
phosphoryation but not other receptor tyrosine kinases 
A human phospho-RTK array was employed to identify the relative levels of 
phosphorylation of 42 different RTKs (see Appendices: Table 1). In this array, capture 
and control antibodies had been spotted, in duplicate, on the nitrocellulose membrane. 
Cell lysates were first diluted and then incubated with the array. After binding the 
extracellular domains of both phosphorylated and unphosphorylated RTKs, unbound 
materials were washed away. A pan anti-phospho-tyrosine antibody conjugated with 
horseradish peroxidase was then used to detect the chemiluminescence signals released 
by the phosphorylated tyrosine residues of specific, activated receptors. As shown in 
Figure 3-2, BT474 cells were treated with HRG to induce the tyrosine phosphorylation of 
the ErbB receptors and the phosphorylation pattern was analyzed using the above-
described human phospho-RTK array. Phosphorylation of EGFR (or ErbB1) and ErbB3 
(or HER-3) were slightly increased upon HRG treatment compared to the control, 
whereas phosphorylation of HER-2 (or ErbB2) was significantly enhanced (more than 2-
fold) upon HRG treatment as compared to the control. No other RTKs included in the 
array were phosphorylated by HRG treatment. Therefore, HRG is a specific ligand for the 
ErbB family RTKs, involved in the specific activation of the EGFR/HER-1, HER-2 and 
HER-3 receptors only.  
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Figure 3-2. HRG is specific in its activation of EGFR, HER-2 and HER-3, as shown 
by the Human Phospho-RTK array. BT474 breast cancer cells at 70-80% confluence 
were serum-starved for 20 h and then treated with HRG (3 nM) or DMSO (control) for 30 
minutes. Cells were harvested and subjected to human phospho-RTK array analysis as 
described in Materials and Methods. HRG specifically stimulated the tyrosine 
phosphorylation of EGFR/HER-1, HER-2/ErbB2 and HER-3/ErbB3 only. 
 
3.2.3 HRG stimulates phosphorylation of the HER-2 receptor/ErbB2 and its 
downstream interacting signalling molecules                 
To examine whether the downstream interactive partners of the HER-2/neu signalling 
cascade were also activated by HRG, Western blot analysis on the known and well 
studied downstream signalling molecules of the HER-2/neu-linked signalling cascade 
such as the AKT and ERK1/2 pathways were performed. Treatment of BT474 breast 
cancer cells with HRG showed that phosphorylation of HER-2 as well as its key 
downstream modulators, AKT and ERK ½ were time dependent. As shown in Figure 3-3, 
when the cells were treated with HRG for 30 min, phosphorylation of HER-2, ERK1/2 
and AKT were highly enhanced, as determined by Western blotting with their respective 
phospho-specific antibodies. 
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Figure 3-3. HRG stimulated phosphorylation of HER-2 and its downstream 
interacting signalling molecules. BT474 breast cancer cells at 70-80% confluence were 
serum-starved for 20 h and then treated with HRG (3 nM) or DMSO (control) for 5 
minutes, 10 minutes and 30 minutes. Cells were harvested and phosphorylation of HER-
2, AKT and ERK1/2 were determined by Western blotting with their respective 
antibodies, as described in Materials and Methods. The relative phosphorylation levels of 
HER-2, ERK1/2 and AKT were normalized to their respective basal levels. Significant 
differences of treatment effects with respective controls at different time intervals were 
analyzed using the Student t-test. * p<0.05, ** p<0.01. Data represent average of 
triplicate experiments. 
 
3.2.4 Differential tyrosine phosphorylation profiles between the HRG-treated and 
DMSO-treated (control) BT474 cells, derived using signal transduction antibody 
arrays 
To investigate the tyrosine-phosphorylated molecules regulated by HER-2/neu signalling, 
the BT474 cells were treated with HRG or DMSO (as control) for 30 min and signal 
transduction antibody arrays were used to study the changes of tyrosine phosphorylation 
of different signalling modulators. The signal transduction antibody array contains 400 
antibodies (see Appendices: Table 2) that are immobilized on a membrane, each at a 
predetermined position. These antibodies recognize and capture the corresponding 
specific antigen-associated proteins. The proteins captured are then detected by 
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and detecting protein tyrosine phosphorylation. Figure 3-4 A shows the differential 
tyrosine phosphorylation patterns on the filter between the HRG-treated and control 
BT474 cells.  80 of the 400 arrayed molecules (20%) were found to show significant 
differences in the spot intensities of treated samples vs. controls. The tyrosine-
phosphorylated and dephosphorylated proteins identified are listed in Table 3-1. 
 
Functional analysis (Gene Ontology) showed that these proteins are mainly involved in 
cell apoptosis (25%), signal transduction (25%), and transcriptional activity (16%) 
(Figure 3-4. B). Not surprisingly,  several known HER-2/neu-regulated proteins, e.g. Src 
homology 2 domain-containing transforming protein (SHC), Stat-1 transcription factor, 
Src-related protein tyrosine kinases (Syk), ErbB2, and AKT, were found to be highly 
tyrosine-phosphorylated after HRG treatment, which further confirms the efficiency of 
the antibody array in dissecting the tyrosine-phosphorylated protein profiles. Most 
importantly,  a group of proteins whose tyrosine phosphorylations have not been 
previously linked to HER-2/neu signalling was also reported. For example, cell 
apoptosis-related proteins such as apoptosis repressor with CARD domain protein (ARC) 
and FAS-associated death domain protein (FADD), the cell motility-associated protein 
villin 2 (Ezrin), and protein phosphatase type 2A (PP2A), were highly tyrosine-
phosphorylated in the HRG-treated BT474 cells. Interestingly, only 2 proteins, p-EGFR 
and CD3 epsilon (Figure 3-4 A, located at K4 and C7) were found to be highly 
dephosphorylated under the HRG-enhanced HER-2/neu signalling. Collectively,   a large 
number of HER-2-regulated tyrosine-phosphorylated and -dephosphorylated signal 
proteins, including several novel signal modulators, as listed in Table 3-1, were 




         
           
 
 
Figure 3-4. Differential tyrosine phosphorylation profiles between the HRG-treated 
and DMSO-treated (control) BT474 cells, detected on signal transduction antibody 
arrays. A: Representative filters showing the differential tyrosine phosphorylation 
profiles. Serum-starved BT474 cells (70-80% confluence) were treated with HRG or 
DMSO for 30 min and equal amounts of proteins were separately incubated with two 
signal transduction arrays. An anti-phosphotyrosine antibody conjugated to horseradish 
peroxidase (HRP) was used to detect phosphorylated tyrosine residues of specific 
proteins. Signals were captured with the MULTI GENIUS Bio Imaging System 
(Syngene) and the signal intensity of each spot was analyzed using the Syngene 
GeneTools software. The relative tyrosine phosphorylation level of each protein was 
interpreted as the ratio of spot intensity in the HRG-treated sample to the corresponding 
spot intensity in the control sample. Spots K4 and C7 represent p-EGFR and CD3 epsilon 
with reduced phosphotyrosine signals in the HRG-treated BT474 cells. Other spots (L7: 
HER2; S7: Ezrin; T7: FADD and H15: PP2A) show the increased phosphotyrosine 
signals in the HRG-treated BT474 cells. Underlined spots represent the proteins involved 
A 
B 
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in cell apoptosis. B: Grouping of identified tyrosine phosphorylated and –
dephosphorylated molecules. Only the proteins with a ratio of at least 1.5-fold difference 
or only detected in either of the two filters were selected and functionally grouped in the 
pie chart.  




Table 3-1. Identified tyrosine-phosphorylated proteins from HRG-treated BT474 cells. Relative tyrosine phosphorylation was 
expressed as the ratio of spot intensity on filter probed with the HRG-treated samples to that on the filter treated with control sample. 
Only the proteins with a ratio of >1.5-fold increase (or decrease) or only those detected on the filter probed with HRG-treated samples 
(or on the filter probed with control sample) were considered as increased (or decreased) in their tyrosine phosphorylations. 
 












erbB2 L7 Increased Cell cycle and cell 
proliferation 
CUL-1 T5 Increased 
 
PI3K p85 E15 Increased  Cyclin D3 C6 Increased 
 
AKT 1/2 F1 Increased  GADD45 R8 Increased 
 
SHC L17 Increased  GADD153 S8 Increased 
 
Stat1 L18 Increased  P45 skp2 G14 Increased 
 
Syk B19 Increased Signal transduction- 
related proteins 
HCAM K3 Increased 
 






BOK D2 Increased  CD28 M4 Increased 
 
Bcl-2 G2 Increased  Crk R5 Increased 
 
BID N2 Increased  EphA4 I7 Increased 
 
Bim O2 Increased  Eps8 K7 Increased 
 
BAP1 R2 Increased  p-EGFR C7 Decreased 
 
Caspase3 R3 Increased  Frizzled P8 Increased 
 
Caspase4 S3 Increased  HS1 Q9 Increased 
 
CD40 O4 Increased  IRAK Q10 Increased 
 
FADD T7 Increased  JNK1,2,3 E11 Increased 
 
FLASH K8 Increased  p-c-Raf-1 E16 Increased 
 
FLIPs/1 L8 Increased  Rap2 J16 Increased 
 
GADD34 Q8 Increased  RXR a,b,r L16 Increased 
 
raidd F16 Increased  TCR α E19 Increased 
 
PAR-4 P14 Increased  TCR β F19 Increased 
 
SODD S17 Increased  Patched O14 Increased 




Apaf1 M1 Increased  PDGF R A15 Increased 
 
TNFR1 M19 Increased  Rab1 S15 Increased 
 
TNFR2 N19 Increased  TANK D19 Increased 
 




ARC O1 Increased     
 
TRAF1 Q19 Increased Cell adhesion-related 
proteins 
VCAM-1 N3 Increased 
 
TRAF2 R19 Increased  Bcl-6 M2 Increased 
 





ATF-2 P1 Increased Immune response and 
cytokine regulation 
IL1R1 D10 Increased 
 
Elongin A G7 Increased  IRF2 S10 Increased 
 
HDAC1 L9 Increased  SOCS-1 R17 Increased 
 
ICSBP S9 Increased Tumour suppressors Maspin P11 Increased 
 
Id1 T9 Increased  PP2A,2B H15 Increased 
 
Max Q11 Increased DNA repair and drug 
resistant proteins 
Rad52 C16 Increased 
 











RACK1 A16 Increased  Ezrin S7 Increased 
 
Rar R K16 Increased  B7-1 S1 Increased 
 
c-Rel T16 Increased     
 
Smad4 Q17 Increased     
 
VDR L20 Increased     
   





3.2.5 Validation of antibody array results 
To confirm the HRG-enhanced tyrosine phosphorylation of the signal proteins identified 
by the antibody array, the BT474 cells were treated with HRG for 30 min and the 
tyrosine phosphorylated levels of 2 proteins (Shc and Stat1) that are previously known to 
be directly regulated by HER-2/neu signalling, and 4 other proteins (FADD, ARC, Ezrin 
and PP2A) that had not been previously reported to be associated with HER-2/neu 
signalling, were analysed by immunoprecitation and Western blotting. As shown in 
Figure 3-5 A, HRG significantly enhanced phosphorylation of Shc and Stat1, two 
important mediators in the HER-2/neu signalling pathway (Dankort et al., 2001) , relative 
to that observed in the control cells treated with DMSO. Similarly, tyrosine 
phosphorylation of PP2A, Ezrin, ARC and FADD were highly increased after HRG 
treatment (Figure 3-5 B). 2-dimensional electrophoresis (2-DE) was employed to 
examine the post-modification patterns of these signal modulators upon treatment. 
Immunoblot analysis of these 4 proteins after 2-DE separation revealed additional multi-
spots with increased intensities, appearing on the acidic side of the main spots of PP2A, 
Ezrin, FADD and ARC in the HRG-treated cells (Figure 3-5 C), giving further evidence 
of phosphorylation modification of these proteins under HRG stimulation.  
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Figure 3-5. Validation of differential tyrosine phosphorylation of identified proteins 
by Western blotting. A: Known proteins associated with HER2/neu signalling. B: Novel 
tyrosine-phosphorylated proteins under HER2/neu signalling. BT474 breast cancer cells 
(70-80% confluence) were treated with HRG (3 nM) or DMSO for 30 minutes, and equal 
amount of proteins were used for Western blotting, as described in Materials and 
Methods. The levels of proteins and their tyrosine-phosphorylated forms were detected 
with their respective specific antibodies. For proteins (FADD, ARC and Ezrin) without 
specific phosphotyrosine antibodies, immunoprecipitation (IP) was carried out with the 
primary antibody and protein A-Sepharose or protein G-Sepharose. The protein 
complexes were separated and the tyrosine phosphorylation was detected with an anti-
phosphotyrosine antibody. C: 2-dimensional electrophoresis and immunoblot. Equal 
amounts of proteins (50 µg) from both HRG-treated and control BT474 cells were 
separated with IPG strips (70 mm, pH 3 to 10 or pH 4 to 7), followed by SDS-PAGE. 
Protein spots were detected with their respective antibodies and visualized with a 
chemiluminescent substrate, as described in Materials and Methods. Arrows indicate the 
enhancement of multi-spots in HRG-treat BT474 cells. IP: immunoprecipitation; WB, 
Western blotting.  
 
 




Tyrosine phosphorylation is one of the central regulatory mechanisms of signal 
transduction in cancer progression. Proteins transiently or stably phosphorylated at 
tyrosine residues constitute the tyrosine phosphoproteome, a complex network leading to 
malignant transformation and disease. In breast cancer, the HER-2/neu oncogene 
modulates cell survival and apoptosis by regulating its downstream signalling cascade of 
interlinked pathways, including those involving PI3K/AKT, Raf/MEK1/ERK and p38 
MAPK. To fully inventorize the tyrosine phosphoproteins involved in the HER-2/neu 
signalling network, phosphoproteomic profiles have been compiled using a variety of 
methods based on the SILAC, IMAC/Nano-LC-MS/MS and antibody microarray 
platforms and novel tyrosine phosphoproteins have been identified (Mukherji et al., 
2006; Bose et al., 2006; Gembitsky et al., 2004). These investigations were designed to 
support the concept that dissecting the changes in tyrosine phosphorylation of signal 
molecules would represent a fundamental task to elucidate the biologic/biochemical basis 
of disease progression and to develop therapeutic drugs targeting specific tyrosine-
phosphoproteins. Findings from some of these studies have provided the proof-of-
concept sought. 
 
In this study, the HER-2-driven tyrosine phosphorylation profiles of the key signal 
modulators involved in various cellular functions were investigated using the 
TransSignalling antibody array (Hypromatrix), and  78 tyrosine-phosphorylated proteins 
and 2 tyrosine-dephosphorylated proteins, tyrosine phosphorylation of which were 
stimulated or suppressed following HRG-enhanced HER-2/neu signalling were 
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identified. These differentially phosphorylated molecules are involved in diverse essential 
cell functions (apoptosis, transcription, cell adhesion, etc., as listed in Table 3-1). In 
addition to specific downstream proteins (e.g., Shc, Stat1 and AKT) that were previously 
known to be upregulated by HER-2/neu signalling, most of the apoptosis-related proteins 
were also found to be tyrosine phosphorylated when the BT474 cells were treated with 
HRG. For example, the HER-2-driven tyrosine phosphorylation of Fas-associated Death 
Domain (FADD) showed significantly enhanced HER-2-linked phosphorylation, as 
verified by Western blotting (Figure 3-5 B), a first-time finding. FADD was originally 
identified as a mediator of apoptosis upon activation of the death receptor protein Fas. In 
addition to this well-characterized proapoptotic signalling cascade, the nonapoptotic 
function of FADD had been reported earlier (Park et al., 2005). Matsuyoshi et al. found 
that FADD phosphorylation at its Ser194 residue was regulated by the c-jun N-terminal 
kinase (JNK), affected cell cycle arrest and inhibited cell invasion (Matsuyoshi et al., 
2006), but whether tyrosine phosphorylation of FADD inactivated its apoptotic activity 
remains unclear. More recently, Shackleton et al. reported an unexpected role for FADD 
in modulating mammary epithelial cell survival after the establishment of lactation in 
transgenic mice that overexpressed the truncated FADD protein (Shackleton et al., 2009), 
however, the mechanism of how FADD regulates the cell survival was not worked out. 
Mapping the tyrosine phosphorylation sites and elucidating its role in cancer cells would 
be critical to understanding the cross-talk between HER-2/neu signalling and related 
intracellular apoptotic signals.  
 
The Apoptosis Repressor with CARD Domain (ARC) and ezrin were first time reported 
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to be tyrosine-phosphorylated by the HER-2-driven signalling in BT474 breast cancer 
cells (Figure 3-5 B). ARC is reported to be highly expressed primarily in brain and 
myogenic tissues (Koseki et al., 1998). When cells are triggered by stimuli such as 
hydrogen peroxide, hypoxia and the Fas ligand, ARC appears to assume a protective role, 
inhibiting the cells from undergoing apoptosis (Ekhterae et al., 1999; Hong et al., 2003). 
Mercier et al. reported the presence of ARC in multiple colon cancer cell lines as well as 
primary human colon adenocarcinomas, which indicates that ARC may be a novel 
marker of human colon cancer (Mercier et al., 2008). An abundance of ARC protein was 
also detected in the epithelium of primary human breast cancers compared to that of  
benign breast tissue and conferred chemo- and radio-resistance (Mercier et al., 2005; 
Wang et al., 2005). However, little is known about the mechanism by which HER-2/neu 
signalling regulates tyrosine phophorylation of ARC in cancer cells.  
 
Ezrin, an important member of the ezrin-radixin-moesin family involved in cell surface 
structures (Bretscher, 1999), has been shown to regulate the PI3K/AKT pathway and 
promote cell survival (Gautreau et al., 1999). Li et al. demonstrated that ezrin shRNA 
specifically inhibits ezrin expression of MDA-MB231 cells with high metastasis potential 
and deregulates several functions such as cell motility and invasion indicating that ezrin 
may play a role in the development of human breast cancer cells through regulating the 
activation of Src kinases (Li et al., 2008). A recent immunohistochemical study showed 
that phosphorylated ezrin was mostly found in HER-2/neu-positive breast tumours (Sarrió 
et al., 2006). Data from this study provide further support that HER-2-driven 
phosphorylation of ezrin may contribute to the metastatic potential of breast cancer.  
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Most intriguingly, PP2A, a major protein serine/threonine phosphatase that participates in 
many signalling pathways in mammalian cells (Janssens and Goris, 2001), was 
demonstrated to be intrinsically involved in the HER-2 signalling cascade. PP2A, which 
appears to be critically involved in cellular growth control and potentially in the 
development of cancer (Schönthal, 2001), was found to be highly phosphorylated at the 
tyrosine 307 residue of its catalytic subunit in the HRG-treated BT474 cells (Figure 3-5 
B). PP2A modulates cell survival and apoptosis and tyrosine phosphorylation of PP2A 
results in inactivation of its phosphatase activity (Chen et al., 1992; Chen et al., 1994) 
and loss of its function as a tumour suppressor (Ruediger et al., 2001). Despite the full 
recognition of the importance of tyrosine phosphorylation in regulating its activity, the 
molecular mechanism of HER-2-triggered tyrosine phosphorylation of PP2A remains 
unknown. 
 
In summary, the tyrosine phosphoproteomics study with the antibody arrays identified 
numerous novel signal modulators that are highly phosphorylated (78 of 80) or 
dephosphorylated (2 of 80), in response to HER-2/neu signalling activation. These 
molecules constitute a group of potential targets in the development of novel treatment 
regimes to arrest tumour progression in HER-2/neu-positive breast cancer cells by 
modulating their tyrosine phosphorylation status. 
 






REGULATION OF PP2A BY HER-2/neu 
4.1 Overview 
Many cellular processes, including cell cycle progression, growth factor signalling and 
cell transformation, is regulated by protein phosphorylation. Reversible phosphorylation 
of proteins by kinases and phosphatases is a key regulatory mechanism in the control of 
cell survival to cell death. PP2A has been shown to have a tumour suppressive function 
as a mutation deletion was found in human lung, breast, colon cancers as well as 
melanoma (Ruediger et al., 2001). It is a heterotrimer consisting of a 36-kDa catalytic 
subunit (PP2A/C), a 65-kDa structural A subunit (PP2A/A), and a variable regulatory 
subunit ranging in size from 50 to 130 kDa (PP2A/B). The dynamic combinations of 
regulatory B subunit assembly determine the specificity and regulation of PP2A 
(Janssens and Goris, 2001). The findings of tyrosine phosphorylation of PP2A in 
response to growth stimulation and v-scr transformation of fibroblasts provide strong 
evidence of PP2A activity being acutely regulated by tyrosine phosphorylation (Chen et 
al., 1994). However, much remains to be discovered about the modulation and 
physiological significance of PP2A regulation and functions in vivo. 
 
In 1992, D.L. Brautigan’s group published their findings in Science showing that an in 
vitro study, several receptor and non-receptor tyrosine kinases phosphorylated the 
catalytic subunit of PP2A in a stoichiometric reaction at pY307 (Chen et al., 1992). Thus, 
the phosphorylation of the catalytic subunit seems to be under the regulation of PP2A. In 
1994, the same group analyzed phosphorylation of PP2A in whole cell lysates using two-
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dimensional gel electrophoresis and immunoblotting. This data further support their 
hypothesis that the activity of PP2A is regulated by tyrosine phosphorylation in intact 
cells. PP2A thus appears to function as a growth suppressor and its activity is negatively 
regulated by oncogenic signals (Chen et al., 1994). It was then reported that PP2A 
activity was higher in ER-positive breast cancer cell lines than in ER-negative cell-lines 
(Gopalakrishna et al., 1999). In their experiments, PKC-phosphorylated histone H1 was 
used as a substrate for the PP2A assay. The authors also showed that the higher levels of 
PP2A in ER-positive cell lines inversely correlated with the PKC activity profiles.  
 
A new role of PP2A was proposed in a study of adenovirus type 5 E1A-mediated 
sensitization to anticancer drug-induced apoptosis, which showed that upregulation of 
PP2A/C expression results in repression of AKT activation and upregulation of p38 
activation (Liao and Hung, 2004). The study was well designed and used both siRNA 
technology and commercially available inhibitors of PP2A as tools to study the 
mechanism of action of PP2A. Interestingly, PP2A may also be involved in TNF-α-
induced PARP cleavage and apoptosis (Liao and Hung, 2004). Another kinase that plays 
a pivotal role in breast cancer progression is the mitogen-activated protein kinase 
(MAPK). It was reported that increased PP2A and reduced phospho-ERK1/2 were 
detected when the anti-carcinogenic dietary fatty acid, conjugated linoleic acid (CLA), 
was used on breast cancer cells (Miglietta et al., 2006). This suggested that PP2A may 
play a role in the deactivation of ERK1/2, a cell survival signal modulator. 
 
Protein phosphorylation of PP2A at pY307 regulates its phosphatase activity. Thus far, 
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there is little data linking the phosphorylation status of PP2A with breast cancer 
progression. Although oncogenes such as HER2/neu are detected in 20-30% of breast 
cancer patients, the causal relationship between PP2A and oncogenic HER2/neu has, 
however, not yet been reported and  thus, it is important  to focus on investigating the 
interactive roles between these two signal transducers.  
 
As mentioned in Chapter 3 (page 62), PP2A was found to be highly tyrosine-
phosphorylated at pY307 in a time-dependent manner when HER-2/neu signalling was 
enhanced in the HRG-treated BT474 breast cancer cells. To further verify the role of 
HER-2/neu signalling in the regulation of PP2A phosphorylation,  the HER-2/neu 
signalling was blocked by treating BT474 cells with tyrphostin AG825, a specific HER-
2/neu kinase inhibitor (Tsai et al., 1996). The conceptual role of HER-2/neu signalling in 
modulating tyrosine phosphorylation of PP2A was supported by the finding of PP2A as 
one of the identified signal modulators linked to HER-2/neu activation, from the signal 
transduction array results (see Chapter 3, page 67). As reported in the next section, 
further inhibition studies with various specific inhibitors showed that the PI3K/AKT and 
Raf/Ras/MEK pathways positively regulate, whereas the p38 MAPK pathway negatively 









4.2.1 Inhibition of HER-2/neu signalling using AG825 
BT474 cells were treated with AG825, a selective ATP-competitive inhibitor of the 
tyrosine kinase activity of HER-2/neu. In cell-free assays, AG825 was shown to inhibit 
HER-2/neu, EGFR, and PDGFR autophosphorylation, with IC50 values of 0.35, 19, and 
40 µM, respectively (Reese and Slamon, 1997). In this study, optimization of the AG825 
concentration and optimal time treatment to obtain maximal inhibition of the tyrosine 
kinase activity was carried out with three different concentrations of AG825 at 5 µM, 50 
µM and 100 µM, and at three different time points of 5, 10 and 30 minutes, as shown in 
Figure 4-1. The tyrosine kinase activity was measured by its (tyrosine-) phosphorylation 
level using Western blotting. These results showed that the phosphorylation level of 
HER-2/neu was significantly decreased with 100 µM of AG825 treatment after 10 min 
(p<0.01) and 30 min (p<0.05) of incubation. Thereafter,  this optimized condition was 












Figure 4-1. Inhibition of HER-2/neu activation by AG825. BT474 breast cancer cells 
at 70-80% confluence were serum-starved for 20 h and then treated with different 
amounts of AG825 or DMSO (control) for 5 min, 10 min and 30 min. Cells were 
harvested and phosphorylation levels were determined by Western blotting with the 
respective antibody, as described in Materials and Methods (page 49). HER-2/neu 
phosphorylation was inhibited by AG825 in a dose- and time-dependent manner. 
Maximal suppression of HER-2/neu phosphorylation, which should have been observed 
upon HER-2/neu activation in the absence of inhibitors, was observed after addition of 
100 µM of AG825, and after 10 min and 30 min treatment. Analysis of the significant 
differences of treatment versus control results at different time intervals was by the 
Student t-test. * p<0.05, ** p<0.01. Data shown represent the average of triplicate 
experiments. 
 
4.2.2 HER2/neu signalling regulates tyrosine phosphorylation of PP2A 
To further verify the role of HER-2/neu signalling in the regulation of PP2A 
phosphorylation, the phosphorylation of PP2A was examined by blocking the HER-2/neu 
signalling using AG825. BT474 cells were treated with both HRG to stimulate the 
activation of HER-2/neu signalling and AG825 to inhibit its activation, and examined the 
phosphorylation at pY307 of PP2A by Western blotting. As shown in Figure 4-2 A, 
activation of HER-2/neu by HRG stimulated the activation of PP2A phosphorylation. 
When the HER-2/neu phosphorylation was inhibited using AG825, just as the 
phosphorylation of HER-2/neu was reduced in cells treated with AG825, pY307 of PP2A 
was decreased in the same way (Figure 4-2 B). Following that, the cells were treated with 
HRG and followed by AG825 to examine whether phosphorylation of pY307-PP2A was 
regulated by HER-2/neu activation. When the serum-starved BT474 cells were treated 
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with HRG for 30 min, followed by treatment with AG825 with HRG (Figure 4-2 C, lanes 
2-5) or without HRG (lanes 6-7), the HRG-enhanced phosphorylation of PP2A was 
significantly suppressed by AG825, after 10 min (lane 3) and after 30 min (lane 4) and 
the effect was reversed at the 60 min treatment time (lane 5). These results demonstrated 
the regulatory role of HER-2/neu signalling in tyrosine phosphorylation of PP2A.  
      
Figure 4-2. Regulation of tyrosine phosphorylation (pY307) of PP2A by HER2/neu 
signalling. A: Time-dependent tyrosine phosphorylation of PP2A by HRG treatment. 
Serum-starved BT474 cells were treated with HRG for 10 and 30 min and the levels of 
PP2A and its tyrosine-phosphorylated form pY307-PP2A were detected by Western 
blotting. B: Reduction of pY307 of PP2A by HER-2/neu kinase inhibitor AG825. BT474 
cells at 70-80% confluence were treated with AG825 (100 µM) for 10 and 30 min and the 
phospho-HER-2, HER-2, PP2A and pY307-PP2A were detected with their respective 
antibodies by Western blotting. C: Attenuation of pY307 of PP2A by AG825 in the 
HRG-treated BT474 cells. Serum-starved BT474 cells were treated with HRG α1 for 30 
min, and inhibitor AG825 (100 µM) was added to the cultures for further treatment for 
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10, 30 and 60 min (lanes 3-5), or the HRG was removed and fresh medium with AG825 
(100 µM) was added to treat the cells for 10 and 30 min (lanes 6-7).  Cells were harvested 
and both PP2A and pY307-PP2A were detected by Western blotting. The levels of 
ERK1/2 and phosphor-ERK were assayed to indicate the AG825-inhibited HER-2/neu 
signalling. The relative tyrosine phosphorylation levels of HER-2/neu and PP2A were 
normalized with its basal level (p-HER-2/HER-2, pY307-PP2A/PP2A), respectively. The 
fold change of relative phosphorylation was interpreted as the ratio of the relative 
phosphorylation level of the experimental cultures vs that in the control culture which is 
arbitrarily assigned as 1. Data shown represent the average of triplicate experiments. The 
Student t-test was used for the analysis of significance.     * p<0.05, ** p<0.01 
 
 
4.2.3    Inhibition of PI3K/AKT, MEK/ERK and p38 MAPK pathways 
HER-2/neu signalling activates several downstream signalling pathways, such as 
PI3K/AKT, thus leading to dysregulated cell proliferation and enhanced cell survival 
(Jorissen et al., 2003). To further understand the regulatory mechanism of PP2A 
phosphorylation as driven by HER-2/neu signalling, different inhibitors targeting 
PI3K/AKT, MEK/ERK, and p38 MAPK were used to block the respective pathway. As 
shown in Figure 4-3, LY294002 a specific inhibitor of the p110 catalytic subunit of PI3K 
targeting PI3K/AKT (Kataoka et al., 2010; Nelson and Fry, 2001), PD98059 a specific 
inhibitor targeting MEK/ERK (Dudley et al., 1995; Pang et al., 1995), and SB203580, a 
specific inhibitor targeting p38 MAPK (Wen et al., 2006), were used to target their 
respective pathways. The deactivation of each of these three individual signal modulators 
was assessed by measuring their respective phosphorylation level versus those recorded 
for their respective controls, by Western blotting. LY294002 inhibited the activation of 
AKT significantly at 30 min (p<0.01) (Figure 4-3 A); similarly, PD98059 also inhibited 
the activation of MEK/ERK significantly at 30 min (p<0.01) (Figure 4-3 B); and 
SB203580 inhibited the activation of p38 MAPK, albeit slightly less significantly at 30 
min (p<0.05) (Figure 4-3 C).                
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Figure 4-3. Inhibition of PI3K/AKT, MEK/ERK, and p38 MAPK pathway 
activation using their respective inhibitors. BT474 breast cancer cells at 70-80% 
confluence were serum-starved for 20 h and then treated with different amounts of the 
respective specific inhibitors or DMSO (control) for 10 min and 30 min. Cells were 
harvested and phosphorylation levels were determined by Western blotting with their 
respective antibodies, as described in Materials and Methods (see page 49). A. The 
PI3K/AKT pathway was deactivated by 10 µM of LY294002. B. The MEK/ERK 
pathway was inhibited by 10 µM of PD98059. C. The phosphorylation level of p38 
MAPK decreased upon treatment of 40 µM of SB203580. Significant differences of 
treatment versus control at different time intervals were analyzed using the Student t-test.    
* p<0.05, ** p<0.01. Data shown represent the average of triplicate experiments. 
 
 
4.2.4 PI3K/AKT and MEK/ERK positively regulate, whereas p38 MAPK 
negatively regulates tyrosine phosphorylation of PP2A  
To investigate the effect of specific inhibitors blocking the activation of HER-2/neu 
downstream signal modulators on PP2A phosphorylation, the level of phosphorylated 
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PP2A at its tyrosine 307 residue (pY307-PP2A) in the BT474 cells at different time 
points post-treatment, were analyzed by Western blotting. When the intrinsic PI3K 
activity in the BT474 cells was blocked with the specific PI3K inhibitor, LY294002, the 
amount of pY307-PP2A formed was significantly reduced (p<0.05) (Figure 4-4 A). 
Similarly, a significant reduction of the pY307-PP2A levels (p<0.05) also occurred when 
the intrinsic MEK/ERK pathway was interrupted with the MEK I specific inhibitor, 
PD98059, which targets the MEK/ERK pathway (Figure 4-4 B). However, the cells 
treated with SB203580, a specific inhibitor of p38 MAPK, showed a notably increased 
level of pY307-PP2A (p<0.05) (Figure 4-4 C), implying that activation of p38 MAPK 
reduces tyrosine phosphorylation of PP2A. This is consistent with the function of p38 as 
a tumour suppressor: activation of p38α/β causes cell growth arrest, senescence and/or 
apoptosis while inhibition of p38α/β interrupts their growth arrest and resumes cell 
proliferation (Bulavin and Fornace, 2004; Aguirre-Ghiso et al., 2003). The enhanced 
level of pY307-PP2A at the inhibitory state of p38 MAPK (as shown in Figure 4-4 C) 
could be attributed to inactivation of PP2A activity as a tumour suppressor, thereby 
facilitating cell survival. 
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Figure 4-4. Effects of different inhibitors on tyrosine phosphorylation of PP2A. 
BT474 cells at 70-80% confluence were incubated with fresh medium containing either 
the PI3K inhibitor LY294002 (10 µM), or the MEK 1 inhibitor PD98059 (10 µM), or the 
p38 MAPK inhibitor SB 203580 (40 µM), respectively, for 10 and 30 min. Cells were 
harvested and the levels of PP2A and pY307-PP2A were detected by Western blotting. 
A: Inhibition of PI3K specific inhibitor LY294002 on PP2A phosphorylation in BT474 
cells. B: Inhibition of MEK I inhibitor, PD98059, on the PP2A phosphorylation in BT474 
cells. C: Enhancement of p38 MAPK inhibitor, SB203580, on the PP2A phosphorylation 
in BT474 cells. The relative tyrosine phosphorylation of PP2A was normalized to its 
basal level (pY307-PP2A/PP2A), and interpreted as the fold change. Data shown 
represent the average from triplicate experiments. * p<0.05, (Student t-test) 
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4.2.5 Stimulation of PP2A by HRG and the effects of inhibitors on tyrosine 
phosphorylation of PP2A 
To further investigate the regulatory role of these inhibitors on pY307 of PP2A in BT474 
cells subjected to the HRG-enhanced HER-2/neu signalling, the serum-starved BT474 
cells were induced with HRG for 30 min, followed by treatment with the respective 
inhibitors, with or without HRG in the medium. As indicated in the western blotting 
results in Figure 4-5, the HRG-enhanced pY307 of PP2A was significantly decreased by 
both the PI3K inhibitor, LY294002 (Figure 4-5 A) and the MEK 1 inhibitor, PD98059 
(Figure 4-5 B), in a time-dependent manner. In contrast, addition of the p38 MAPK 
inhibitor, SB203580, to the HRG-treated cells continued to increase the level of pY307 of 
PP2A (Figure 4-5 C)). Taken together,  these results clearly demonstrated that the 
tyrosine phosphorylation of PP2A in the cells was regulated by a complex multi-
signalling network, with PI3K/AKT and MEK/ERK exerting a positive effect, whereas 
p38 MAPK has a negative effect, on this essential process. Activation of PI3K or MEK 
could inactivate PP2A activity by enhancing its tyrosine phosphorylation. In contrast, 
activation of p38 MAPK could activate PP2A by inhibiting its tyrosine phosphorylation.  
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Figure 4-5. Stimulation of HRG and the effects of different inhibitors on tyrosine 
phosphorylation of PP2A. To test the role of different inhibitors on the HRG-enhanced 
PP2A phosphorylation, BT474 cells were serum-starved for 20 h and then treated for 30 
min with HRG. Different inhibitors were directly added to the HRG-treated cultures 
(lanes 3-5) or added with fresh medium after removing HRG (lanes 6-7). HRG-treated 
BT474 cells were further treated with the inhibitors at the indicated time intervals and the 
PP2A phosphorylation levels were detected by Western blotting.  A: Attenuation of 
pY307-PP2A by LY294002 in the HRG-treated BT474 cells. Serum-starved BT474 cells 
were treated with HRG α1 for 30 min, and inhibitor LY294002 (10 µM) was added to the 
cultures for further treatment for 10, 30 and 60 min (lanes 3-5), or the HRG was removed 
and fresh medium with LY294002 (10 µM) was added to treat the cells for 10 and 30 min 
(lanes 6-7).  Cells were harvested and both PP2A and pY307-PP2A were detected by 
Western blotting. B: Attenuation of pY307-PP2A by PD98059 in the HRG-treated 
BT474 cells. Serum-starved BT474 cells were treated with HRG α1 for 30 min, and 
inhibitor PD98059 (10 µM) was added to the cultures for further treatment for 10, 30 and 
60 min (lanes 3-5), or the HRG was removed and fresh medium with PD98059 (10 µM) 
was added to treat the cells for 10 and 30 min (lanes 6-7).  Cells were harvested and both 
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PP2A and pY307-PP2A were detected by Western blotting. C: Enhanced expression of 
pY307-PP2A by SB203580 in the HRG-treated BT474 cells. Serum-starved BT474 cells 
were treated with HRG α1 for 30 min, and inhibitor SB203580 (40 µM) was added to the 
cultures for further treatment for 10, 30 and 60 min (lanes 3-5), or the HRG was removed 
and fresh medium with SB203580 (40 µM) was added to treat the cells for 10 and 30 min 
(lanes 6-7).  Cells were harvested and both PP2A and pY307-PP2A were detected by 
Western blotting. In all three experimental groups, the relative tyrosine phosphorylation 
levels of PP2A were normalized to the corresponding basal levels (pY307-PP2A/PP2A), 
and interpreted as the fold change observed. The fold change of relative phosphorylation 
was interpreted as the ratio of the relative phosphorylation level of the experimental 
cultures vs that in the control culture which is arbitrarily assigned as 1. Data shown 




4.3 Discussion  
It has been found that phosphorylation at tyrosine 307 and/or methylation of the catalytic 
C subunit (PP2A/C) are the crucial steps in regulating PP2A activity (Chen et al., 1994; 
Favre et al., 1994). Thus the posttranslational modification of PP2A is a critical 
regulatory step in exerting its role in mammalian cells, especially in cancer cells where it 
regulates the intricate balance between cell survival and apoptosis by manipulating the 
activities of the key signal molecules, such as AKT, Bax, Calpains, etc. (Andrabi et al., 
2007; Kong et al., 2004; Grethe and Pörn-Ares, 2006; Xin and Deng, 2006). Given the 
importance of PP2A as a multifunctional modulator, the molecular regulation of PP2A 
activity by the intrinsic and/or extrinsic signal network will decide the cell’s destination.  
 
An earlier study showed that the Simian virus 40 small T antigen (SV40 ST) directly 
inhibits the activity of PP2A in promoting cell transformation (Sontag and Sontag, 2006). 
On the other hand, oncogenic signals enhanced by non-receptor- and receptor-linked 
tyrosine kinases, including the EGFR and the insulin receptor, stimulate tyrosine 
phosphorylation of PP2A and thereby inhibit its activity (Tsai et al., 1996). Considering 
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the fact that EGF and the related HER-2/neu RTKs are the most prevalent oncogenes in 
breast cancer, therefore, the hypothesis in this study is that HER-2/neu signalling may 
also play a key role in “tuning” PP2A activity by regulation of tyrosine phosphorylation 
as well.  
 
As hypothesised, tyrosine phosphorylation of PP2A was found significantly affected 
either by switching on HER-2/neu signalling with HRG or by switching off HER-2 
signalling with its specific inhibitor AG825 (Figure 4-2). This data further emphasized 
the importance of oncogenic signalling in regulating PP2A activity. Furthermore, the 
inhibitor experiments targeting PI3K, MEK1 and p38 MAPK demonstrated their 
respective contributions to the tyrosine phosphorylation of PP2A (Figure 4-3 and Figure 
4-4). Tyrosine phosphorylation of PP2A was highly inhibited in both HRG-treated and 
untreated BT474 cells by PI3K (Figure 4-5 A) or MEK1 (Figure 4-5 B) inhibitors 
(LY294002 and PD98059, respectively), but was markedly increased in these same cells 
upon addition of the p38 MAPK inhibitor, SB203580 (Figure 4-5 C). These results 
indicated that the PI3K/AKT and Raf/MEK1/ERK pathways positively regulate, whereas 
the p38 MAPK pathway negatively regulates, PP2A activity in breast cancer cells. These 
observations are consistent with the cell survival role of activated PI3K/AKT (Park and 
Kim, 2007) (Zhou et al., 2004) and Raf/MEK1/ERK and with the cell pro-apoptotic role 
of activated p38 MAPK in HER-2/neu breast cancer progression (Neve et al., 2002).  
 
This data address and add credence to the concept that the key HER-2-linked downstream 
pathways constitute an interactive network to regulate the phosphorylation status of 
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PP2A. This tyrosine phosphorylation-based modification of PP2A activity by the cross-
signalling pathways in cancer cells further highlights its central role in regulating cell 
survival and apoptotic behaviour. 
 
In summary, the complicated regulatory mechanism of PP2A phosphorylation by the 
downstream pathways of HER-2/neu signalling reveals its essential role, at least in part, 
in deciding the destiny of these cells: the activated PI3K- and Raf/MEK pathways 
stimulate PP2A phosphorylation and attenuate its activity to facilitate cell survival, 
whereas the activated p38 MAPK pathway reduces PP2A phosphorylation and increases 
its activity to accelerate cell apoptotic activity. 
 






CORRELATION OF PP2A AND BREAST CANCER 
5.1 Overview 
PP2A is a heterotrimer holoenzyme with different activities and diverse substrate 
specifications (Janssens and Goris, 2001). The three distinct functional components 
(structural, catalytic and regulatory subunits) give rise to the holoenzyme complex which 
plays an important role as a serine/threonine phosphatase. The catalytic subunit is 
encoded by two distinct ubiquitously expressed gene, the Cα and Cβ subunits which 
share 97% sequence identity (Fellner et al., 2003). Phosphophorylation occurs at either 
Tyrosine 307 or Threonine 304 (Longin et al., 2007). Phosphorylation at Tyrosine 307 
inhibits the recruitment of the regulatory B subunits to the core enzyme (Longin et al., 
2004). There is very little data available about the correlation of pY307-PP2A in relation 
to cancer. Thus far, pY307-PP2A has been reported to be highly expressed in parallel 
with tau hyperphosphorylation in Alzheimer’s disease (Liu et al., 2008). 
 
The PP2A/A subunit has two isoforms- the α- and β-isoforms, which are encoded by 
PPP2R1A and PPP2R1B, respectively (Hemmings et al., 1990). Somatic alterations in 
15% (5 out of 33) of primary lung tumours, 6% (4 out of 70) of lung tumour-derived cell 
lines, and 15% (2 out of 13) of primary colon tumours were detected by sequencing the 
PPP2R1B gene, located on human chromosome 11q22-24. One deletional mutation was 
revealed, forming a truncated PP2A-Aβ protein that was unable to bind to the catalytic 
subunit. This clearly showed that the PPP2R1B gene is altered in human lung and 
colorectal carcinomas, suggesting a role in human tumourigenesis (Wang et al., 1998). 
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Another report from Calin et al. described low frequency mutations being detected in 
breast and lung carcinoma, and in melanomas, involving both PPP2R1A and PPP2R1B. 
An exon deletion affecting PPP2R1B was found in four breast carcinomas while 
nucleotide substitutions changing highly conserved amino acids and frame-shift 
mutations were detected in PPP2R1A (Calin et al., 2000). However, it still remains 
unclear whether these low frequency mutations are causal or accidental.  Nevertheless, 
the mutation detected in the PP2A/A subunit strengthens the potential role of PP2A in 
human tumourigenesis. The most recent study by Dupont et al. revealed that in a cohort 
study of 450 women with history of benign breast disease, specific haplotypes of genes 
that encode PP2A subunits are associated with breast cancer and interact with benign 
proliferative breast disease to modify risk (Dupont et al., 2009).  
 
PP2A phosphorylation is clearly regulated by HER-2/neu in the in vitro study (Chapter 
4). To further examine if there is any differential expression of PP2A and pY307-PP2A 
in breast non-tumorigenic and breast cancer cell lines, as well as in clinical (tumour) 
samples, total proteins from mammary epithelial cell lines, breast cancer cell lines as well 
as frozen tissue samples were extracted and subjected them to Western blotting analysis 
using the appropriate respective antibodies. The level of tyrosine-phosphorylated PP2A at 
the tyrosine307 residue (pY307-PP2A) was found to be increased in the HER-2-positive 
breast cancer tissue samples and in related cell lines. The clinical significance of this as a 
prognostication biomarker of cancer progression was further assessed in a panel of 206 
clinical specimens in a tissue microarray. Enigmatically, the immunohistochemical 
staining on the tissue microarray showed that expression of pY307-PP2A was highly 
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correlated with breast cancer progression. DNA sequencing of the full length of the 
PP2A/C subunit gene sequence extracted from both the breast cancer cell lines and breast 
tumour tissues were performed subsequently. Howvever, no mutations were found.  
 
5.2 Results 
5.2.1 pY307-PP2A was highly expressed in HER-2/neu-positive breast cancer cell 
lines 
The expression of PP2A and its phosphorylated derivative, pY307-PP2A, in a non-
tumorigenic MCF12A cell line, and two HER-2/neu-positive breast cancer cell lines, 
BT474 and SKBR3 were analysed. As shown in Figure 5-1 A, the expression of the basal 
PP2A was similar in the three cell lines. However, the expressed levels of both pY307-
PP2A (normalized to β-actin, Figure 5-1 B) as well as the relative phosphorylation of 
PP2A (pY307-PP2A/PP2A, normalized to basal PP2A, Figure 5-1 D) were significantly 
higher in both the BT474 and SKBR3 HER-2/neu-positive breast cancer cells compared 
to the MCF12A cells (p<0.05). No significant difference in PP2A expression (normalized 
to β-actin, Figure 5-1 B) was observed in the 3 cell lines.  
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Figure 5-1. Expression of PP2A and tyrosine-phosphorylated PP2A (pY307-PP2A) 
in breast non-tumorigenic and cancer cell lines. A: Western blotting of PP2A and 
pY307-PP2A in the human non-tumorigenic mammary epithelial cell line, MCF12A and 
the HER-2/neu-positive breast cancer cell lines, BT474 and SKBR3.  Total protein 
lysates were extracted from the cell lines and subjected to 10% SDS-PAGE, transferred 
to PVDF membranes, and immunodetected using anti-PP2A and anti-pY307-PP2A 
antibodies, followed by conjugated secondary antibody. The fluorescence signals were 
captured using the MULTI GENIUS Bio Imaging System and signal intensities analysed 
by the GeneTools software (Syngene). B: Expression levels of pY307-PP2A normalized 
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to β-actin. C: Expression levels of PP2A normalized to β-actin. D: Relative 
phosphorylation of PP2A normalized to total PP2A (pY307-PP2A/PP2A) in the three cell 
lines. Data shown represent the mean ±SD of triplicate experiment. Bars, SD; *p<0.05  
 
5.2.2 pY307-PP2A was highly expressed in HER-2/neu-positive breast tumours  
The expression of PP2A and pY307-PP2A in a panel of clinical specimens were 
investigated. As indicated in Figure 5-2 A, PP2A was expressed in both the tumour and 
non-tumour tissues. However, PP2A (normalized to β-actin) was highly expressed in the 
non-tumour tissues and downregulated in the tumour tissues (Figure 5-2 B), further 
supporting the role of PP2A as a tumour suppressor in breast cancer progression. pY307-
PP2A is found only detected in the tumour tissues (Figure 5-1 A, right panel) and that the 
level of pY307-PP2A (normalized to β-actin) is significantly increased in the HER-2/neu-
positive tumours, compared to the corresponding levels observed in the HER-2/neu-
negative tumours (Figure 5-2 D). However, the relative phosphorylation level of PP2A 
(pY307-PP2A/PP2A) was not markedly enhanced in the HER-2/neu-positive tumours 
(Figure 5-2 C). Taking into account that phosphorylation of PP2A is a transient process 
under growth factor stimulation, as reported by Chen et al. (Chen et al., 1994), and as 
demonstrated in this present study in an in vitro cell system, this transient phenomenon 
may not be readily observed in the tumour specimens.  
 





Figure 5-2. Expression of PP2A and tyrosine-phosphorylated PP2A (pY307-PP2A) 
in clinical non-tumour and tumour breast specimens. A: Western blotting of PP2A 
and pY307-PP2A in tumour and non-tumour tissues. Total soluble proteins from both 
frozen breast tumour and non-tumour tissues were solubilised in Tissue Protein 
Extraction Reagent® (Pierce, Rockford, IL), after grounded to powder in liquid nitrogen. 
Proteins (40 µg) were separated by SDS-PAGE (10%), transferred to PVDF membranes, 
and immunodetected using anti-pY307-PP2A and anti-PP2A antibodies, followed by 
HRP-conjugated secondary antibody. Signals were captured with the MULTI GENIUS 
Bio Imaging System and the signal intensities were analyzed by the GeneTools software 
(Syngene). B: Level of PP2A normalised to β-actin in breast tissues. C: Level of pY307-
PP2A normalized to β-actin in breast tissues. D: Relative phosphorylation of PP2A 
normalized to total PP2A (pY307-PP2A/PP2A) in breast tissues. Data shown represent 
the mean ± SD of triplicate experiments. * p < 0.05, ** p < 0.01 (Students’ t-test).  
 
5.2.3 Expression levels of pY307-PP2A correlated with breast cancer progression  
To investigate whether pY307-PP2A expression is associated with breast cancer 
progression, the level of pY307-PP2A was further analyzed by immunohistochemistry 
with the specific antibody to pY307-PP2A (Epitomics Inc., CA, USA) in all 206 tissue 
cores included in the tissue microarray (TMA) purchased from Biomax ( Rockville, MD, 
USA). The TMA included 206 different cases, with 32 cases of metastatic breast 
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carcinomas, 116 malignant breast carcinomas, 44 non-malignant tissues and 16 non-
tumours (see Appendices: Table 3). Scoring of the staining intensity of each case was 
made by two independent pathologists and one principal investigator. The staining 
intensity was classified as negative and weak (score 0), moderate (score 1) and strong 
(score 2) to indicate the expression of pY307-PP2A in the different tissue specimens. In 
cases in which a discrepancy was noted, a subsequent review carried out to reach a 
consensus was mostly but not always successful; discordant results were excluded from 
statistical data analysis. Representative cases with different scores are shown in Figure 5-
3 (A, B, C). Of the 34 non-malignant tissues including benign growths, hyperplasia and  
inflammation, only 2 cases (6%) showed strong staining intensity (score 2) and 12 (35%) 
moderate staining intensity (score 1), whereas in the 106 malignant carcinomas, 21 cases 
(20%) were strongly stained and 57 moderately stained (54%) (p < 0.01). Noticeably, 
pY307-PP2A was strongly stained in 8 of the 30 (27%) metastatic carcinomas, and with a 
higher frequency than that observed in the malignant carcinomas (20%), although not at a 
significant level (p = 0.15). None of the 14 normal tissues showed high expression of 
pY307-PP2A. Collectively, expression of pY307-PP2A was found to be progressively 
increased with the tumour stage progression of the patients being assessed (Figure 5-3 D). 




Figure 5-3. Representative immunohistochemical staining of pY307-PP2A on tissue 
cores in a breast tissue microarray. A-C showed increasing staining levels of score 0 to 
score 2. Sections were deparaffinised in xylene and rehydrated in graded alcohols. After 
unmasking antigen and removing endogenous peroxidases, sections were incubated for 1 
h with antibodies against pY307-PP2A at room temperature, followed by detection with 
labelled dextran polymer conjugated with peroxidase and DAB+-substrate chromagen 
solution. Nuclei were lightly stained with Mayer’s haematoxylin. The extent of staining 
was scored as 0, 1 and 2, according to the staining intensity of the tumour cells. D: 
Distribution of pY307-PP2A expression in breast tissues. Breast tissues on the 
microarrays were classified as normal, non-malignant, malignant and lymph node 
metastasis (malignant cases). Data were expressed as percentage of cases with various 
scores in each subgroup. p < 0.05 was considered as significant (Fisher’s exact test). * 
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5.2.4 DNA sequencing of the PP2A catalytic subunit 
Given that the PP2A/A mutations were detected in breast, lung, and colon carcinomas 
and in melanomas (Wang et al., 1998; Calin et al., 2000), whether there were any 
mutations in the PP2A/C subunits of those samples that demonstrated strong pY307-
PP2A expression and staining, were investigated in both breast cancer cell lines and 
tumour tissues. Five human breast cell lines - one human non-tumourigenic breast cell 
line MCF12A; two HER-2/neu-negative breast cancer cell lines, MDA-MB231 and 
BT549, and two HER-2/neu-positive breast cancer cell lines, BT474 and SKBR3, were 
processed and analyzed for the presence of mutations in PP2A/C by DNA sequencing. 
Seven breast cancers together with their respective normal paired tissue samples from the 
same patients’ biopsies obtained from the Tissue Repository of the National University 
Hospital (Singapore) were also subjected to DNA sequencing. However, there were no 
mutations found in any of the processed samples (Figure 5-4) (see Appendices: Table 4) 
amongst both the cancer cell lines and tumour samples. 




Figure 5-4. DNA Sequencing of the PP2A catalytic subunit (PP2A/C). 
Representatives of sequence chromatograms showed that there was no mutation found in 
both tumour cell lines and clinical sample as compared to their non-tumourigenic cell 




PP2A activity was shown to be required for cells to progress through the early phase of 
the cell cycle to enter the S phase (Yan and Mumby, 1999), and to exert an anti-apoptotic 
effect on malignant testicular germ cell tumours (Schweyer et al., 2007). The contrasting 
functions of PP2A may be attributed to its existence as a multitasking, enzyme complex 
rather than as a single enzyme entity (Janssens and Goris, 2001). Whilst it had been 
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reported that PP2A activity was higher in ER-positive breast cancer cell lines than in the 
ER-negative cell lines (Gopalakrishna et al., 1999), there is scanty information of pY307-
PP2A expression in human breast tissues. Recently, Liu et al. reported a consistent 
increase in the levels of pY307-PP2A in parallel with tau hyperphosphorylation in 
Alzheimer’s disease. Their immunohistochemistry and immunofluorescence confocal 
microscopy showed an accumulation of pY307-PP2A in pretangled neurons preceding 
PHF-tau accumulation. This suggests that the post-translational modification of pY307-
PP2A could be an early event in the pathogenesis of Alzheimer’s disease-related tau 
pathology (Liu et al., 2008).  
 
To further investigate the distribution and expression of PP2A and pY307-PP2A in breast 
cancer specimens, and to determine whether the level of pY307-PP2A is associated with 
cancer progression, the levels of both PP2A and pY307-PP2A expression in a panel of 
resected breast tumours as well as numerous breast cell lines were tested. The relative 
expressions of the PP2A and pY307-PP2A in HER-2/neu-positive breast cancer cells 
(BT474 and SKBR3) and non-tumorigenic mammary epithelial cells (MCF12A) were 
analyzed by western blots (Figure 5-1). The pY307-PP2A expression in the BT474 and 
SKBR3 cells was found to be higher (with statistically significant differences) compared 
to that in the MCF12A cells. This suggested that PP2A phosphatase activity is inactivated 
in both the HER-2/neu-positive cell lines, and that the loss of function of PP2A as a 
tumour suppressor arguably contributes to the aggressiveness of the HER-2/neu-positive 
breast tumours. 
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A comparison of the PP2A expression between tumour and non-tumour clinical samples 
(Figure 5-2) further supported the role of PP2A as a tumour suppressor in breast cancer. 
For the tumour samples, notably, the observation that pY307-PP2A was only detected in 
all the tumour samples studied (n=11), but not in any of the non-tumour samples (n=9) 
(Figure 5-2 A), strongly suggests the inactivation of PP2A in tumours. Interestingly, the 
relative tyrosine phosphorylation of PP2A (pY307-PP2A/PP2A) was not significantly 
different in the HER-2-positive and –negative tumours (Figure 5-2 C). This is not 
surprising when one considers that as tyrosine phosphorylation induced by the oncogenic 
HER-2/neu signalling is a transient response, as verified by this study and supported by 
data from other studies using an in vitro cell system (Chen et al., 1994). These transient 
signals may not be readily observed or captured in the tumour samples, without the use of 
real-time bioimaging techniques. The increased expression of pY307-PP2A in the HER-
2/neu-positive breast tumours is consistent with the subsequent tyrosine phosphorylation 
and inactivation of PP2A expressed in this subtype of breast tumours. Moreover, tumours 
with higher positive staining of pY307-PP2A were associated with patients in the later 
stages of breast cancer progression, most notably in those with malignancy and lymph 
node metastasis (Figure 5-3). This tissue microarray study supported the strong 
association of pY307-PP2A with tumour progression, and further highlighted the 
potential of pY307-PP2A as a viable targeted therapy candidate to block off 
tumorigenesis by its inherent property of reactivating PP2A activity. The results of this 
study also indicate that pY307-PP2A has a potential prognostic value in determining 
breast cancer progression.   
 
                                                                                Chapter 5 Correlation of PP2A and breast cancer 
104 
 
DNA sequencing was performed to examine whether there were any inherent mutations 
that could have caused the differential pY307 expression in any or all of the breast 
tumour cell lines and/or resected tumour tissues studied. No mutation in both breast 
cancer cell lines and tumour tissue samples (Figure 5-4) was found and this may imply 
that the overexpression of pY307 could be caused by its upstream oncogenic mechanisms 
arising from other oncogenic signal modulators such as HER-2/neu or Src proteins. 
 
In summary, higher expression level of pY307-PP2A in tumour cell lines and tissues 
specimens may indicate that the loss of function of phosphatases in cancerous cells 
contribute to their malignant transformation and disease progression. As reported in this 
findings, in both the breast cancer cell lines and clinical tumour specimens, pY307-PP2A 
is highly increased in the more aggressive HER-2-positive breast tumours and also 
markedly associated with tumour progression. In this context, cells that express high 
expression of inactivated PP2A could be prone to be more oncogenic. This investigation 
further indicates pY307-PP2A as an important prognostic factor in breast cancer 
development.  






FUNCTIONAL ROLE OF PP2A IN HER-2/neu BREAST CANCER CELL LINES 
6.1 Overview 
PP2A is highly conserved and ubiquitously expressed. It is very much involved in a 
multitude of cellular processes by dephosphorylating specific substrates, and thus 
providing a negative feedback to signals initiated by upstream protein kinases. PP2A 
phosphatase activity is involved in regulating cell cycle, signal transduction, DNA 
replication, transcription and translation (Schönthal, 2001; Janssens and Goris, 2001). 
Several studies had shown that PP2A can potently restrict migration and invasion of 
various cell types (Xu and Deng, 2006; Pullar et al., 2003; Young et al., 2003; Young et 
al., 2002). Dysregulation of PP2A has been reported to lead to potentially debilitating 
diseases such as cancer (Schönthal, 2001) and Alzheimer’s disease (Liu et al., 2008; Qian 
et al., 2009).  
 
The HER-2/neu proto-oncogene-encoded receptor has been found to be overexpressed in 
about one-third of breast cancer tumours (Rubin and Yarden, 2001). This ligandless 
receptor is able to heterodimerize with itself or with other members of the receptor 
tyrosine kinase family and causes autophosphorylation, wherein the signal transduction 
events are triggered (Warren and Landgraf, 2006). Thus, in cancer cells numerous 
heterodimers are formed, resulting in unabated aggressive tumour growth and death. 
However, relatively little is known about the cellular phosphatase(s) responsible in the 
activation/deactivation of the HER-2/neu signalling cascade. Three recent studies 
reported that protein tyrosine phosphatase 1B (PTP1B) is required for HER-2/neu 
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transformation in human breast epithelial cells and inhibition of PTP1B delays HER-
2/neu-induced mammary tumorigenesis (Arias-Romero et al., 2009; Julien et al., 2007; 
Bentires-Alj and Neel, 2007). Overexpression of wild-type PTP1B has been reported to 
enhance PP2A activity, accompanied by dephosphorylation of PP2A/C and thus, it was 
suggested that PTP1B is associated with PP2A in the regulation of sterol regulatory 
element-binding protein-1 gene expression in the insulin resistance/metabolic syndrome 
(Shi et al., 2007; Ugi et al., 2009). The results in Chapter 3demonstratedthe use of breast 
cancer cell lines as an in vitro model, and that PP2A was phosphorylated upon HRG-
enhanced-HER-2/neu signalling. In addition,  evidences were provided to emphasis that 
pY307-PP2A was highly increased in HER-2/neu-positive breast tumours and 
significantly related to breast cancer progression (Chapter 5). Therefore, both PTP1B- 
and PP2A-related interactions may play a role in HER-2/neu-driven tumorigenesis. 
Furthermore, PP2A phosphatase activity could therefore also be inactivated by 
phosphorylation in HER-2/neu-positive cells. This has been supported by the studies 
showing that receptor tyrosine kinases and non-protein receptor tyrosine kinases 
inactivate PP2A phosphatase activity by phosphorylation of the PP2A/C at the Y307 site 
(Chen et al., 1992; Chen et al., 1994; Brautigan, 1995).  
 
Given the importance of the role of PP2A in cancer progression, the molecular regulation 
of PP2A was hypothesized may contribute significantly to the cell survival or cell death 
in HER-2/neu-overexpressed breast cancer cells. Although the role of pY307-PP2A is 
well documented, it remains to be determined whether the HER-2/neu-encoded receptor 
can phosphorylate the carboxy-terminal region of the C subunit of PP2A (Y307), 
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resulting in inhibition of phosphatase activity in a similar manner as Src, p56lck, the 
epidermal growth factor (EGF) receptor and the insulin receptor (Chen et al., 1992; Chen 
et al., 1994). To investigate the resultant consequences of PP2A knockdown on cellular 
behaviour in HER-2/neu-positive breast cancer cells and its downstream signalling 
cascade, namely the PI3K/AKT, Ras/Raf/ERK and p38 MAP kinase pathways, the 
PP2A/C subunit in the HER-2/neu-positive breast cancer cell lines, BT474 and SKBR3 
was silenced. The silencing of PP2A/C was demonstrated to cause the HER-2/neu-
positive breast cancer cells to undergo apoptosis via the p38 MAPK-related pathway. 
These results further supported the essential role of pY307-PP2A in cell survival in HER-
2/neu-positive breast cancer cells. 
 
6.2 Results 
6.2.1 Silencing of PP2A/C using siRNA 
To determine the effect of silencing PP2A/C in HER-2/neu-positive breast cancer cell 
lines, BT474 and SKBR3 were transfected with siPP2A/Cα and the scrambled siRNA 
negative control. After a 48- or 72-h transfection (depending on cell type), total proteins 
from each control and transfectant were extracted to examine the knock-down effects by 
western blotting and immunofluorescence staining. The morphology of all the cells was 
not altered after silencing. As indicated in Figure 6-1, siPP2A/Cα-treated BT474 (BT474 
siP, Figure 6-1 A) and SKBR3 (SKBR3 siP, Figure 6-1 C) cells showed a significant 
reduction (up to 70%) of PP2A as compared to the siRNA negative control (BT474 siC 
and SKBR3 siC) and their parental cells (p<0.01). The immunofluorescence staining 
analysis further substantiated the efficiency of silencing using siRNA, with both BT474 
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siP and SKBR3 siP showing weak/negligible PP2A staining (Figure 6-1 B and D).  
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Figure 6-1. Silencing of PP2A/C using siRNA from siGENOME SMARTpool® 
PP2A. A: Western blotting of PP2A expression levels and graphical representations of 
silencing efficiency after 72-h transfection with siRNA on BT474 cell line compared to 
the negative control siC, at different concentrations of siRNA. B: Immunofluorescent 
detection of PP2A expression in parental BT474, BT474 siC and BT474 siP cells. Cells 
on the cover slip were fixed with 4% paraformaldehyde for 15 min and permeabilized 
with 1% Triton-X for 10 min. After washing, cells were incubated with anti-PP2A 
antibody, followed by incubation with Alexa Fluor® 532 for 1 h. Cells were then 
counterstained with DAPI and signals were captured by confocal microscopy (X60 
magnifications, oil lens). C: Western blotting of PP2A expression levels and graphical 
representations of silencing efficiency after 48-h transfection with siRNA on SKBR3 cell 
line compared to the negative control siC, at different concentrations of siRNA. B: 
Immunofluorescent detection of PP2A expression in parental SKBR3, SKBR3 siC and 
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SKBR3 siP cells. Data shown represent the mean ±SD of triplicate experiments. Bars, 
SD; **p<0.01 with respect to siC. 
 
 
6.2.2 Silencing of PP2A/C caused a decrease in pY307-PP2A expression and 
attenuated tyrosine phosphatase activities   
Upon silencing of PP2A/C as described above in section 6.2.1, the expression of pY307-
PP2A was also significantly reduced in both BT474 siP and SKBR3 siP as compared to 
the controls BT474 siC and SKBR3 siC (p<0.05), as shown in the immunoblots (Figure 
6-2 A).  
 
The effect of silencing on cellular tyrosine phosphatase activity was further assessed. 
Knocking down of the PP2A/C subunit in both BT474 and SKBR3 cells highly decreased 
cellular protein tyrosine phosphatase activity when compared to the BT474 siC and 
SKBR3 siC (p<0.05). Noticeably, in comparison with SKBR3 cells, silencing of PP2A/C 
in BT474 cells showed a higher efficiency in the reduction of tyrosine phosphatase 


















Figure 6-2. Silencing of PP2A/C reduced pY307-PP2A expression and its tyrosine 
phosphatase activity. A: The expression levels of pY307-PP2A were analyzed in  
BT474 siC, BT474 siP and SKBR3 siC, SKBR3 siP, upon treatment with siRNA for 72 h 
and 48 h respectively, and subjected to Western blotting analysis. β-actin was used as the 
loading (baseline) control. The expression of both pY307-PP2A normalized with β-actin 
expression level and its relative phosphorylation of PP2A normalized to total PP2A 
(pY307-PP2A/PP2A) were expressed as fold-change relative to the siC controls. B: 
Tyrosine phosphatase assay was performed, as described in Materials and Methods 
(section 2.2.14.I) to measure the protein tyrosine phosphatase activity. Purified enzymes 
were reacted for 5 min at 30oC with Tyr-phosphopeptide-1 (PP-1) and -2 (PP-2). 
Reactions carried out without addition of enzyme and substrates served as negative 
controls. Data showed that both PP-1 and PP-2 activities were reduced upon silencing of 
PP2A/C catalytic subunit in both BT474 and SKBR3 cells. Bars, SD;  *p<0.05  
 




6.2.3 Silencing of PP2A/C led to a slight increase of the sub G1 phase in the cell 
cycle  
The phosphorylated PP2A/C, pY307-PP2A, were investigated to check whether they are 
involved in cell cycle regulation in the HER-2/neu-positive cancer cells. As shown in 
Figure 6-3, knockdown of PP2A/C in both BT474 and SKBR3 cells did not result in any 
significant changes to the percentage of cells in G0/G1, S and G2/M phases when 
compared to the scrambled siRNA control cells. However, both siPP2A/Cα-treated 
BT474 (Figure 6-3 A) and SKBR3 cells (Figure 6-3 B) showed an increased cell 
population (5-fold and 2-fold increase, respectively) in the sub G1 phase, indicating that 








Figure 6-3. Silencing of PP2A/C caused a slight increase of the sub G1 phase in cell 
cycle. For cell cycle analysis, cells were treated with siRNA, as described in Materials 
and Methods (section 2.2.14.IV). Cells were washed with PBS and harvested by 
trypsinization and fixed with ice-cold 70% ethanol. Cells were then stained with 1 ml of 
propidium iodide/RNAase stain for 1 h and analyzed by flow cytometry. Cell distribution 
at various phases of cell cycle was expressed as percentage in bar charts (upper panels). 
Representative of cell cycle diagram of BT474 siC and BT474 siP (lower panels, left) as 
well as SKBR3 siC and SKBR3 siP (lower panels, right). Note that a more prominent sub 
G1 peak, suggestive of apoptosis, was evident in both the BT474 (Fig. 5A) and SKBR3 
(Fig. 5B) cells, after treatment with siPP2Acα, compared to the negative siC controls. 
Bars, SD; *p<0.05, **p<0.01   
 
6.2.4 Silencing of PP2A/C facilitated cell apoptosis 
To further verify the results presented above in section 6.2.3, the apoptotic activities of 
both the siPP2A/Cα and siC treated cells were assessed using the TUNEL assay. 
Silencing of PP2A/Cα in both BT474 and SKBR3 cells significantly enhanced cell 
apoptosis (Figure 6-4 A). Furthermore, the caspase 3 and its targeted substrate, poly 
(ADP-ribose) polymerase (PARP), were cleaved in both siPP2A/Cα-treated BT474 and 
SKBR3 cells, suggesting the involvement of caspase 3 in siPP2A/Cα-driven apoptosis 
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(Figure 6-4 B). This was also supported by the elevated caspase 3 activities as assessed 
with the Caspase-Glo®3/7 assay in the siPP2A/Cα-treated BT474 and SKBR3 cells 
(Figure 6-4 C).  
 
             
 
 















                      
Figure 6-4. Silencing of PP2A/C caused caspase 3-dependent apoptosis. A: The Dapi 
and fluorescence images are representative of the siPP2A/Cα-driven cell apoptosis 
results, using the TUNEL assay. DNA of apoptotic cells was labeled with fluorescein-12-
dUTP by Terminal Deoxynucleotidyl Transferase (rTdT) and visualized using 
fluorescence microscopy. The number of apoptotic fluorescent cells (green, as indicated 
by arrows) was calculated for each sample (five randomly selected fields per sample) and 
the mean percentage of apoptotic cells ±SD is indicated in the BT474 siP and SKBR3 siP 
panels. The arrows in the DAPI staining panels indicate nucleus staining. B: Western 
blotting of caspase 3 and cleaved caspase 3 as well as its target PARP. Cleaved caspase 3 
and PARP were detected in both BT474 siP and SKBR3 siP indicating the apoptosis is 
caspase 3-dependent. C: Cells were plated in 96-well plates and treated with siRNA as 
described in Materials and Methods (section 2.2.14.III). Caspase-Glo®3/7 reagent was 
added to the wells and luminescence was measured after 2 h of incubation. Results were 
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subtracted from those from wells containing culture medium without cells. Both BT474 
siP and SKBR3 siP showed enhanced caspase 3 activities compared with the respective 
siC controls and parental cells. Bars, SD; *p<0.05  
 
6.2.5 Silencing of PP2A/C caused cell apoptosis via the p38 MAPK/Hsp27 
signalling pathway 
The HER-2/neu downstream signalling pathways of PI3K/AKT, Ras/Raf/ERK and p38 
MAPK form an essential part of the central network within cells that regulate cell 
survival and apoptosis. Activation of these pathways is modulated by the phosphorylation 
status of key modulators such as AKT, ERK and p38 MAPK. The effect of silencing 
PP2A/C on the phosphorylation status of AKT, ERK 1/2 and p38 MAPK in BT474 siP 
and SKBR3 siP cells was further examined. As shown in Figure 6-5 A, expression of 
phosphorylated ERK 1/2 were significantly decreased upon silencing of PP2A/C in both 
BT474 siP and SKBR3 siP (p<0.05). In contrast, expression of the phosphorylated form 
of AKT was significantly enhanced in BT474 siP by 2-fold compared to the BT474 siC 
(p<0.05). However, this was not observed in SKBR 3 siP (Figure 6-5 B). This may 
further indicate that silencing of the PP2A/C and its phosphorylation could lead to a 
decrease in its phosphatase activity that then may possibly result in constitutive activation 
of kinases such as AKT, especially in the case of BT474 siP-treated cells. 
 
Considering the fact that activation of p38 MAPK leads to cell growth arrest, senescence 
and/or apoptosis (Tanaka et al., 2003; Aburai et al., 2010; Segreto et al., 2010),  further 
investigation was carried out to determine whether silencing PP2A/C causes any changes 
in p38 MAPK phosphorylation. The phosphorylation of p38 MAPK was found to be 
remarkably stimulated in both BT474 siP and SKBR3 siP as compared to BT474 siC 
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(p<0.01) and SKBR3 siC (p<0.05), as shown in Figure 6-5 C. Activation of p38 
signalling was further supported by enhanced phosphorylation of Hsp27 Ser78, a 
downstream target of p38 MAPK, by silencing of PP2A/Cα in both BT474 (p<0.01) and 
SKBR3 cells (p<0.05) (Figure 6-5 D). Clearly, these results indicated that siPP2A/Cα-
mediated cell apoptosis in HER-2/neu-positive cells is involved in a multi-faceted 
activation/inactivation of the central signalling network and the p38 MAPK pathway 
could be the pathway mediating apoptosis upon PP2A/Cα silencing.  
 
 
Figure 6-5. Silencing of PP2A/C reduced phospho-ERK 1/2 expression and 
enhanced phospho-AKT, phospho-p38 MAPK and phospho-Hsp27 Ser 78 
expression. Western blotting was performed to compare the downstream modulators of 
the HER-2/neu signalling pathway.  A: Relative phosphorylation of ERK1/2 normalized 
to total ERK1/2. B: Relative phosphorylation of pAKT Ser473 normalized to total AKT. 
C: Relative phosphorylation of p38 MAPK Thr180 Tyr182 normalized to total p38 
MAPK. D: Relative phosphorylation of Hsp27 Ser78 normalized to total Hsp27. β-actin 
was used as the loading (baseline) control. Relative phosphorylation of each signal 
modulator was normalized to total basal level and expressed as fold-change of the 
respective siC controls. Data shown represent the mean ±SD of triplicate experiments. 
*p<0.05, **p<0.01 (Student t-test). 
 




HER-2/neu receptors activate a multiplicity of intracellular pathways via their ability to 
interact with numerous signal transducers. A wide array of antibodies and inhibitors have 
been invented to exploit them as therapeutic targets (Davoli et al., 2010). Many kinases 
are involved in the activation of this signalling cascade. However, the roles of 
phosphatases that facilitate these effects are generally not well defined, although recently 
there is  growing evidence of the importance of PTP1B in HER-2/neu tumorigenicity 
(Arias-Romero et al., 2009; Julien et al., 2007; Bentires-Alj and Neel, 2007; Brown-
Shimer et al., 1992; Zhai et al., 1993; Wiener et al., 1994). 
 
Breast cancer cells that overexpress HER-2/neu-encoded receptors are dependent on this 
oncogene for their proliferation and survival. In  previous study (Chapter 5),  the high 
expression of pY307-PP2A was detected in HER-2/neu-positive tumour samples. In this 
functional study, BT474 and SKBR3, the two HER-2/neu-positive breast cancer cell lines 
were used as an in vitro model to decipher the role of PP2A/C in the HER-2/neu-positive 
breast cancer subgroup. Upon silencing the PP2A/C in both BT474 and SKBR3 cells 
using siRNA against PP2A/C, the pY307-PP2A expression level was significantly 
decreased relative to the decrease in the PP2A expression level. This further implied that 
the phosphatase activity of PP2A had been reduced. The tyrosine phosphatase assay also 
showed a markedly decreased activity in both BT474 and SKBR3 cells. These 
observations are consistent with the cellular pro-oncogenic role of activated protein 
tyrosine phosphatase such as PTP1B. PTP1B expression is linked to promotion of 
aberrant cell division and survival in human breast epithelial cells (Arias-Romero et al., 
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2009). Given that PTP1B is required for HER-2/neu transformation and its association 
with PP2A is critical for PP2A activation, it is postulated that the decrease in tyrosine 
phosphatase activity could be contributed by PTP1B. However, the association of 
PTP1B-PP2A and HER-2/neu remains to be further elucidated. These results suggested 
that silencing of the PP2A/C leads to reduced tyrosine phosphatase activity that could be 
partly mediated by PTP1B, and thus, contribute to the deceleration of the cell 
proliferation and survival rate in HER-2/neu breast cancer cells.  
 
Removal of PP2A/C has been proven to be fatal to cells. Deletion of the PP2A/Cα in 
homozygous null mutant mice, was embryonically lethal (Götz et al., 1998). Knocking 
down of PP2A/A or /C or both B56-targeting subunits led to development of the 
morphological and biochemical changes characteristic of programmed cell death (Li et 
al., 2002). He et al found that silencing of PP2A/C greatly decreased PP2A activity and 
developed localized death in plant stems and cells (He et al., 2004). In this study, a sub-
G1 peak which is an indicator of early apoptosis was observed when the PP2A/C was 
silenced. In addition, the induction of siPP2A/Cα caused a noticeably accelerated cell 
death in both BT474 and SKBR3 cells.  This finding was further supported by both 
enhanced caspase 3 activities and evidence of cleaved caspase 3 and PARP in Western 
and immunoblots in siPP2A/Cα treated cells. The apoptosis induced by silencing PP2A is 
therefore caspase 3-dependent. Altogether, these findings clearly supported the role of 
PP2A in regulating HER-2/neu positive breast cancer signalling. 
 
PP2A was reported to promote apoptosis by dephosphorylating p38 MAPK in 
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neutrophils. Dephosphorylation of p38 MAPK in turn was reported to reconstitute the 
impaired caspase 3 activity and enabling the activated caspase 3 to initiate the apoptosis 
in the neutrophils (Alvarado-Kristensson and Andersson, 2005). However,  the above 
results was intriguing as silencing of PP2A/C was shown to cause enhanced 
phosphorylation of p38 MAPK which later on initiated apoptosis via caspase 3 activity. 
This finding indicates that PP2A plays a role in regulating apoptosis via modulating p38 
MAPK phosphorylation in a cell-type dependent manner. These results agreed with the 
recent report by Boudreau et al. showing a direct association between PP2A and p38 
MAPK in human T leukemia cells (Boudreau et al., 2007). They found that PP2A was 
involved in maintaining the equilibrium that exists between cell survival and cell death in 
cultures of T leukemia cells and also demonstrated the contribution of p38 MAPK to 
cellular homeostasis in leukemia cells. 
 
Interestingly, in another study (Cairns et al., 1994), PP2A had been reported as primarily 
responsible for the dephosphorylation/phosphorylation of Hsp27 in MRC-5 fibroblasts 
cells. Cairns J et al. showed that when the PP2A/C was phosphorylated at its tyrosine  
residue, it was no longer able to dephosphorylate Hsp27 (Cairns et al., 1994). Our group 
had earlier shown that the phosphorylation of Ser78 of Hsp27 was correlated with HER-
2/neu status and lymph node positivity (Zhang et al., 2007), which corroborated with the 
suggestion that phosphorylation of Hsp27Ser78 in the HER-2/neu cells was 
predominantly mediated by the p38 MAPK pathway, although the specific role of Hsp27 
Ser78 has yet to be fully elucidated. Here,  Hsp27 Ser78, regulated by p38 MAPK, was 
found to be highly phosphorylated upon silencing of PP2A/C. This further demonstrated 
                                          Chapter 6 Functional role of PP2A in HER-2/neu breast cancer cell lines 
122 
 
the significant correlation of p38 MAPK/Hsp27 with PP2A. 
  
Knocking down PP2A/C or its regulatory subunits results in apoptosis (Götz et al., 1998; 
Li et al., 2002; Strack et al., 2004; Kong et al., 2004). However, we cannot completely 
exclude the possibility that silencing PP2A/C also changes the binding of regulatory B 
subunits and this may cause the aberrant response of cell apoptosis. It is therefore 
necessary to identify the variable B subunit complexes that may play a role or are 
responsible in directing the phosphorylation cascade in HER-2/neu activated signalling 
pathway.  
 




Figure 6-6. Proposed role of PP2A in HER-2/neu signalling pathway. The schematic 
diagram proposes that inhibition of the PP2A/C and its phosphorylation lead to a 
decrease in its phosphatase activity that could possibly result in constitutive activation of 
kinases such as PI3K/AKT that play a contributory role in aggressive tumour growth. The 
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counteracting signal modulator, p38 MAPK, however, is therein activated, by enhanced 
phosphorylation of p38 MAPK and Hsp27 that trigger the cells to undergo apoptosis in a 
caspase-3 dependent manner in HER-2/neu positive breast cancer cell lines.  
 
In this model, we propose that inhibition of the PP2A/C and its phosphorylation lead to a 
decrease in its phosphatase activity, that could possibly result in constitutive activation of 
kinases such as AKT that play a role in aggressive tumour growth. The counteracting 
signal modulator, p38 MAPK, however, is therein activated, triggering the cells to 
undergo apoptosis via the caspase 3-dependent pathway and it would appear from this 
study that the latter predominates, at least in the BT474 and SKBR3 breast cancer cell 
lines. 
 
In summary, these results suggest that inhibition of PP2A/C-induced apoptosis in HER-
2/neu breast cancer cells occurs via p38 MAPK/Hsp27 mediation, in a caspase 3-
dependent manner. Therefore, by targeting the PP2A/C in HER-2/neu-positive cancer 
cells, it may reduce the aggressiveness of the cancerous cell proliferation rate. These 
findings imply that patients with HER-2/neu-positive breast cancers may benefit from the 
inhibition of pY307-PP2A as a form of targeted therapy. 






GENERAL DISCUSSION AND CONCLUSION 
7.1 The significance of deciphering the role of tyrosine phosphorylation in HER-
2/neu breast cancer cells  
Phosphorylation, in particular tyrosine phosphorylation, is featured prominently in the 
biology of cancer. The tyrosine kinase and their substrates are potential molecular cancer 
markers that aid in predicting clinical outcome and responses to drug (Lim, 2005).  
Understanding of the tyrosine phosphorylation in HER-2/neu positive breast cancer could 
help in discovering attractive drug targets.  For example, trastuzumab was the first 
biological agent developed and approved for the use in HER-2/neu breast cancer 
treatment. Trastuzumab inhibits HER-2/neu activation and subsequently interrupts its 
downstream pathways. Other tyrosine kinase inhibitors such as Lapatinib, Neratinib, etc. 
are currently being developed to treat HER-2/neu-positive breast cancer patients by 
inhibiting the tyrosine phosphorylation that leads to activation of downstream growth 
promoting pathways (Roy and Perez, 2009).  
 
This study showed that activation of HRG-mediated HER-2/neu signalling causes 
tyrosine phosphorylation in a group of signal transductors in HER-2/neu-positive breast 
cancer cells. HRG, a 45kDa protein existing in multiple secreted isoforms derived from 
alternatively spliced genes (Tan et al., 1999), was used to trigger the activation of HER-
2/neu signalling. Studies elsewhere had shown that tyrosine phosphorylation was 
expressed in response to HRG in NIH 3T3 cells expressing both HER-2 and HER-3 or 
HER-2 and HER-4 (Reese and Slamon, 1997). The effects of activation of HER-2/neu on 
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its phosphorylation status as well as those of key downstream modulators such as 
PI3K/AKT and Ras/Raf/ERK were examined and confirmed by western blotting. In 
addition, an antibody array was employed to study the tyrosine phosphorylation profiles 
of key metabolites involved in the HER-2/neu activating pathway. The results showed 
that HER-2/neu activation is able to trigger many other signal modulators. Of special 
interest to us was the finding that pY307-PP2A is highly activated upon HRG activation 
and that it is related to breast cancer progression. Pharmacological inhibition with the 
HER-2/neu inhibitor AG825, PI3K inhibitor LY294002, MEK1/2 inhibitor PD98095, and 
p38 MAPK inhibitor SB203580, further confirmed that PP2A phosphorylation was 
modulated by the complicated, HER-2/neu-driven downstream signal network, with the 
PI3K and MEK1/2 positively, while the p38 MAPK negatively, regulating its tyrosine 
phosphorylation. These data confirmed the correlation of HER-2/neu activation and 
PP2A tyrosine phosphorylation, which led us to further study the functional role of 
PP2A. 
 
The correlation of PP2A tyrosine phosphorylation with HER-2/neu and its association 
with tumour progression was first reported by our group (Wong et al., 2009). To 
substantiate that finding, much effort was further needed to study the role of pY307-
PP2A in HER-2/neu signalling and to translate the basic research knowledge to clinical 
usage. The work presented in this thesis represent our approaches in understanding the 
tyrosine phosphorylation regulated by HER-2/neu signalling, which hopefully has 
contributed to the discovery of a potential phosphoprotein biomarker of breast cancer 
biology.  
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7.2 Antibody array-based technologies for cancer protein profiling and 
functional proteomics analyses 
A signal transduction antibody array was used in this study to decipher the tyrosine 
phosphorylation profile of the key signalling modulators that are regulated by HRG-
mediated HER-2/neu signalling pathways. Previous work by many other research groups 
had unraveled the different pathways that are related to HER-2/neu signalling such as the 
MAPK pathway, PI3K/AKT signalling pathway, phospholipase C-γ (PLC)-associated 
pathway, cell cycle regulation, wnt signalling pathways, NF-kappa B pathways, etc 
(Reese and Slamon, 1997; Zhou and Hung, 2003). From this recent work, other 
additional signal modulators that had not been previously reported to be related to HER-
2/neu were unveiled. 78 tyrosine-phosphorylated proteins and 2 tyrosine-
dephosphorylated proteins, tyrosine phosphorylation of which were stimulated or 
suppressed following HRG-enhanced HER-2/neu signalling were identified. Four of 
them, namely, Ezrin, PP2A, FADD and ARC, were validated as reported in Chapter 3. 
Each of these signal molecules wields an impact in controlling the cellular function and 
fate. This work further emphasized the complexity of HER-2/neu-driven biology within 
the cancer cells, which contribute to their high proliferation rate and aggressive 
behaviour. 
 
Antibody arrays have become a prominent tool for gathering information required to 
better understanding of disease biology. Comparing to cDNA analysis by microarray 
used in gene expression profiling, antibody arrays can provide additional information on 
protein interactions, localization and correlation. It is widely known that the mRNA 
                                                          Chapter 7 General discussion and conclusions 
127 
 
transcript abundance level might not directly correlate with the protein abundance level 
as not all mRNA is translated into protein. Thus the use of antibody arrays in the 
characterization of signalling networks and in cancer biomarker discovery (Alhamdani et 
al., 2009; Sanchez-Carbayo, 2010). Hudelist et al. identified a number of proteins that 
showed increased expression levels in malignant breast tissues, such as casein kinase Ie, 
p53, annexin XI, CDC25C, eIF-4E and MAP kinase 7, using a protein microarray system 
which contains 378 well characterized monoclonal antibodies. They were investigating 
the differential gene expression patterns of malignant and adjacent normal breast tissues 
in a patient with primary breast cancer (Hudelist et al., 2004).  Other reports on bladder 
cancer (Sanchez-Carbayo et al., 2006), colorectal cancer (Sreekumar et al., 2001; Hao et 
al., 2008; Madoz-Gúrpide et al., 2007), prostate cancer (Miller et al., 2003; Shafer et al., 
2007; Fujita et al., 2008), pancreatic cancer (Orchekowski et al., 2005; Chen et al., 2007; 
Ingvarsson et al., 2008) and lung cancer (Kullmann et al., 2008; Gao et al., 2005) have 
showed the power of antibody array in providing useful, clinically relevant data.  
 
Precautionary steps were carried out when using the antibody array. The specific 
downstream proteins such as Shc, Stat1 and AKT, which were previously known to be 
upregulated by HER-2/neu signalling, were identified by the array were checked and 
validatedby Western blot analysis. In each case, the results obtained by Western blots 
matched the data obtained by the antibody array system. This is important so as to avoid 
any misinterpretation of the array results. The vast majority of antibody arrays have been 
generated using monoclonal and polyclonal antibodies that are commercially available. 
There are legitimate concerns about the performance of these antibodies. In this study, 
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antibodies bought from other companies and not from the antibody array provider were 
used for validation by Western blots. This measure assured the authenticity of the 
findings. 
 
7.3 PP2A as a tumour suppressor or proto-oncogene? 
A few phosphatases have been shown to have dual specificity. Some phosphatases, such 
as CDC25, have been shown to be potential human oncogenes. Both CDC25A and 
CDC25B are important regulators of cell cycle progression and are able to transform cell 
in culture and therefore are oncogenic. CDC25B was overexpressed in 32% of human 
primary breast cancers tested (Galaktionov et al., 1995). On the other hand, PTEN, the 
phosphatase of the PI3K and AKT pathways, was found to be a tumour suppressor as 
mutation and deletion of this gene was found in various cancer cell types (Simpson and 
Parsons, 2001).  
 
There are evidences showing that PP2A is a negative regulator of cell growth and as a 
potential tumour suppressor (Guy et al., 1992; Schönthal, 2001). However, there are a 
couple of observations contradicting this view and proposing that PP2A exerts both 
positive and negative effects in cell growth regulation and tumorigenesis.   
 
The two main evidences for PP2A as a tumour suppressor are its potential contributions 
to cellular growth and its involvement in cellular transformation. Okadaic acid (OA) has 
been widely used to bind the PP2A/C and shown to efficiently block its enzymatic 
activities (Bialojan and Takai, 1988). OA is a potent tumour promoter; hence inhibition 
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of OA decreases the phosphatase activity and hence contributes to tumour formation. 
Cells that are treated with OA demonstrated enhanced phosphorylation in an array of 
cellular proteins (Guy et al., 1992). PP2A is inactivated by this compound and causes 
elevated expression of c-fos and c-jun, two proto-oncogenes regulating cell proliferation 
(Schönthal, 2001). Furthermore, treatment of OA activates the MAP kinase pathway and 
thus acts as a negative regulator of cell growth (Sontag et al., 1993). In addition, PP2A 
plays a role in inhibition of transformation. For example, PP2A can be inactivated in 
response to cell growth stimulation by receptor tyrosine kinase or non-receptor tyrosine 
kinase (Chen et al., 1994). PP2A also inhibits telomerase, an enzyme that is found to be 
elevated in cancer cells (Li et al., 1997). In colorectal cancers in which the APC tumour 
suppressor is mutated, PP2A rapidly dephosphorylates β-catenin and prevents it from 
entering into the downstream ubiquitination machinery, leading to its stabilization and 
high levels of accumulation and the development of cancer (Su et al., 2008). In another 
study, increased PP2A/C was found to reduce the rate of transformation of mouse 
fibroblasts by H-Ras and the polyoma virus medium T oncogenes in vitro (Baharians and 
Schönthal, 1999).  
 
Studies also revealed that mice lacking the PP2A/C alpha isoforms are not viable (Götz et 
al., 1998), and impaired function of PP2A may contribute to tumorigenesis. PP2A has 
been shown to be a regulator of Raf-1, a (proto)oncogene product -- PP2A is able to form 
a stable complex with Raf-1 and thereby facilitate kinase activation (Abraham et al., 
2000). This finding is indeed surprising as PP2A inhibits other modulators further 
downstream of MAP kinase pathway (Schönthal, 2001). PP2A may have both a positive 
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and a negative role in cell cycle regulation. In the G1 phase, inhibition of PP2A activity 
results in the decreased expression of cyclin D2, cyclin E and cyclin A, which are 
essential regulatory subunits of the CDK complexes and results in G1 phase arrest (Yan 
and Mumby, 1999; Schönthal and Feramisco, 1993). Thus, PP2A is required for cells to 
progress through the early phases of the cell cycle to enter S phase. On the contrary, 
during the G2/M phase transition, PP2A inhibits the activation of M-phase-specific 
CDKs, such as cdk-1 cyclin B complex, which are essential for entry and progression 
through this phase of the cell cycle (Kawabe et al., 1997; Kinoshita et al., 1993; Félix et 
al., 1990; Clarke et al., 1993; Lee et al., 1994). 
 
In this study,  siRNA was chosen and not OA, which has been widely used by other 
groups, to study the role of PP2A. OA has been shown to inhibit other phosphatases such 
as serine/threonine phosphatase 1, PP1 (Dawson and Holmes, 1999). Therefore, an 
experiment design that uses solely OA may have to be interpreted carefully since there is 
a potential that other than PP2A, the other phosphatases are inhibited as well.  
Alternatively, a combination of OA, siRNA and other drugs can be tried out and used, if 
they yield improved results.  
 
From the above, there are prevailing evidences to support PP2A as a potent tumour 
suppressor. However, unlike other classical tumour suppressors such as p53 and RB, 
mice with deficient p53 and RB are viable though prone to tumour development (Sharan 
and Bradley, 1995), whereas mice with deficient PP2A are lethal (Götz et al., 1998). 
Whilst p53 and RB inactivation or inhibition promotes proliferation, inactivation of PP2A 
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or deletion, in contrast, promotes cell death. In this study, PP2A is associated with 
tumorigenesis and loss of PP2A/C does not cause cell proliferation but causes apoptosis 
instead. Hence, PP2A cannot be classified as a tumour suppressor in this case but more as 
a proto-oncogene. In the light of the diversity of PP2A subunits and their ability to form a 
large repertoire of different holoenzyemes, PP2A has been described as a multitasking 
enzyme and characterization of the relevant combinations and assigned roles will be an 
important and challenging study. 
 
7.4 The role of PP2A in HER-2/neu-overexpressing breast cancer 
Treatment of HER-2/neu-positive breast cancer has undergone advanced improvement 
with the current focus on targeted therapy, from use of Trastuzumab in chemotherapy to 
the imminent introduction of Lapatinib as well as other tyrosine kinase inhibitors. Hence, 
it is important to understand the mechanisms of action of HER-2/neu and to further 
develop new therapeutic options in controlling the aggressiveness of the cancer cells.  
 
From literature reviews,  PP2A has been shown to play an important role in control of 
cell cycle, apoptosis and cell fate determination. The PP2A/C makes up to 0.1% of total 
cell protein and is encoded by two genes, the Cα and Cβ subunits. The levels of PP2A/C 
are tightly controlled in the cell at the translational or post-translational levels. From this 
study,  targeting the expression of PP2A/C in HER-2/neu-positive breast cancer cells 
could result in the cancer cells undergoing apoptosis. This is an important finding since 
HER-2/neu gene amplification is associated with increased cell proliferation, cell 
motility, tumour invasiveness, progressive regional and distant metastases, accelerated 
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angiogenesis, and reduced apoptosis (Moasser, 2007). This present study revealed that 
following HER-2/neu activation, the activated PI3K- and Raf/MEK pathways stimulate 
PP2A phosphorylation and attenuate its activity to facilitate cell survival, whereas the 
activated p38 MAPK pathway reduces PP2A phosphorylation and increases its activity to 
accelerate cell apoptotic activity. This data showed the important role of PP2A in HER-
2/neu oncogenic signalling. This is first time  reported that the inhibition of the PP2A/C 
and its phosphorylation not only lead to a decrease in its phosphatase activity that could 
possibly result in constitutive activation of kinases such as AKT that play a role in 
aggressive tumour growth, but also at the same time trigger the counteracting signal 
modulator p38 MAPK. Thus, the cells are committed to undergo apoptosis via the 
caspase 3-dependent pathway. These findings provide an understanding of the role of 
PP2A in HER2/neu-positive breast cancer cells and thus provide insight into new targets 
for breast cancer therapy.  
 
7.5 Use of siRNA in cancer therapy 
The tissue microarray study supported the strong association of pY307-PP2A with breast 
tumour progression and postulated that pY307-PP2A has a potential prognostic value in 
determining breast cancer progression. In HER-2/neu-positive breast cancer cell lines and 
breast tumour samples, the higher expression of pY307-PP2A showed that pY307-PP2A 
could serve as a target therapy to block off tumorigenesis by its inherent property of 
reactivating PP2A activity. To reactivate the PP2A activity, expression of pY307 needs to 
be decreased since the phosphatase activity is regulated by pY307. Alternatively, the 
phosphoryation of pY307-PP2A could be reduced or inactivated by inhibitors or siRNA. 
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In the functional studies of PP2A/C in HER-2/neu-positive cells,  siRNA was used to 
target the catalytic subunit where the pY307 resides and knock down its expression. The 
results showed that these cells undergo apoptosis. Therefore, it will be exciting if either 
an activator of PP2A activity or an inhibitor of its phosphorylation could be developed to 
treat the aggressive tumours cells in HER-2/neu-positive breast cancer patients, in 
combination of other forms of chemotherapy. 
 
Recently, a nanomedicine-based approach for the delivery of siRNA in cancer has 
become a hot topic, in relation to achieving personalized cancer treatment. The first 
targeted delivery of siRNA in a patient was administered with four doses of Calando’s 
CALAA-01 for the treatment of cancer in a clinical trial. This development showed 
another milestone for siRNA technology, which many proponents have high hopes for in 
the treatment of a diverse range of illness (Davis, 2009). Ongoing clinical trials using 
siRNA involve chemically modified or naked siRNA and locally administered siRNA to 
topical diseases such as age-related macular degeneration, diabetic macular oedema and 
respiratory virus infection and pachyonychia congenital (Fattal and Bochot, 2006; Bitko 
et al., 2005). Recently, systemic administrations of siRNA in ongoing clinical cancer 
trials are gaining popular. Nanoliposomal siRNA was shown to be more effective for 
systemic delivery of siRNA into tumour tissue and a Phase 1 clinical trial using this 
nanoliposomal delivery mode is ongoing (Ozpolat et al., 2010). Eguchi et al. created a 
peptide-transduction domain-double stranded RNA binding domain (PTD-DRBD) fusion 
protein to bind the siRNA and deliver it into primary tumour cells where it specifically 
targets mRNA from cancer-promoting genes without being toxic to the cells (Eguchi et 
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al., 2009; Eguchi and Dowdy, 2010). In glioblastoma treatment, combinatorial targeting 
of EGFR and AKT2 (but not AKT1 or AKT3), by PTD-DRBD delivered siRNAs 
synergized to induce tumour cell-specific apoptosis. In vivo PTD-DRBD delivery of 
EGFR and AKT2 siRNAs induced tumour-specific apoptosis and significantly increased 
survival in intracerebral glioblastoma mouse models (p < 0.0005), whereas delivery of 
irrelevant control siRNAs did not alter longevity. Thus, siRNA-induced synthetic lethal 
RNAi responses have great potential for personalized treatment of cancer (Michiue et al., 
2009). 
 
With the aids of biotechnology, development of appropriately designed siRNAs targeting 
the pY307-PP2A to turn off the insistent growth switch in HER-2/neu-positive breast 
cancer cells to grow and proliferate, will be feasible. Both conventional cancer therapy 
using chemotherapy and radiotherapy cause complications to the cancer patients. The 
advent of nanomedicine combined with siRNA therapy, which appears to have less 
cytotoxicity and minimal side effects, offer promising options for cancer treatment. 
 
7.6 Conclusion 
Cancer research is a challenging field to work on. Each time when  a particular 
gene/protein function is unravelled, it helps the reseachers to have a better understanding 
of the disease pathways and hopefully offer a better clinical treatment to the affected 
patients.  
 
Deciphering the signalling pathway in cancer initiation and progression has paved the 
                                                          Chapter 7 General discussion and conclusions 
135 
 
way for the development of numerous therapeutic leads. To this end, PP2A appears to be 
a new candidate in regulating the oncogenic role of HER-2/neu. Recent studies on a few 
potent and selective PP2A inhibitors such as cantharidin and its derivatives have shown 
therapeutic effects against various cancers by attenuating the growth of cancer cell 
through G2/M cell cycle arrest and apoptosis (Huh et al., 2004) (Li et al., 2010). Here, 
the study demonstrated that silencing of PP2A/C caused HER-2/neu-positive breast 
cancer cell lines to undergo apoptosis via the p38 MAPK-mediated caspase 3/PARP 
pathway.  
 
7.7 Future works 
This study provides another platform for understanding the role of tyrosine 
phosphorylation in HER-2/neu-positive breast cancer. The novel findings of correlation 
of HER-2/neu and PP2A will provide the groundwork for better understanding of the 
aggressiveness of HER-2/neu phenotype. As  only the functional study of PP2A was 
examined in this study, it will be beneficial if the other identified proteins could be 
further analyzed. These proteins include those involved in cell cycle regulation, cell 
apoptosis and cell growth.  
 
In vitro system was used to examine the functional role of PP2A/C in HER-2/neu-
positive breast cancer cell lines in this study. In vivo studies should be followed up next 
to assess the functions of PP2A/C in a knock-out model, employing both genetic and 
pharmacological approaches, before the knowledge can be translated into drug 
development. Transgenic mice (NDL2 mice) with a deletion mutation in the region of 
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ErbB2 encoding its extracellular domain have been generated by Siegel et al. These 
transgenic NDL2 female mice develop multiple mammary tumours with elevated levels 
of ErbB2 and ErbB3 with phosphorylated tyrosine. Furthermore this mouse model 
mimics human breast cancer as the alternative spliced form of ErbB2 that is analogous to 
the ErbB2 deletion mutant in NDL2 has been found in human breast cancer (Siegel et al., 
1999). Deletion of the PP2A activity in the NDL2 transgenic mice by either breeding 
with PP2A/C-deficient mice or by treatment with PP2A siRNA or specific inhibitor is 
proposed and followed by examining the results of the mammary gland and 
tumorigenesis. With this approach, it will  enable us to understand the role of PP2A/C in 
tumorigenesis and investigate whether the development of PP2A inhibitor or siRNA 
therapy can be used as a new targeted treatment on HER-2/neu-overexpressing breast 
cancer patients.  
 
Furthermore, the TMA result demonstrated that PP2A is associated with breast cancer 
progression and was highly expressed in HER-2/neu-positive breast cancer. It will be 
important to conduct an extended study with a bigger number of patient samples, and 
correlate the results with other clinicopathological parameters, such as tumour stage and 
AJCC staging. This will enhance our understanding of the role of PP2A in HER-2/neu-
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Table 1: Human phospho-RTK array. Refer to the table below for the human 
phospho-RTK array coordinates. 
 





Table 2: The signal transduction antiboday array. Refer to table below for the antibody list by position on the array. 





Table 2: The signal transduction antiboday array (continued) 





Table 3: Tissue Microarray (US Biomax, Rockville, MD, USA). Refer to the table below for the histopathological 
parameters of tissue microarray used. 
Catalogue Position Sex Age Organ Pathology Grade Type 
'BR2082 'A1 'F '40 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A2 'F '55 'Lymph node 
'Metastatic invasive ductal 
carcinoma '1 'Metastasis 
'BR2082 'A3 'F '56 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A4 'F '48 'Lymph node 
'Metastatic invasive ductal 
carcinoma (adipose tissue) '- 'Metastasis 
'BR2082 'A5 'F '57 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A6 'F '56 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A7 'F '42 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A8 'F '49 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A9 'F '66 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A10 'F '38 'Lymph node 
'Metastatic invasive ductal 
carcinoma '1 'Metastasis 
'BR2082 'A11 'F '51 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A12 'F '39 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A13 'F '53 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
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'BR2082 'A14 'F '56 'Lymph node 
'Metastatic invasive ductal 
carcinoma (adipose tissue and 
blood vessel) '- 'Metastasis 
'BR2082 'A15 'F '44 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'A16 'F '55 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B1 'F '47 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B2 'F '39 'Lymph node 
'Metastatic invasive ductal 
carcinoma '1 'Metastasis 
'BR2082 'B3 'F '52 'Lymph node 
'Metastatic invasive ductal 
carcinoma of No. 81 '2 'Metastasis 
'BR2082 'B4 'F '60 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B5 'F '52 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B6 'F '28 'Lymph node 
'Metastatic invasive ductal 
carcinoma '3 'Metastasis 
'BR2082 'B7 'F '58 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B8 'F '42 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B9 'F '42 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B10 'F '48 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B11 'F '80 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B12 'F '59 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
Table 3: Tissue Microarray (continued) 
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'BR2082 'B13 'F '60 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B14 'F '28 'Lymph node 
'Metastatic invasive ductal 
carcinoma of No. 79 '2 'Metastasis 
'BR2082 'B15 'F '55 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'B16 'F '62 'Lymph node 
'Metastatic invasive ductal 
carcinoma '2 'Metastasis 
'BR2082 'C1 'F '30 'Breast 'Invasive ductal carcinoma '1 'Malignant 
'BR2082 'C2 'F '44 'Breast 'Invasive ductal carcinoma (sparse) '1 'Malignant 
'BR2082 'C3 'F '37 'Breast 'Invasive ductal carcinoma '1 'Malignant 
'BR2082 'C4 'F '61 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C5 'F '50 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C6 'F '39 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C7 'F '42 'Breast 'Invasive ductal carcinoma '1 'Malignant 
'BR2082 'C8 'F '41 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C9 'F '65 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C10 'F '63 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C11 'F '71 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C12 'F '43 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C13 'F '54 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C14 'F '38 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C15 'F '47 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'C16 'F '44 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D1 'F '53 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D2 'F '42 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D3 'F '59 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D4 'F '38 'Breast 'Invasive ductal carcinoma '2 'Malignant 
Table 3: Tissue Microarray (continued) 
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'BR2082 'D5 'F '43 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D6 'F '48 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D7 'F '41 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D8 'F '38 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D9 'F '45 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D10 'F '42 'Breast 
'Invasive ductal carcinoma 
(fibrofatty tissue) '- 'Malignant 
'BR2082 'D11 'F '41 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D12 'F '32 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D13 'F '62 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D14 'F '50 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D15 'F '68 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'D16 'F '44 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E1 'F '45 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E2 'F '29 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E3 'F '67 'Breast 'Invasive ductal carcinoma '1 'Malignant 
'BR2082 'E4 'F '50 'Breast 
'Invasive ductal carcinoma (breast 
tissue) '- 'Malignant 
'BR2082 'E5 'F '54 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E6 'F '35 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E7 'F '43 'Breast 
'Invasive ductal carcinoma 
(fibrofatty tissue) '- 'Malignant 
'BR2082 'E8 'F '29 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E9 'F '55 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E10 'F '50 'Breast 'Invasive ductal carcinoma (sparse) '2 'Malignant 
'BR2082 'E11 'F '43 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E12 'F '43 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E13 'F '45 'Breast 'Invasive ductal carcinoma '2 'Malignant 
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'BR2082 'E14 'F '50 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E15 'F '28 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'E16 'F '55 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F1 'F '52 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F2 'F '38 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F3 'F '49 'Breast 'Invasive ductal carcinoma (sparse) '- 'Malignant 
'BR2082 'F4 'F '46 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F5 'F '62 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F6 'F '42 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F7 'F '53 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F8 'F '45 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F9 'F '32 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F10 'F '29 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F11 'F '65 'Breast 
'Invasive ductal carcinoma 
(fibrofatty tissue) '- 'Malignant 
'BR2082 'F12 'F '64 'Breast 'Invasive ductal carcinoma (sparse) '2 'Malignant 
'BR2082 'F13 'F '63 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F14 'F '51 'Breast 'Invasive ductal carcinoma '3 'Malignant 
'BR2082 'F15 'F '56 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'F16 'F '62 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'G1 'F '37 'Breast 
'Invasive ductal carcinoma (skeletal 
muscle and blood vessel) '- 'Malignant 
'BR2082 'G2 'F '32 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'G3 'F '55 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'G4 'F '53 'Breast 'Invasive ductal carcinoma '2 'Malignant 
'BR2082 'G5 'F '50 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G6 'F '38 'Breast 
'Invasive lobular carcinoma (breast 
tissue) '- 'Malignant 
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'BR2082 'G7 'F '47 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G8 'F '51 'Breast 'Invasive lobular carcinoma (sparse) '- 'Malignant 
'BR2082 'G9 'F '69 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G10 'F '70 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G11 'F '59 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G12 'F '35 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G13 'F '38 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G14 'F '42 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G15 'F '52 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'G16 'F '41 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'H1 'F '47 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'H2 'F '50 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'H3 'F '66 'Breast 'Invasive lobular carcinoma (sparse) '- 'Malignant 
'BR2082 'H4 'F '46 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'H5 'F '48 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'H6 'F '38 'Breast 
'Invasive lobular carcinoma 
(fibrofatty tissue) '- 'Malignant 
'BR2082 'H7 'F '45 'Breast 'Invasive lobular carcinoma (sparse) '- 'Malignant 
'BR2082 'H8 'F '52 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'H9 'F '45 'Breast 'Invasive lobular carcinoma '- 'Malignant 
'BR2082 'H10 'F '52 'Breast 'Invasive lobular carcinoma (sparse) '- 'Malignant 
'BR2082 'H11 'F '41 'Breast 'Squamous cell carcinoma '1&ndash;2 'Malignant 
'BR2082 'H12 'F '37 'Breast 'Squamous cell carcinoma '2 'Malignant 
'BR2082 'H13 'F '48 'Breast 'Squamous cell carcinoma '2 'Malignant 
'BR2082 'H14 'F '47 'Breast 'Squamous cell carcinoma '2 'Malignant 
'BR2082 'H15 'F '49 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'H16 'F '46 'Breast 'Intraductal carcinoma (sparse) '- 'Malignant 
'BR2082 'I1 'F '38 'Breast 'Intraductal carcinoma '- 'Malignant 
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'BR2082 'I2 'F '42 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I3 'F '27 'Breast 
'Intraductal carcinoma (fibrous 
tissue) '- 'Malignant 
'BR2082 'I4 'F '30 'Breast 
'Intraductal carcinoma (breast 
tissue) '- 'Malignant 
'BR2082 'I5 'F '41 'Breast 
'Intraductal carcinoma (hyperplasia 
of breast duct) '- 'Malignant 
'BR2082 'I6 'F '43 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I7 'F '32 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I8 'F '58 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I9 'F '67 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I10 'F '30 'Breast 
'Intraductal carcinoma (breast 
tissue) '- 'Malignant 
'BR2082 'I11 'F '49 'Breast 
'Intraductal carcinoma with early 
infiltration '- 'Malignant 
'BR2082 'I12 'F '32 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I13 'F '81 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I14 'F '39 'Breast 
'Intraductal carcinoma (breast 
tissue) '- 'Malignant 
'BR2082 'I15 'F '43 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'I16 'F '35 'Breast 
'Intraductal carcinoma (fibrous 
tissue) '- 'Malignant 
'BR2082 'J1 'F '46 'Breast 'Intraductal carcinoma (sparse) '- 'Malignant 
'BR2082 'J2 'F '60 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'J3 'F '64 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'J4 'F '40 'Breast 'Intraductal carcinoma '- 'Malignant 
'BR2082 'J5 'F '48 'Breast 
'Lobular carcinoma in situ (breast 
tissue) '- 'In Situ 
'BR2082 'J6 'F '54 'Breast 'Lobular carcinoma in situ '- 'In Situ 
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'BR2082 'J7 'F '49 'Breast 'Lobular carcinoma in situ '- 'In Situ 
'BR2082 'J8 'F '62 'Breast 
'Lobular carcinoma in situ (fibrous 
tissue) '- 'In Situ 
'BR2082 'J9 'F '44 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'J10 'F '27 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'J11 'F '23 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'J12 'F '23 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'J13 'F '19 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'J14 'F '23 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'J15 'F '42 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'J16 'F '25 'Breast 'Fibroadenoma '- 'Benign 
'BR2082 'K1 'F '48 'Breast 'Mild hyperplasia of breast duct '- 'Hyperplasia 
'BR2082 'K2 'F '43 'Breast 'Adenosis with hyperplasia of duct '- 'Hyperplasia 
'BR2082 'K3 'F '41 'Breast 'Adenosis with hyperplasia of duct '- 'Hyperplasia 
'BR2082 'K4 'F '34 'Breast 'Mild hyperplasia of breast duct '- 'Hyperplasia 
'BR2082 'K5 'F '40 'Breast 
'Atypical hyperplasia in duct (grade 
II) '- 'Hyperplasia 
'BR2082 'K6 'F '76 'Breast 'Hyperplasia (fibrofatty tissue) '- 'Hyperplasia 
'BR2082 'K7 'F '70 'Breast 'Hyperplasia (fibrous tissue) '- 'Hyperplasia 
'BR2082 'K8 'F '37 'Breast 
'Adenosis with mild hyperplasia of 
duct '- 'Hyperplasia 
'BR2082 'K9 'F '45 'Breast 
'Adenosis with mild hyperplasia of 
duct '- 'Hyperplasia 
'BR2082 'K10 'F '32 'Breast 'Hyperplasia (fibrofatty tissue) '- 'Hyperplasia 
'BR2082 'K11 'F '48 'Breast 'Hyperplasia (fibrous tissue) '- 'Hyperplasia 
'BR2082 'K12 'F '45 'Breast 
'Atypical hyperplasia of duct (grade 
II-III) '- 'Hyperplasia 
'BR2082 'K13 'F '40 'Breast 'Cyclomastopathy '- 'Hyperplasia 
'BR2082 'K14 'F '22 'Breast 'Cyclomastopathy '- 'Hyperplasia 
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'BR2082 'K15 'F '28 'Breast 'Cyclomastopathy (sparse) '- 'Hyperplasia 
'BR2082 'K16 'F '35 'Breast 'Hyperplasia (fibrofatty tissue) '- 'Hyperplasia 
'BR2082 'L1 'F '61 'Breast 'Plasma cell mastitis '- 'Inflammation 
'BR2082 'L2 'F '28 'Breast 'Plasma cell mastitis '- 'Inflammation 
'BR2082 'L3 'F '55 'Breast 'Plasma cell mastitis '- 'Inflammation 
'BR2082 'L4 'F '26 'Breast 'Plasma cell mastitis '- 'Inflammation 
'BR2082 'L5 'F '78 'Breast 'Plasma cell mastitis '- 'Inflammation 
'BR2082 'L6 'F '46 'Breast 'Plasma cell mastitis '- 'Inflammation 
'BR2082 'L7 'F '28 'Breast 'Chronic inflammation '- 'Inflammation 
'BR2082 'L8 'F '10 'Breast 'Acute mastitis '- 'Inflammation 
'BR2082 'L9 'F '45 'Breast 'Mild chronic inflammation '- 'Inflammation 
'BR2082 'L10 'F '57 'Breast 'Mild chronic inflammation '- 'Inflammation 
'BR2082 'L11 'F '33 'Breast 'Mild chronic inflammation '- 'Inflammation 
'BR2082 'L12 'F '39 'Breast 
'Chronic inflammation of fibrous 
tissue '- 'Inflammation 
'BR2082 'L13 'F '67 'Breast 'Granulomatous mastitis '- 'Inflammation 
'BR2082 'L14 'F '40 'Breast 'Chronic inflammation '- 'Inflammation 
'BR2082 'L15 'F '36 'Breast 'Chronic inflammation '- 'Inflammation 
'BR2082 'L16 'F '44 'Breast 
'Plasma cell mastitis with ductal 
ectasia '- 'Inflammation 
'BR2082 'M1 'F '61 'Breast 
'Cancer adjacent normal breast 
tissue '- 'NAT 
'BR2082 'M2 'F '31 'Breast 
'Cancer adjacent normal breast 
tissue (cyclomastopathy) '- 'NAT 
'BR2082 'M3 'F '45 'Breast 
'Cancer adjacent normal breast 
tissue '- 'NAT 
'BR2082 'M4 'F '53 'Breast 
'Cancer adjacent normal breast 
tissue '- 'NAT 
'BR2082 'M5 'F '36 'Breast 'Cancer adjacent normal breast '- 'NAT 
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'BR2082 'M6 'F '35 'Breast 
'Cancer adjacent normal breast 
tissue '- 'NAT 
'BR2082 'M7 'F '44 'Breast 
'Cancer adjacent normal breast 
tissue (fibrous tissue) '- 'NAT 
'BR2082 'M8 'F '33 'Breast 
'Cancer adjacent normal breast 
tissue (fibrous tissue) '- 'NAT 
'BR2082 'M9 'F '58 'Breast 
'Cancer adjacent normal breast 
tissue (adipose tissue) '- 'NAT 
'BR2082 'M10 'F '46 'Breast 
'Cancer adjacent normal breast 
tissue '- 'NAT 
'BR2082 'M11 'F '15 'Breast 'Normal breast tissue '- 'Normal 
'BR2082 'M12 'F '21 'Breast 'Normal breast tissue (sparse) '- 'Normal 
'BR2082 'M13 'F '21 'Breast 'Normal breast tissue '- 'Normal 
'BR2082 'M14 'F '35 'Breast 
'Normal breast tissue (with mild 
ductal ectasia) '- 'Normal 
'BR2082 'M15 'F '19 'Breast 
'Normal breast tissue (fibrous 
tissue) '- 'Normal 
'BR2082 'M16 'F '27 'Breast 
'Normal breast tissue (fibrous 
tissue) '- 'Normal 
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